Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 2203 articles:
HTML format



Single Articles


    February 2024
  1. ROWLEY F, Cottrell S, Howard C, Meredith N, et al
    Use of invitations and reminders are associated with higher levels of Herpes zoster (shingles) vaccination uptake. A cross-sectional survey of general practices in Wales, and ecological analysis of uptake data, 2022.
    Vaccine. 2024 Feb 14:S0264-410X(24)00193-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  2. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    Erratum to "BCGDeltaBCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice" [Vaccine 41(26) (2023) 3824-3835].
    Vaccine. 2024 Feb 14:S0264-410X(24)00176-2. doi: 10.1016/j.vaccine.2024.
    PubMed    


  3. DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
    U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.
    Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  4. BORYS D, Rupp R, Smulders R, Chichili GR, et al
    Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
    Vaccine. 2024 Feb 14:S0264-410X(24)00145-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  5. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  6. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  7. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  8. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  9. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  10. MCDERMID P, Blazek K, Mougin N, Thomson A, et al
    Attitudes and behaviors of maternal Tdap vaccination in Panama, Peru, and Colombia: An international cross-sectional study.
    Vaccine. 2024 Feb 13:S0264-410X(24)00143-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  11. LI Y, Sun X, Fu Y, You X, et al
    Literature review to identify evidence of secondary transmission of pentavalent human-bovine reassortant rotavirus vaccine (RV5) strains to unvaccinated subjects.
    Vaccine. 2024 Feb 13:S0264-410X(24)00107-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  12. BHARUCHA T, Gangadharan B, Clarke R, Fernandez LG, et al
    Repurposing rapid diagnostic tests to detect falsified vaccines in supply chains.
    Vaccine. 2024 Feb 13:S0264-410X(24)00019-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  13. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  14. MABALE MAA, Tejero LMS, Montes LA, Collante MTM, et al
    Implications of information heard about Dengvaxia on Filipinos' perception on vaccination.
    Vaccine. 2024 Feb 12:S0264-410X(24)00123-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  15. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  16. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  17. MANNING J, Manna S, Dunne EM, Bongcaron V, et al
    Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in mice.
    Vaccine. 2024 Feb 12:S0264-410X(24)00131-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  18. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  19. DE WALS P, Desjardins M
    Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine.
    Vaccine. 2024 Feb 12:S0264-410X(24)00163-4. doi: 10.1016/j.vaccine.2024.
    PubMed    


  20. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  21. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  22. MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
    COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
    Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  23. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  24. NGUYEN KH, Chen S, Zhao R, Vasudevan L, et al
    Vaccination patterns and up-to-date status of children 19-35 months, 2011-2021.
    Vaccine. 2024 Feb 9:S0264-410X(24)00122-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  25. FORTUNATO F, Musco A, Iannelli G, Meola M, et al
    Effectiveness of the combined MMRV Priorix-Tetra vaccine against varicella in a large Italian region: A case-control study.
    Vaccine. 2024 Feb 9:S0264-410X(24)00146-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  26. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  27. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  28. SERRANO-MAYORGA CC, Ibanez-Prada ED, Restrepo-Martinez JM, Garcia-Gallo E, et al
    The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia.
    Vaccine. 2024 Feb 8:S0264-410X(24)00109-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  29. AMINZADEH A, Hilgers L, Paul Platenburg P, Riou M, et al
    Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Vaccine. 2024 Feb 8:S0264-410X(24)00101-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  30. WELDEGEBRIEL GG, Okot C, Majingo N, Oumer NJ, et al
    Resurgent rotavirus diarrhoea outbreak five years after introduction of rotavirus vaccine in Botswana, 2018.
    Vaccine. 2024 Feb 7:S0264-410X(24)00108-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  31. CHEN M, Feng X, Liu J, Wang J, et al
    Prokaryote-derived phosphorylated Tau epitope vaccine is immunogenic and non-T-cell activated in the mice model.
    Vaccine. 2024 Feb 7:S0264-410X(23)01517-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  32. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  33. LAMBACH P, Orenstein W, Silal S, Sbarra AN, et al
    Report from the World Health Organization's immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13 September 2023.
    Vaccine. 2024 Feb 6:S0264-410X(24)00160-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  34. SOBLE A, Ko M, Gilchrist S, Malvolti S, et al
    A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches.
    Vaccine. 2024 Feb 6:S0264-410X(23)01493-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  35. KOHLI K, Jain B, Dee EC, Ho BL, et al
    Addressing cultural and political drivers of vaccine hesitancy: Considerations for the African and Asian contexts.
    Vaccine. 2024 Feb 6:S0264-410X(24)00159-2. doi: 10.1016/j.vaccine.2024.
    PubMed    


  36. SMITH TC, Gorski DH
    Infertility: A common target of antivaccine misinformation campaigns.
    Vaccine. 2024;42:924-929.
    PubMed     Abstract available


  37. PENG Y, Yan H, Zhang J, Peng R, et al
    Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold.
    Vaccine. 2024;42:732-737.
    PubMed     Abstract available


  38. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  39. KIM NE, Kim MJ, Park BJ, Kwon JW, et al
    A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses.
    Vaccine. 2024 Feb 5:S0264-410X(24)00114-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  40. HOUY N, Flaig J
    Value of information dynamics in Disease X vaccine clinical trials.
    Vaccine. 2024 Feb 3:S0264-410X(24)00075-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  41. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  42. HWANG YH, Byeon Y, Ahn SH, Kim MY, et al
    Live attenuated smallpox vaccine candidate (KVAC103) efficiently induces protective immune responses in mice.
    Vaccine. 2024 Feb 2:S0264-410X(24)00076-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  43. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
    Vaccine. 2024 Feb 2:S0264-410X(24)00068-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  44. LI D, Han M, Cao Y, Du J, et al
    Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine.
    Vaccine. 2024 Feb 2:S0264-410X(24)00062-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  45. WANG ZJ, Zhang RR, Wu M, Zhao H, et al
    Development of a live-attenuated chimeric vaccine against the emerging Usutu virus.
    Vaccine. 2024 Feb 2:S0264-410X(24)00098-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  46. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  47. SUMNER T, Clark RA, Mukandavire C, Portnoy A, et al
    Modelling the health and economic impacts ofM72/AS01(E) vaccination and BCG-revaccination: Estimates for South Africa.
    Vaccine. 2024 Feb 1:S0264-410X(24)00096-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  48. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  49. DE DEUS N, Chissaque A, Bauhofer A, Barata A, et al
    Safety of incidental exposure to the novel oral poliovirus vaccine type 2 in pregnancy: A longitudinal observational study in Mozambique, 2022-2023.
    Vaccine. 2024 Feb 1:S0264-410X(24)00095-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  50. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    January 2024
  51. SCHONBORN L, Pavord S, Chen VMY, Pai M, et al
    Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Jan 31:S0264-410X(24)00057-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  52. SLAVKOVSKY R, Callen E, Pecenka C, Mvundura M, et al
    Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Vaccine. 2024 Jan 31:S0264-410X(24)00118-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  53. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  54. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  55. KOFF WC, Anandkumar A, Poland GA
    AI and the future of vaccine development.
    Vaccine. 2024 Jan 30:S0264-410X(24)00071-9. doi: 10.1016/j.vaccine.2024.
    PubMed    


  56. POLAND GA, Black S
    Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.
    Vaccine. 2024 Jan 30:S0264-410X(24)00070-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  57. BURNS KE, Dube E, Nascimento HG, Meyer SB, et al
    Erratum to "Examining vaccine hesitancy among a diverse sample of Canadian adults" [Vaccine 42(2) (2024) 129-135].
    Vaccine. 2024 Jan 30:S0264-410X(24)00061-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  58. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  59. XIAOFEI L, Yudan LI, Qinghui C, Jiaming S, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
    Vaccine. 2024 Jan 30:S0264-410X(24)00080-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  60. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  61. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  62. VIDLUND J, Gelalcha BD, Gillespie BE, Agga GE, et al
    Efficacy of novel staphylococcal surface associated protein vaccines against Staphylococcus aureus and non-aureus staphylococcal mastitis in dairy cows.
    Vaccine. 2024 Jan 27:S0264-410X(24)00079-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  63. MURATA F, Maeda M, Ono R, Fukuda H, et al
    Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
    Vaccine. 2024 Jan 27:S0264-410X(24)00072-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  64. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  65. HALL E, Mahon BE, Peacock G
    The U.S. COVID-19 vaccination program: A look back and future directions.
    Vaccine. 2024 Jan 26:S0264-410X(24)00065-3. doi: 10.1016/j.vaccine.2024.
    PubMed    


  66. LEVIN A, Yeung KHT, Hutubessy R
    Systematic review of cost projections of new vaccine introduction.
    Vaccine. 2024 Jan 25:S0264-410X(24)00024-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  67. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  68. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    PubMed     Abstract available


  69. FERRERAS-COLINO E, Contreras M, Risalde MA, Sevilla IA, et al
    Heat-inactivated mycobacteria activate the toll-like receptor 2 and 4 pathways in the zebrafish model of tuberculosis.
    Vaccine. 2024;42:403-409.
    PubMed     Abstract available


  70. KHAN A, Hussain I, Rhoda DA, Umer M, et al
    Determinants of immunization in polio super high-risk union councils of Pakistan.
    Vaccine. 2024;42:583-590.
    PubMed     Abstract available


  71. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  72. RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
    Lessons learned: COVID-19 vaccinations and people with disabilities.
    Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  73. WANG CP, Lin YT, Du YZ, Zhang T, et al
    Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: A retrospective study.
    Vaccine. 2024 Jan 23:S0264-410X(24)00030-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  74. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  75. HARANAKA M, Young Song J, Huang KC, de Solom R, et al
    A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults?>/=?60 years of age in Japan, South Korea, and Taiwan.
    Vaccine. 2024 Jan 23:S0264-410X(24)00008-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  76. ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
    Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
    Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  77. HADLER SC, Shefer AM, Cavallaro KF, Ebama M, et al
    Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments - New tools and approaches.
    Vaccine. 2024 Jan 23:S0264-410X(24)00035-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  78. CLOTHIER HJ, Shetty AN, Mesfin Y, Mackie M, et al
    What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Vaccine. 2024 Jan 22:S0264-410X(24)00025-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  79. CAO H, Li H, Luan N, Zhang H, et al
    A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
    Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  80. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  81. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  82. CATALDI JR, Suresh K, Brewer SE, Perreira C, et al
    Boot Camp Translation using Community-Engaged messaging for adolescent Vaccination: A Cluster-Randomized trial.
    Vaccine. 2024 Jan 21:S0264-410X(24)00054-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  83. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  84. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  85. KUMWICHAR P, Chongsuvivatwong V, Vasoppakarn S, Atthakul N, et al
    Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
    Vaccine. 2024 Jan 20:S0264-410X(24)00026-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  86. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  87. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  88. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  89. MUNKWASE G
    Implications of vaccine non-specific effects on licensure of new vaccines.
    Vaccine. 2024 Jan 18:S0264-410X(24)00060-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  90. CHRISTOPH R, Giovanni A, Arne S, Sebastian V, et al
    Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis.
    Vaccine. 2024 Jan 18:S0264-410X(24)00022-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  91. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  92. FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al
    The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.
    Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  93. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  94. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  95. FAN J, Song Y, Cong S, Millman AJ, et al
    Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
    Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  96. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  97. TIAN X, Wang J, Chen H, Ding M, et al
    In vivo functional immunoprotection correlates for vaccines against invasive bacteria.
    Vaccine. 2024 Jan 16:S0264-410X(24)00018-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  98. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  99. KANG DW, Kim CR, Song JY, Park SK, et al
    Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Vaccine. 2024 Jan 14:S0264-410X(24)00031-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  100. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  101. BEARSON SMD, Monson MS, Bearson BL, Whelan SJ, et al
    Commercial vaccine provides cross-protection by reducing colonization of Salmonella enterica serovars Infantis and Hadar in turkeys.
    Vaccine. 2024 Jan 13:S0264-410X(23)01500-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  102. GUO W, Wang C, Song X, Xu H, et al
    Immunogenicity and protective efficacy of a trimeric full-length S protein subunit vaccine for porcine epidemic diarrhea virus.
    Vaccine. 2024 Jan 13:S0264-410X(24)00020-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  103. NAUTA J
    Estimand for non-inferiority influenza vaccine immunogenicity trials.
    Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  104. RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
    A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
    Vaccine. 2024;42:162-174.
    PubMed     Abstract available


  105. VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
    Vaccine. 2024;42:146-155.
    PubMed     Abstract available


  106. KURATA T, Kaida Y, Kanbayashi D, Motomura K, et al
    Achieving measles elimination and emerging modified measles: Longitudinal measles epidemiology from 1982 to 2021 in Osaka Prefecture, Japan.
    Vaccine. 2024;42:271-286.
    PubMed     Abstract available


  107. SMITH CL, Richardson B, Rubsamen M, Cameron MJ, et al
    Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation.
    Vaccine. 2024;42:229-238.
    PubMed     Abstract available


  108. THOMPSON KM, Kalkowska DA, Kidd SE, Burns CC, et al
    Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
    Vaccine. 2024 Jan 12:S0264-410X(23)01541-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  109. KNIJFF M, van Lier A, Boer M, de Vries M, et al
    Parental intention, attitudes, beliefs, trust and deliberation towards childhood vaccination in the Netherlands in 2022: Indications of change compared to 2013.
    Vaccine. 2024 Jan 11:S0264-410X(23)01539-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  110. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    Assessing the relationship between existing childhood, adolescent and adult immunization programmes and national COVID-19 vaccination capacities in 2021.
    Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  111. JOACHIM GE, Wagner AL, Naseem M, Boulton ML, et al
    Trends in childhood vaccination in Pakistan and associated factors; 2006-2018.
    Vaccine. 2024 Jan 10:S0264-410X(24)00015-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  112. SHARP M, Lozano P, Southworth A, Peters A, et al
    Mixed methods approach to understanding COVID-19 vaccine hesitancy among immigrants in the Chicago.
    Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  113. LIN HH, Wu YS, Chang MT, Shyur LF, et al
    Plant-derived galactolipids enhance specific antibody production and induce class-switch as vaccine adjuvant.
    Vaccine. 2024 Jan 9:S0264-410X(24)00002-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  114. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  115. MULLER MP, Navarro C, Wilson SE, Shulha HP, et al
    Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Vaccine. 2024 Jan 9:S0264-410X(23)01514-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  116. OKUMOTO A, Nomura Y, Okuda S, Shikano M, et al
    Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process.
    Vaccine. 2024 Jan 9:S0264-410X(23)01504-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  117. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  118. CARROLL JC, Herbert SMC, Nguyen TQ, Schork CJ, et al
    Vaccination equity and the role of community pharmacy in the United States: A qualitative study.
    Vaccine. 2024 Jan 8:S0264-410X(23)01509-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  119. ROZENBAUM MH, Huang L, Perdrizet J, Cane A, et al
    Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Vaccine. 2024 Jan 7:S0264-410X(23)01503-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  120. COSTA M, Mansilla F, Manuel Sala J, Saravia A, et al
    Fasciola hepatica infection modifies IgG1 specific immune response to foot-and-mouse disease virus induced by vaccination.
    Vaccine. 2024 Jan 6:S0264-410X(23)01513-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  121. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  122. DOBROVOLSKIENE N, Balevicius R, Mlynska A, Zilionyte K, et al
    Immunomodulatory properties of bacteriophage derived dsRNA of different size and their use as anticancer vaccine adjuvants.
    Vaccine. 2024 Jan 5:S0264-410X(23)01518-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  123. STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
    Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
    Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  124. REIS JN, Azevedo J, de Oliveira AML, Menezes APO, et al
    Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Vaccine. 2024 Jan 5:S0264-410X(23)01501-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  125. ENYINNAYA JC, Anderson AA, Kelp NC, Long M, et al
    The Social Ecology of Health Beliefs and Misinformation Framework: Examining the impact of misinformation on vaccine uptake through individual and sociological factors.
    Vaccine. 2024 Jan 5:S0264-410X(24)00001-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  126. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  127. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  128. ALVAREZ CA, Hall RG 2nd, Lin S, Perkins AR, et al
    Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population.
    Vaccine. 2024 Jan 3:S0264-410X(23)01532-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  129. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  130. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  131. YAEGASHI M, Matsui H, Yoshida A, Ban H, et al
    A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Vaccine. 2024 Jan 2:S0264-410X(23)01540-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  132. HUSSEIN I, Vanska S, Sivela J, Leino T, et al
    Factors associated with parental Human Papillomavirus (HPV) vaccination intention of daughter: A national survey in Finland.
    Vaccine. 2024 Jan 2:S0264-410X(23)01473-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  133. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  134. DE PINHO RB, Barbosa TN, Dall'Agno L, da Rocha Fonseca B, et al
    Mycobacterium bovis BCG expressing the proteins CP40 or CP09720 of Corynebacterium pseudotuberculosis promotes protection in mice after challenge.
    Vaccine. 2024;42:33-39.
    PubMed     Abstract available


  135. VASHI MD, Watkins M
    Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    PubMed     Abstract available


    December 2023
  136. ZOLA MATUVANGA T, Lariviere Y, Lemey G, Isekah Osang'ir B, et al
    Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo.
    Vaccine. 2023 Dec 31:S0264-410X(23)01530-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  137. ROMANO IG, Core SB, Lee NR, Mowry C, et al
    A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood.
    Vaccine. 2023 Dec 29:S0264-410X(23)01533-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  138. TO A, Wong TAS, Ball AH, Lieberman MM, et al
    Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.
    Vaccine. 2023 Dec 28:S0264-410X(23)01499-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  139. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  140. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  141. OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al
    Development of COVID-19 vaccine policy - United States, 2020-2023.
    Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  142. SURTEES TC, Granade CJ, Wells C, Banks M, et al
    CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.
    Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  143. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  144. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  145. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  146. MIRANDA MCR, Nunes CM, Santos LF, da Silva LB, et al
    Ordered mesoporous silicas for potential applications in solid vaccine formulations.
    Vaccine. 2023 Dec 24:S0264-410X(23)01478-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  147. SEESKIN ZH, Ganesh N, Maitra P, Herman P, et al
    Estimating county-level vaccination coverage using small area estimation with the National Immunization Survey-Child.
    Vaccine. 2023 Dec 23:S0264-410X(23)01492-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  148. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  149. MAHMOOD S, Skinner P, Warren CJ, Mayers J, et al
    In vivo challenge studies on vaccinated chickens indicate a virus genotype mismatched vaccine still offers significant protection against NDV.
    Vaccine. 2023 Dec 23:S0264-410X(23)01483-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  150. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  151. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  152. LANGLEY JM, Gantt S, Halperin SA, Ward B, et al
    An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2023 Dec 22:S0264-410X(23)01452-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  153. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  154. LEVITAN B, Hadler SC, Hurst W, Izurieta HS, et al
    The Brighton collaboration standardized module for vaccine benefit-risk assessment.
    Vaccine. 2023 Dec 21:S0264-410X(23)01109-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  155. JORDAN Z, Rowland E
    Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review.
    Vaccine. 2023 Dec 20:S0264-410X(23)01491-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  156. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  157. LINK-GELLES R, Britton A, Fleming-Dutra KE
    Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
    Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  158. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  159. STUMPF J, Anders L, Siepmann T, Schwobel J, et al
    9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  160. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  161. PILIOU S, Farman TA, Marini A, Manoharan S, et al
    Commensal Neisseria cinerea outer membrane vesicles as a platform for the delivery of meningococcal and gonococcal antigens to the immune system.
    Vaccine. 2023;41:7671-7681.
    PubMed     Abstract available


  162. DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
    Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  163. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  164. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  165. ZHAN XY, Chen Y, Zhang X, Shi Q, et al
    Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
    Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  166. BAJRACHARYA D, Jansen RJ
    Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
    Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  167. JIANG W, Lu C, Yan X, Tucker JD, et al
    Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  168. BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
    Examining vaccine hesitancy among a diverse sample of Canadian adults.
    Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  169. DONG C, Ma Y, Zhu W, Wang Y, et al
    Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
    Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  170. FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
    Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
    Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  171. CAO Z, Yu R, Yuan Q, Ji W, et al
    Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
    Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  172. SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al
    Monitoring and reporting the US COVID-19 vaccination effort.
    Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  173. LYU Y, Choong A, Chow EPF, Seib KL, et al
    Vaccine value profile for Neisseria gonorrhoeae.
    Vaccine. 2023 Dec 13:S0264-410X(23)00086-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  174. O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
    The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
    Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  175. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
    An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  176. YAMADA N, Nakatsuka K, Tezuka M, Murata F, et al
    Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study.
    Vaccine. 2023 Dec 11:S0264-410X(23)01442-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  177. YANG X, Shi N, Liu C, Zhang J, et al
    Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies.
    Vaccine. 2023 Dec 11:S0264-410X(23)01397-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  178. LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
    Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
    Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  179. LO VECCHIO A, Scarano SM, Palladino R, Del Bene M, et al
    Co-administration with Men-B vaccine increases Rotavirus vaccination coverage: A 5-year regionwide retrospective cohort study (STORM study).
    Vaccine. 2023 Dec 9:S0264-410X(23)01436-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  180. SKIRROW H, Foley K, Bedford H, Lewis C, et al
    Impact of pregnancy vaccine uptake and socio-demographic determinants on subsequent childhood Measles, Mumps and Rubella vaccine uptake: A UK birth cohort study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01431-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  181. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  182. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
    Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  183. BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al
    The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01420-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  184. JONGEN VW, Groot Bruinderink ML, Boyd A, Koole JCD, et al
    What determines mpox vaccination uptake? Assessing the effect of intent-to-vaccinate versus other determinants among men who have sex with men.
    Vaccine. 2023 Dec 9:S0264-410X(23)01449-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  185. SUI Y, Andersen H, Li J, Hoang T, et al
    SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
    Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  186. DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
    Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  187. MALAKER R, Hasanuzzaman M, Hooda Y, Rahman H, et al
    Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
    Vaccine. 2023 Dec 8:S0264-410X(23)01440-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  188. LI J, Ding J, Chen K, Xu X, et al
    Protective effects of a novel chimeric virus-like particle vaccine against virulent NDV and IBDV challenge.
    Vaccine. 2023 Dec 8:S0264-410X(23)01430-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  189. CHENG DR, Reimer H, Le D, Crawford NW, et al
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    PubMed     Abstract available


  190. REEF SE, Icenogle JP, Plotkin SA
    The path to eradication of rubella.
    Vaccine. 2023;41:7525-7531.
    PubMed     Abstract available


  191. LESCOP J, Pennes B, Epaulard O
    Mind the gap: Concordance between perceptions regarding vaccination as declared by patients and their evaluation by their general practitioner.
    Vaccine. 2023 Dec 7:S0264-410X(23)01433-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  192. YU Y, Zhang X, Lau MMC, Lau JTF, et al
    The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
    Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  193. GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
    Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
    Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  194. CHOKEPHAIBULKIT K, Puthanakit T, Chaithongwongwatthana S, Bhat N, et al
    Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
    Vaccine. 2023 Dec 6:S0264-410X(23)01386-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  195. HUANG L, Chen Z, Song Y, Tan J, et al
    Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01212-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  196. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  197. ENUL H, Uzar S, Satir E, Sarac F, et al
    Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirkoy strain sheep pox vaccine under field conditions.
    Vaccine. 2023 Dec 5:S0264-410X(23)01388-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  198. CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
    The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  199. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  200. SATO S, Katsuta T, Kawazoe Y, Takahashi M, et al
    Immune thrombocytopenic purpura and Guillain-Barre syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Vaccine. 2023 Dec 2:S0264-410X(23)01399-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  201. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
    Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  202. JENNINGS MC, Sauer M, Manchester C, Soeters HM, et al
    Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries.
    Vaccine. 2023 Dec 1:S0264-410X(23)01379-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    November 2023
  203. BAQAR S, Bonavia A, Louis Bourgeois A, Campo JJ, et al
    The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
    Vaccine. 2023 Nov 29:S0264-410X(23)01391-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  204. BANERJEE S, Barry EM, Baqar S, Louis Bourgeois A, et al
    The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations.
    Vaccine. 2023 Nov 28:S0264-410X(23)01364-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  205. WANG Y, Hu Y, Ma Y, Li P, et al
    RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
    Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  206. NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
    Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
    Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  207. TANAKA T, Kakiuchi S, Tashiro M, Fujita A, et al
    Adherence to recommended vaccination policies for pre- and post-solid organ transplantation patients: A national questionnaire survey in Japan.
    Vaccine. 2023 Nov 24:S0264-410X(23)01377-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  208. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  209. DUCASA N, Benencio P, Mauro E, Anders M, et al
    Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  210. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
    Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  211. SOWE A, Namatovu F, Cham B, Gustafsson PE, et al
    Missed opportunities for vaccination at point of care and their impact on coverage and urban-rural coverage inequity in the Gambia.
    Vaccine. 2023 Nov 22:S0264-410X(23)01385-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  212. WANG B, McDonough J, Chen G, Ong JJ, et al
    Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  213. NEELY SR, Hao F
    Breakthrough COVID-19 infections and perceived vaccine effectiveness.
    Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  214. ECONOMIDOU EC, Soteriades ES
    Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  215. KAUR R, Gonzalez E, Pham M, Pichichero M, et al
    Naturally-induced serum antibody levels in children to pneumococcal polysaccharide 15B that correlate with protection from nasopharyngeal colonization but anti-serotype 15B antibody has low functional cross-reactivity with serotype 15C.
    Vaccine. 2023;41:7265-7273.
    PubMed     Abstract available


  216. NEUHANN JM, Stemler J, Carcas AJ, Frias-Iniesta J, et al
    Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults >/=75 years (EU-COVAT-1).
    Vaccine. 2023;41:7166-7175.
    PubMed     Abstract available


  217. LARIVIERE Y, Matuvanga TZ, Lemey G, Osang'ir BI, et al
    Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  218. LAW AW, Judy J, Atwell JE, Willis S, et al
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  219. NAUGLE D, Tibbels N, Dosso A, Benie W, et al
    "I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  220. MAN-LIK CHOI E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, et al
    Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in
    Vaccine. 2023 Nov 17:S0264-410X(23)01257-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  221. SHRESTHA AC, Field E, Rajmokan M, Lambert SB, et al
    Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia.
    Vaccine. 2023 Nov 16:S0264-410X(23)01327-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  222. CHANDPA HH, Panda AK, Meena CL, Meena J, et al
    Beyond the polysaccharide and glycoconjugate vaccines for Streptococcus pneumoniae: Does protein/peptide nanovaccines hold promises?
    Vaccine. 2023 Nov 16:S0264-410X(23)01332-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  223. YU Z, Keskinocak P, Orenstein WA, Toktay LB, et al
    A mixed integer programming model for vaccine pricing within a group purchasing organization.
    Vaccine. 2023 Nov 15:S0264-410X(23)01223-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  224. ANRAAD C, van Empelen P, Ruiter RAC, van Keulen H, et al
    Effects of an online tailored decision aid to promote informed decision making about maternal pertussis vaccination in the Netherlands: A randomized controlled trial.
    Vaccine. 2023 Nov 15:S0264-410X(23)01281-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  225. CHRISTENSEN S, Bouguermouh S, Ilangovan K, Pride MW, et al
    A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
    Vaccine. 2023 Nov 15:S0264-410X(23)01296-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  226. HAEDER SF
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  227. CHOI Y, Park S, Lee J, Kim Y, et al
    Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  228. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  229. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  230. CHOE S, Park GN, Kim KS, Shin J, et al
    Efficacy of an orally administered classical swine fever live marker vaccine (Flc-LOM-BE(rns) strain) in pigs.
    Vaccine. 2023 Nov 14:S0264-410X(23)01286-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  231. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  232. GUBERNOT D, Menis M, Whitaker B
    Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
    Vaccine. 2023;41:6922-6929.
    PubMed     Abstract available


  233. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  234. JIANG X, Wang J, Li C, Yeoh EK, et al
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  235. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
    "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  236. LIU YY, Xu YQ, Zhong Y, Wei F, et al
    Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01329-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  237. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  238. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  239. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  240. ANDERSON EC, Blair PS, Finn A, Ingram J, et al
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  241. WIDDERSHOVEN V, Reijs RP, Eskes A, Verhaegh-Haasnoot A, et al
    Maternal pertussis vaccination behavior: Psychosocial, attitudinal and organizational factors.
    Vaccine. 2023 Nov 9:S0264-410X(23)01325-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  242. TECHAKRIENGKRAI N, Aryuman S, Vanlarat K, Karnchanapraphas C, et al
    Impacts of shelter management on canine rabies immune status.
    Vaccine. 2023 Nov 9:S0264-410X(23)01330-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  243. YANG C, Zheng Z, Zheng P, Chen J, et al
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  244. TSAI SA, Lu CY, Chen TI, Huang SP, et al
    Adverse events from HPV vaccination in Taiwan.
    Vaccine. 2023 Nov 8:S0264-410X(23)01321-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  245. TAMIR TT, Kassie AT, Zegeye AF
    Prevalence and determinants of two or more doses of tetanus toxoid-containing vaccine immunization among pregnant women in sub-Saharan Africa: Evidence from recent demographic and health survey data.
    Vaccine. 2023 Nov 8:S0264-410X(23)01305-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  246. MVUNDURA M, Slavkovsky R, Debellut F, Naddumba T, et al
    Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Vaccine. 2023 Nov 8:S0264-410X(23)01306-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  247. GSELL PS, Giersing B, Gottlieb S, Wilder-Smith A, et al
    Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report.
    Vaccine. 2023 Nov 8:S0264-410X(23)01210-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  248. COOPER LV, Stuart JM, Okot C, Asiedu-Bekoe F, et al
    Corrigendum to "Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana" [Vaccine 37(37) (2019) 5657-5663].
    Vaccine. 2023 Nov 7:S0264-410X(23)01293-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  249. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  250. HAEDER SF
    Assessing vaccine hesitancy and support for vaccination requirements for pets and potential Spillovers from humans.
    Vaccine. 2023 Nov 5:S0264-410X(23)01263-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  251. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  252. JONES G, Perry M, Bailey R, Arumugam S, et al
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  253. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
    Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  254. KHALIL I, Anderson JD, Bagamian KH, Baqar S, et al
    Vaccine value profile for enterotoxigenic Escherichia coli (ETEC).
    Vaccine. 2023;41 Suppl 2:S95-S113.
    PubMed     Abstract available


  255. TROTTER CL, Alderson M, Dangor Z, Ip M, et al
    Vaccine value profile for Group B streptococcus.
    Vaccine. 2023;41 Suppl 2:S41-S52.
    PubMed     Abstract available


  256. KAYE PM, Matlashewski G, Mohan S, Le Rutte E, et al
    Vaccine value profile for leishmaniasis.
    Vaccine. 2023;41 Suppl 2:S153-S175.
    PubMed     Abstract available


  257. ARMAH G, Lopman BA, Vinje J, O'Ryan M, et al
    Vaccine value profile for norovirus.
    Vaccine. 2023;41 Suppl 2:S134-S152.
    PubMed     Abstract available


  258. MARTIN LB, Khanam F, Qadri F, Khalil I, et al
    Vaccine value profile for Salmonella enterica serovar Paratyphi A.
    Vaccine. 2023;41 Suppl 2:S114-S133.
    PubMed     Abstract available


  259. HOLDER T, Coad M, Allan G, Hogarth PJ, et al
    Vaccination of calves with Bacillus Calmette-Guerin Danish strain 1331 results in a duration of immunity of at least 52 weeks.
    Vaccine. 2023 Nov 2:S0264-410X(23)01262-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  260. CHEN GL, Yu XY, Luo LP, Zhang F, et al
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  261. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
    Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  262. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


  263. GREYSON D, Goh G
    Education components of school vaccine mandates: An environmental scan.
    Vaccine. 2023 Nov 1:S0264-410X(23)01155-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  264. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
    In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    October 2023
  265. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  266. RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
    A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  267. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  268. TANI N, Ikematsu H, Goto T, Kondo S, et al
    Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Vaccine. 2023;41:6672-6678.
    PubMed     Abstract available


  269. STEFANIZZI P, Di Lorenzo A, Martinelli A, Moscara L, et al
    Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
    Vaccine. 2023 Oct 26:S0264-410X(23)01158-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  270. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  271. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
    "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  272. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  273. BURNETT E, Riaz A, Anwari P, Myat TW, et al
    Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation.
    Vaccine. 2023 Oct 24:S0264-410X(23)01225-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  274. TRICOU V, Winkle PJ, Tharenos LM, Rauscher M, et al
    Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
    Vaccine. 2023 Oct 24:S0264-410X(23)01132-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  275. FLOR N, Garcia MI, Molineri A, Bottasso O, et al
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  276. KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
    Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  277. SHARIF H, Ghani H, Ahmad L, Bagol S, et al
    Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
    Vaccine. 2023 Oct 23:S0264-410X(23)01227-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  278. DI GIUSEPPE G, Pelullo CP, Napoli A, Napolitano F, et al
    Willingness to receive Herpes Zoster vaccination among adults and older people: A cross sectional study in Italy.
    Vaccine. 2023 Oct 23:S0264-410X(23)01247-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  279. LOONEY MM, Hatherill M, Musvosvi M, Flynn J, et al
    Conference report: WHO meeting report on mRNA-based tuberculosis vaccine development.
    Vaccine. 2023 Oct 21:S0264-410X(23)01209-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  280. BRESEE J, Koh M, Chadwick C, Jit M, et al
    The need and ongoing efforts to understand the full value of improved influenza vaccines.
    Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  281. TERADA M, Shimazu T, Saito J, Odawara M, et al
    Age, gender and socioeconomic disparities in human papillomavirus (HPV) awareness and knowledge among Japanese adults after a 7-year suspension of proactive recommendation for the HPV vaccine: A nationally representative cross-sectional survey.
    Vaccine. 2023 Oct 20:S0264-410X(23)01207-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  282. MORI Y, Uchida N, Wake A, Miyawaki K, et al
    Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  283. WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
    Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
    Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  284. PUTRI WCWS, Sawitri AAS, Yuliyatni PCD, Ariawan IMD, et al
    Cost-effectiveness analysis of Japanese Encephalitis (JE) vaccination program in Bali Province, Indonesia.
    Vaccine. 2023 Oct 20:S0264-410X(23)01177-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  285. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  286. VERMA N, Gupta P, Pandey AK, Awasthi S, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among sick and healthy children in northern India: A case-control study.
    Vaccine. 2023;41:6619-6624.
    PubMed     Abstract available


  287. HONGTU Q, BoLi L, Jianguo C, Shusheng P, et al
    Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.
    Vaccine. 2023 Oct 20:S0264-410X(23)01191-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  288. HART R, Feygin Y, Kluthe T, Quinn KG, et al
    Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
    Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  289. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  290. PUCHNER KP, Bottazzi ME, Periago V, Grobusch M, et al
    Vaccine value profile for Hookworm.
    Vaccine. 2023 Oct 18:S0264-410X(23)00540-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  291. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Corrigendum to "Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants" [Vaccine 41(11) (2023) 1892-1901].
    Vaccine. 2023 Oct 18:S0264-410X(23)01216-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  292. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  293. RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
    Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
    Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  294. ANGULO FJ, Zhang P, Halsby K, Kelly P, et al
    A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe.
    Vaccine. 2023 Oct 17:S0264-410X(23)01184-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  295. CHOPRA A, Rodriguez A, Prakash A, Raskar R, et al
    Using neural networks to calibrate agent based models enables improved regional evidence for vaccine strategy and policy.
    Vaccine. 2023 Oct 17:S0264-410X(23)01016-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  296. HAEDER SF
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  297. YANG H, Wang Z, Zhang Y, Xu M, et al
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  298. PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
    Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
    Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  299. WRIGHT J, Science M, Osman S, Arnold C, et al
    Uptake of pertussis immunization in pregnancy and determinants of vaccination in Toronto, Canada.
    Vaccine. 2023 Oct 14:S0264-410X(23)01192-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  300. MUKASA K, Sugawara T, Okutomi Y
    Susceptibility of nursery teachers to measles, rubella, varicella and mumps in Japan.
    Vaccine. 2023;41:6530-6534.
    PubMed     Abstract available


  301. ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
    Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
    Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  302. MOSCA S, Lin Q, Stokes R, Bharucha T, et al
    Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
    Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  303. VAN EWIJK CE, Smit C, Bavalia R, Ainslie K, et al
    Acceptance and timeliness of post-exposure vaccination against mpox in high-risk contacts, Amsterdam, the Netherlands, May-July 2022.
    Vaccine. 2023 Oct 12:S0264-410X(23)01183-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  304. SUKWA N, Mubanga C, Hatyoka LM, Chilyabanyama ON, et al
    Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX(R)) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
    Vaccine. 2023 Oct 12:S0264-410X(23)01138-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  305. RODRIGUEZ VJ, Kozlova S, LaBarrie DL, Liu Q, et al
    Parental anxiety and pediatric vaccine refusal in a US national sample of parents.
    Vaccine. 2023 Oct 11:S0264-410X(23)01187-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  306. NAND KN, Jordan TB, Yuan X, Basore DA, et al
    Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle.
    Vaccine. 2023 Oct 11:S0264-410X(23)01114-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  307. HAUSDORFF WP, Anderson JD 4th, Bagamian KH, Bourgeois AL, et al
    Vaccine value profile for Shigella.
    Vaccine. 2023 Oct 10:S0264-410X(22)01562-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  308. AYDIN I, May M, Pisano F, Mpofu-Maetzig N, et al
    Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study
    Vaccine. 2023 Oct 10:S0264-410X(23)01157-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  309. YAO X, Peng J, Ma Y, Fu M, et al
    Development of a vaccine hesitancy scale for childhood immunization in China.
    Vaccine. 2023 Oct 9:S0264-410X(23)01154-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  310. YU P, Liu Y, Tao X, He Y, et al
    Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains.
    Vaccine. 2023 Oct 9:S0264-410X(23)01161-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  311. PARK H, Jang MS, Choi JA, Kim W, et al
    Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
    Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  312. CHECCHI M, Mesher D, Panwar K, Anderson A, et al
    The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Vaccine. 2023 Oct 9:S0264-410X(23)01162-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  313. MO C, Li X, Wu Q, Fan Y, et al
    SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
    Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  314. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  315. FEBRIANI Y, Mansour T, Sadarangani M, Ulanova M, et al
    Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?
    Vaccine. 2023 Oct 8:S0264-410X(23)01160-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  316. BOPPANA SB, van Boven M, Britt WJ, Gantt S, et al
    Vaccine value profile for cytomegalovirus.
    Vaccine. 2023 Oct 6:S0264-410X(23)00670-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  317. PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al
    Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  318. LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
    Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
    Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  319. PAPACHRISTIDOU S, Lapea V, Charisi M, Kourkouni E, et al
    A multicenter study on the epidemiology of complicated parapneumonic effusion in the era of currently available pneumococcal conjugate vaccines.
    Vaccine. 2023 Oct 5:S0264-410X(23)01164-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  320. CAVIT L, Charania NA
    Exploring factors that influence vaccination uptake for children with refugee backgrounds: An interpretive description study of primary healthcare providers' perspectives.
    Vaccine. 2023 Oct 4:S0264-410X(23)01141-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  321. OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
    How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
    Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  322. BEERENS D, Poland GA
    Latest developments in vaccine research: Selected papers from the 16th annual vaccine congress.
    Vaccine. 2023 Oct 3:S0264-410X(23)01153-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  323. KANEVSKY I, Surendran N, McElwee K, Lei L, et al
    Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Vaccine. 2023 Oct 3:S0264-410X(23)01113-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  324. ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
    Individual variation in vaccine immune response can produce bimodal distributions of protection.
    Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    September 2023
  325. OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
    Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
    Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  326. OVSYANNIKOVA IG, Haralambieva IH, Schaid DJ, Warner ND, et al
    Genome-wide determinants of cellular immune responses to mumps vaccine.
    Vaccine. 2023 Sep 29:S0264-410X(23)01055-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  327. MIAO X, Zhang L, Zhou P, Yu R, et al
    Adenovirus-vectored PDCoV vaccines induce potent humoral and cellular immune responses in mice.
    Vaccine. 2023 Sep 29:S0264-410X(23)01139-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  328. DE COUVREUR LA, Cobo MJ, Kennedy PJ, Ellis JT, et al
    Bibliometric analysis of parasite vaccine research from 1990 to 2019.
    Vaccine. 2023 Sep 28:S0264-410X(23)01105-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  329. KOCHHAR S, Okomo U, Nkereuwem O, Shaum A, et al
    Establishing vaccine pregnancy registries and active surveillance studies in low-and middle-income countries: Experience from an observational cohort surveillance project in The Gambia.
    Vaccine. 2023 Sep 28:S0264-410X(23)01111-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  330. DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
    "The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
    Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  331. TSIRIGOTAKI M, Galanakis E
    Impact of vaccines on Staphylococcus aureus colonization: A systematic review and meta-analysis.
    Vaccine. 2023 Sep 28:S0264-410X(23)01104-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  332. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023 Sep 28:S0264-410X(23)00623-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  333. HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
    Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
    Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  334. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  335. SHEN X, Hao Y, Wang S, Li D, et al
    Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  336. CASSARINO N, Ahnger-Pier KK, Wurcel A
    Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
    Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  337. SANA S, Merkelbach I, Magnee T, Kollmann J, et al
    Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
    Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  338. GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
    Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
    Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  339. SALO H, Perala J, Hannila-Handelberg T, Sarvikivi E, et al
    Decline in varicella cases contacting primary health care after introduction of varicella vaccination in Finland - A population-based register study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01094-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  340. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023 Sep 22:S0264-410X(23)01053-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  341. NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
    Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  342. RAISER F, Davis M, Adelglass J, Cai MR, et al
    Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Vaccine. 2023;41:5965-5973.
    PubMed     Abstract available


  343. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  344. FU Y, Wu K, Wang Z, Yang H, et al
    Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  345. KIM DR, You YA, Ahn HS, Park EL, et al
    Statistical considerations on real time and extended controlled temperature conditions (ECTC) stability data analysis of vaccines.
    Vaccine. 2023 Sep 21:S0264-410X(23)00944-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  346. WILKINSON B, Patel KS, Smith K, Walker R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
    Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  347. DEPEW CE, McSorley SJ
    The role of tissue resident memory CD4 T cells in Salmonella infection: Implications for future vaccines.
    Vaccine. 2023 Sep 20:S0264-410X(23)01066-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  348. ALHARBI HS
    Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
    Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  349. SCHMITZ KS, Comvalius AD, Nieuwkoop NJ, Geers D, et al
    A measles virus-based vaccine induces robust chikungunya virus-specific CD4(+) T-cell responses in a phase II clinical trial.
    Vaccine. 2023 Sep 17:S0264-410X(23)01092-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  350. HAN C, Zhao ZZ, Chan P, Li F, et al
    A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  351. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  352. WANG Y, Ji W, Li D, Sun T, et al
    Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection.
    Vaccine. 2023 Sep 15:S0264-410X(23)01049-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  353. SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
    Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
    Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  354. IRALA S, Hamid S, Penayo E, Michel F, et al
    COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.
    Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  355. SALAT J, Hunady M, Svoboda P, Strelcova L, et al
    Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs.
    Vaccine. 2023 Sep 14:S0264-410X(23)01089-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  356. REID MC, Mittler JE, Murphy JT, Stansfield SE, et al
    Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study.
    Vaccine. 2023 Sep 13:S0264-410X(23)01027-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  357. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023 Sep 12:S0264-410X(23)00946-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  358. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023 Sep 11:S0264-410X(23)01051-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  359. REUSCHENBACH M, Doorbar J, Del Pino M, Joura EA, et al
    Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer.
    Vaccine. 2023 Sep 11:S0264-410X(23)00990-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  360. SU F, Xue Y, Ye S, Yu B, et al
    Integrative transcriptomic and metabolomic analysis in mice reveals the mechanism by which ginseng stem-leaf saponins enhance mucosal immunity induced by a porcine epidemic diarrhea virus vaccination.
    Vaccine. 2023 Sep 11:S0264-410X(23)01085-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  361. SURYAWANSHI YR
    An overview of protein-based SARS-CoV-2 vaccines.
    Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  362. ROY VL, Majumder PP
    Genomic associations with antibody response to an oral cholera vaccine.
    Vaccine. 2023 Sep 10:S0264-410X(23)01084-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  363. FULLER HR, Huseth-Zosel A, Vleet BV, Hajdar M, et al
    Vaccine attitudes and acceptance among older adults in North Dakota: Understanding demographic characteristic variability.
    Vaccine. 2023 Sep 9:S0264-410X(23)01059-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  364. POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
    Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
    Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  365. MCCARTY JM, Bedell L, Mendy J, Coates EE, et al
    Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
    Vaccine. 2023 Sep 8:S0264-410X(23)01052-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  366. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  367. PANDEY MK, Rajukumar K, Senthilkumar D, Kombiah S, et al
    Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate.
    Vaccine. 2023 Sep 7:S0264-410X(23)01047-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  368. MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
    Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Vaccine. 2023;41:5742-5751.
    PubMed     Abstract available


  369. LI P, Jia WY, Zhang X, Wang DB, et al
    Effect of enterovirus 71 vaccine on epidemiological characteristics of hand, foot and mouth disease: An 8-year retrospective intermittent time series analysis.
    Vaccine. 2023 Sep 6:S0264-410X(23)01061-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  370. CHILDS K, Harvey Y, Waters R, Woma T, et al
    Development of a quadrivalent foot-and-mouth disease vaccine candidate for use in East Africa.
    Vaccine. 2023 Sep 5:S0264-410X(23)01054-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  371. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  372. YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
    When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
    Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  373. TIEU HV, Karuna S, Huang Y, Sobieszczyk ME, et al
    Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Vaccine. 2023 Sep 5:S0264-410X(23)00877-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  374. PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
    Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  375. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023 Sep 4:S0264-410X(23)01018-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  376. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023 Sep 4:S0264-410X(23)01040-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  377. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  378. CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
    Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
    Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  379. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  380. ZHOU G, Ma Q, Li Q, Wang S, et al
    The disruption of LPS in Salmonella Typhimurium provides partial protection against Salmonella Choleraesuis as a live attenuated vaccine.
    Vaccine. 2023 Sep 2:S0264-410X(23)01044-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  381. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
    Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  382. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  383. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023 Sep 1:S0264-410X(23)00954-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  384. SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
    Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness.
    Vaccine. 2023 Sep 1:S0264-410X(23)00989-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  385. PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
    Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
    Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  386. PALMER M, Katanoda K, Saito E, Acuti Martellucci C, et al
    Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" [Vaccine 40(41) (2022) 5971-5996].
    Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


    August 2023
  387. FLOOD T, McLaughlin M, Hughes CM, Wilson IM, et al
    Applying the COM-B behaviour model to understand factors which impact school immunisation nurses' attitudes towards designing and delivering a HPV educational intervention in post-primary schools for 15-17 year old students in Northern Ireland, UK.
    Vaccine. 2023;41:5630-5639.
    PubMed     Abstract available


  388. GRILLS LA, Wagner AL
    The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
    Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  389. SAKALA IG, Honda-Okubo Y, Petrovsky N
    Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
    Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  390. DUDLEY HM, O'Mara M, Auma A, Gong J, et al
    Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
    Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  391. REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
    Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
    Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  392. KRISHNA SUSARLA S, Jahagirdar R, Ghosh Uttam K, Srikanth Bhatt S, et al
    Immunogenicity and safety of Mebella vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.
    Vaccine. 2023 Aug 31:S0264-410X(23)01021-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  393. SNIDER CJ, Zaman K, Wilkinson AL, Binte Aziz A, et al
    Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
    Vaccine. 2023 Aug 29:S0264-410X(23)01009-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  394. PUNCHHI G, Negus R, Saif H, Pritchard S, et al
    Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT.
    Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  395. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023 Aug 29:S0264-410X(23)01019-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  396. YI EJ, Kim YI, Song JH, Ko HJ, et al
    Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.
    Vaccine. 2023 Aug 28:S0264-410X(23)00961-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  397. HACKER E, Baker B, Lake T, Ross C, et al
    Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.
    Vaccine. 2023 Aug 27:S0264-410X(23)00959-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  398. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
    Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  399. NYGARD S, Nygard M, Orumaa M, Hansen BT, et al
    Erratum to "Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals" [Vaccine 41(37) (2023) 5469-5476].
    Vaccine. 2023 Aug 26:S0264-410X(23)01010-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  400. UGAI S, Ugai T, Kanayama T, Kamiya H, et al
    Mumps vaccine hesitancy: Current evidence and an evidence-based campaign in Japan.
    Vaccine. 2023 Aug 26:S0264-410X(23)00976-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  401. YANG J, Li B, Yang D, Wu J, et al
    The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  402. MOTTA M, Motta G, Stecula D
    Sick as a dog? The prevalence, politicization, and health policy consequences of canine vaccine hesitancy (CVH).
    Vaccine. 2023 Aug 26:S0264-410X(23)01015-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  403. JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
    The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
    Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  404. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  405. CHEUVART B, Callegaro A, Rosillon D, Meyer N, et al
    Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing.
    Vaccine. 2023 Aug 25:S0264-410X(23)00888-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  406. CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
    Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
    Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  407. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  408. GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
    Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
    Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  409. MOHAMMED IS, Widome R, Searle KM
    COVID-19 vaccine decision-making among Black women: A qualitative study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  410. WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
    The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
    Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  411. STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
    Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
    Vaccine. 2023;41:5351-5359.
    PubMed     Abstract available


  412. TIAN J, Zheng B, Yang L, Guan Y, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study.
    Vaccine. 2023 Aug 23:S0264-410X(23)00973-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  413. HALDER P, Maiti S, Banerjee S, Das S, et al
    Bacterial ghost cell based bivalent candidate vaccine against Salmonella Typhi and Salmonella Paratyphi A: A prophylactic study in BALB/c mice.
    Vaccine. 2023 Aug 23:S0264-410X(23)00992-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  414. SHAPIRO JR, Andreani G, Dube C, Berube M, et al
    Development and characterization of a plant-derived norovirus-like particle vaccine.
    Vaccine. 2023 Aug 23:S0264-410X(23)00968-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  415. HOMAIRA N, Strachan R, Quinn H, Beggs S, et al
    Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91].
    Vaccine. 2023 Aug 23:S0264-410X(23)00870-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  416. KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al
    Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
    Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  417. MAKI Y, Edo N, Mizuguchi M, Ikeda M, et al
    Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen(R)) vaccination on antibody titers; a japanese cross-sectional study.
    Vaccine. 2023 Aug 22:S0264-410X(23)00962-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  418. YAO T, Guo Y, Xu X, Zhang X, et al
    Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
    Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  419. SU Y, Guo Z, Gu X, Sun S, et al
    Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
    Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  420. CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
    Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
    Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  421. ENUJIOKE SC, Shedd-Steele R, Daggy J, Burney HN, et al
    County-level correlates of completed HPV vaccination in Indiana.
    Vaccine. 2023 Aug 18:S0264-410X(23)00875-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  422. KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
    Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  423. MORRISON K, Cullen L, James AB, Chua V, et al
    Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  424. PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
    Lessons learned from the COVID-19 pandemic for improved influenza control.
    Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  425. DALE JB, Aranha MP, Penfound TA, Salehi S, et al
    Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine.
    Vaccine. 2023 Aug 16:S0264-410X(23)00958-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  426. ZUR M, Shelef L, Glassberg E, Fink N, et al
    Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
    Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  427. FILARDO TD, Prasad N, Waddell CJ, Persad N, et al
    Mpox vaccine acceptability among people experiencing homelessness in San Francisco - October-November 2022.
    Vaccine. 2023 Aug 15:S0264-410X(23)00914-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  428. REIFFERSCHEID L, Kiely MS, Lin MSN, Libon J, et al
    Effectiveness of hospital-based strategies for improving childhood immunization coverage: A systematic review.
    Vaccine. 2023;41:5233-5244.
    PubMed     Abstract available


  429. TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
    DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  430. WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
    Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  431. FRANCONERI L, Antona D, Cauchemez S, Levy-Bruhl D, et al
    Two-dose measles vaccine effectiveness remains high over time: A French observational study, 2017-2019.
    Vaccine. 2023 Aug 14:S0264-410X(23)00950-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  432. YIN MZ, Gu YY, Shu JT, Zhang B, et al
    Cost-effectiveness of cytomegalovirus vaccination for females in China: A decision-analytical Markov study.
    Vaccine. 2023 Aug 12:S0264-410X(23)00943-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  433. BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
    Parental acceptability of vaccinating young children against influenza and COVID-19.
    Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  434. MALIRAT V, Caldevilla C, Cardillo S, Espinoza AM, et al
    Broad immunogenic spectrum of monovalent and trivalent foot-and-mouth disease virus vaccines containing O(1) campos, A24 cruzeiro and A Argentina 2001 strains against circulating viral lineages in cattle and pigs.
    Vaccine. 2023 Aug 11:S0264-410X(23)00939-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  435. SUFFEL AM, Walker JL, Williamson E, McDonald HI, et al
    Timeliness of childhood vaccination in England: A population-based cohort study.
    Vaccine. 2023 Aug 11:S0264-410X(23)00926-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  436. BUMATAY S, Dickinson C, Larsen R, Stock I, et al
    A comparison of electronic health records and the Oregon state immunization registry for human papilloma virus vaccine delivery (2005-2022).
    Vaccine. 2023 Aug 10:S0264-410X(23)00949-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  437. EIFFERT SR, Sturmer T, Thorpe CT, Traub R, et al
    Vaccine patterns among patients diagnosed with Guillain-Barre Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020.
    Vaccine. 2023 Aug 10:S0264-410X(23)00947-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  438. CARDONA RSB, Weckx LY, de Moraes-Pinto MI, Ramos BCF, et al
    Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate: A cross-sectional serological study.
    Vaccine. 2023 Aug 10:S0264-410X(23)00940-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  439. HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
    An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
    Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  440. BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
    Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
    Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  441. WARIRI O, Utazi CE, Okomo U, Metcalf CJE, et al
    Mapping the timeliness of routine childhood vaccination in The Gambia: A spatial modelling study.
    Vaccine. 2023 Aug 8:S0264-410X(23)00928-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  442. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  443. KOCHHAR S, Izurieta HS, Chandler RE, Hacker A, et al
    Benefit-risk assessment of vaccines.
    Vaccine. 2023 Aug 8:S0264-410X(23)00872-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  444. PITTS PJ, Poland GA
    Trust and science: Public health's home field advantage in addressing vaccine hesitancy and improving immunization rates.
    Vaccine. 2023 Aug 6:S0264-410X(23)00927-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  445. VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
    Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
    Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  446. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  447. SIMMS AJ, King KD, Tsui N, Edwards SA, et al
    COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
    Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  448. IZULLA P, Wagai JN, Akelo V, Ombeva A, et al
    Vaccine safety surveillance in Kenya using GAIA standards: A feasibility assessment of existing national and subnational research and program systems.
    Vaccine. 2023 Aug 5:S0264-410X(23)00906-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  449. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  450. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  451. XU S, Yu H, Cheng X, Wu J, et al
    Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  452. GRANT LR, Slack MPE, Theilacker C, Vojicic J, et al
    Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Vaccine. 2023 Aug 4:S0264-410X(23)00925-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  453. AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
    Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  454. SINGER D, Salem A, Stempniewicz N, Ma S, et al
    The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Vaccine. 2023 Aug 2:S0264-410X(23)00837-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  455. CARTER A, Msemburi W, Sim SY, Gaythorpe KAM, et al
    Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030.
    Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  456. MO J, Spackman E, Swayne DE
    Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
    Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    July 2023
  457. AMAI M, Nojima M, Yuki Y, Kiyono H, et al
    A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials".
    Vaccine. 2023 Jul 31:S0264-410X(23)00918-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  458. GUNALE B, Farinola N, Yeolekar L, Shrivastava S, et al
    A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Vaccine. 2023 Jul 31:S0264-410X(23)00876-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  459. HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
    An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  460. WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
    A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  461. VAN WALSTIJN C, Verweij S, Care R, Rigsby P, et al
    Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines.
    Vaccine. 2023 Jul 30:S0264-410X(23)00885-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  462. LIU B, Stepien S, Qian J, Gidding H, et al
    Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
    Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  463. AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
    Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
    Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  464. DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al
    Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada.
    Vaccine. 2023 Jul 29:S0264-410X(23)00880-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  465. GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
    COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
    Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  466. LENTSCH V, Aslani S, Echtermann T, Preet S, et al
    "EvoVax" - A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs.
    Vaccine. 2023 Jul 28:S0264-410X(23)00890-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  467. KIM SY, Lee KM, Kim KH
    Differences between DNA vaccine and single-cycle viral vaccine in the ability of cross-protection against viral hemorrhagic septicemia virus (VHSV) and infectious hematopoietic necrosis virus (IHNV).
    Vaccine. 2023 Jul 28:S0264-410X(23)00889-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  468. PADENIYA TN, Hui BB, Wood JG, Seib KL, et al
    The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting.
    Vaccine. 2023 Jul 28:S0264-410X(23)00879-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  469. HAMAD SAIED M, van Straalen JW, de Roock S, de Joode-Smink GCJ, et al
    Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
    Vaccine. 2023 Jul 27:S0264-410X(23)00883-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  470. LAVENDER B, Hooker C, Frampton C, Williams M, et al
    Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
    Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  471. JIANG XY, Gong MQ, Zhang HJ, Peng AQ, et al
    The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial.
    Vaccine. 2023 Jul 27:S0264-410X(23)00878-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  472. NYGARD S, Nygard M, Orumaa M, Hansen BT, et al
    Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Vaccine. 2023 Jul 27:S0264-410X(23)00852-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  473. ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
    BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  474. KABIR A, Randall D, Newall AT, Moore HC, et al
    Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00873-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  475. KIM DH, Lee J, Youk S, Jeong JH, et al
    Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
    Vaccine. 2023;41:4787-4797.
    PubMed     Abstract available


  476. MARTINI M, Orsini D
    The ghost of polio haunts us once again. The appeal of the scientific community is clear: "Vaccinate your kids today!".
    Vaccine. 2023 Jul 24:S0264-410X(23)00850-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  477. TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
    Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
    Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  478. GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
    Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
    Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  479. ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
    Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
    Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  480. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  481. ORAMI T, Aho C, Ford RL, Pomat WS, et al
    Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
    Vaccine. 2023 Jul 19:S0264-410X(23)00838-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  482. CANTARERO D, Ocana D, Onieva-Garcia MA, Rodriguez-Garcia J, et al
    Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
    Vaccine. 2023 Jul 19:S0264-410X(23)00828-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  483. JESUDASON T, Rodarte A, Tordrup D, Carias C, et al
    Systematic review of rotavirus vaccination cost-effectiveness in high income settings utilising dynamic transmission modelling techniques.
    Vaccine. 2023 Jul 19:S0264-410X(23)00749-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  484. CLIMACO MC, de Figueiredo LA, Lucas RC, Pinheiro GRG, et al
    Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis.
    Vaccine. 2023 Jul 19:S0264-410X(23)00832-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  485. PISL V, Vevera J
    COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
    Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  486. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  487. VIETRI J, Sato R, Averin A, Weycker D, et al
    Pneumococcal vaccine uptake among Medicare Beneficiaries aged >/=65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019.
    Vaccine. 2023 Jul 18:S0264-410X(23)00855-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  488. ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
    Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
    Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  489. DAS SK, Khan J
    Timeliness in the uptake of hepatitis B birth dose among Indian children under age five: A population-based study.
    Vaccine. 2023 Jul 17:S0264-410X(23)00827-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  490. BATOOL R, Yousafzai MT, Qureshi S, Muhammad S, et al
    Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
    Vaccine. 2023 Jul 16:S0264-410X(23)00806-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  491. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  492. SCHAEFER GO, Emanuel EJ, Atuire CA, Leland RJ, et al
    Equitable global allocation of monkeypox vaccines.
    Vaccine. 2023 Jul 15:S0264-410X(23)00835-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  493. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  494. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  495. MYERS MG
    Beginning to address vaccine reluctance and refusal.
    Vaccine. 2023 Jul 14:S0264-410X(23)00851-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  496. GIERSING B, Karron R, Tufet-Bayona M, Trotter C, et al
    Vaccine Value profiles.
    Vaccine. 2023 Jul 14:S0264-410X(23)00786-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  497. TALOTTA R
    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  498. GLESER D, Spinner K, Klement E
    Effectiveness of the strain 919 bovine ephemeral fever virus vaccine in the face of a real-world outbreak: A field study in Israeli dairy herds.
    Vaccine. 2023 Jul 12:S0264-410X(23)00747-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  499. ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
    Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
    Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  500. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  501. YAMAGUCHI K, Shimizu H, Takahashi K, Nagatomo T, et al
    Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
    Vaccine. 2023;41:4497-4507.
    PubMed     Abstract available


  502. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  503. MIELLET WR, Pluister G, Sikking M, Tappel M, et al
    Surveillance of Neisseria meningitidis carriage four years after menACWY vaccine implementation in the Netherlands reveals decline in vaccine-type and rise in genogroup e circulation.
    Vaccine. 2023 Jul 7:S0264-410X(23)00781-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  504. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  505. FLEMING JA, Baral R, Higgins D, Khan S, et al
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  506. ZHANG X, Shen P, Liu J, Ji X, et al
    Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
    Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  507. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  508. LE H, de Klerk N, Blyth CC, Gidding H, et al
    Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
    Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  509. ROSHCHINA Y, Rozhkova K, Roshchin S
    Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  510. PATEL UC, Schultz T, Schmidt J
    Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
    Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  511. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  512. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  513. GRUZDEV N, Pitcovski J, Katz C, Ruimi N, et al
    Development of toxin-antitoxin self-destructive bacteria, aimed for salmonella vaccination.
    Vaccine. 2023 Jul 1:S0264-410X(23)00777-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  514. IZUMI F, Miyamoto S, Masatani T, Sasaki M, et al
    Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.
    Vaccine. 2023 Jul 1:S0264-410X(23)00779-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  515. KELLY M, Mandlik A, Charles RC, Verma S, et al
    Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.
    Vaccine. 2023 Jul 1:S0264-410X(23)00738-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    June 2023
  516. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  517. SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  518. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  519. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
    Vaccine. 2023;41:4212-4219.
    PubMed     Abstract available


  520. VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
    Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    Vaccine. 2023;41:4319-4326.
    PubMed     Abstract available


  521. ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
    One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
    Vaccine. 2023;41:4199-4205.
    PubMed     Abstract available


  522. LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
    Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  523. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  524. CARRERA JM, Aktepe TE, Earnest L, Christiansen D, et al
    Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00757-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  525. YUKI Y, Harada N, Sawada SI, Uchida Y, et al
    Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.
    Vaccine. 2023 Jun 27:S0264-410X(23)00754-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  526. DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
    Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
    Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  527. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  528. GONZALES BE, Mercado EH, Castillo-Tokumori F, Montero AE, et al
    Pneumococcal serotypes and antibiotic resistance in healthy carriage children after introduction of PCV13 in Lima, Peru.
    Vaccine. 2023;41:4106-4113.
    PubMed     Abstract available


  529. CARNEIRO GB, Castro JT, Davi M, Miyaji EN, et al
    Immune responses and protection against Streptococcus pneumoniae elicited by recombinant Bordetella pertussis adenylate cyclase (CyaA) carrying fragments of pneumococcal surface protein A, PspA.
    Vaccine. 2023;41:4170-4182.
    PubMed     Abstract available


  530. BAUER BU, Schwecht KM, Jahnke R, Matthiesen S, et al
    Humoral and cellular immune responses in sheep following administration of different doses of an inactivated phase I vaccine against Coxiella burnetii.
    Vaccine. 2023 Jun 23:S0264-410X(23)00746-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  531. DU J, Wang T, Xu L, Wang C, et al
    Clostridium perfringens epsilon prototoxin mutant rpETX(Y30A/Y71A/H106P/Y196A) as a vaccine candidate against enterotoxemia.
    Vaccine. 2023 Jun 23:S0264-410X(23)00719-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  532. HOWARD MC
    Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
    Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  533. BOLIO A, Goldstein I, Rauh L, Ratzan S, et al
    Statement: Multisectoral actions to build trust at the local and community level to promote vaccine acceptance.
    Vaccine. 2023 Jun 23:S0264-410X(23)00693-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  534. CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
    Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  535. HAIST V, Bellebeau-Barbier F, Montange C, Lemaitre L, et al
    Comparison of the local safety of two multi-component feline vaccines, adjuvanted (1 mL) versus non-adjuvanted at reduced volume (0.5 mL), using computed tomography imaging.
    Vaccine. 2023 Jun 23:S0264-410X(23)00720-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  536. TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
    Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  537. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  538. SALEH SN, McDonald SA, Basit MA, Kumar S, et al
    Public perception of COVID-19 vaccines through analysis of Twitter content and users.
    Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  539. DE MELO ARAUJO AC, da Silva Aragao J, de Souza WV, Rodrigues LC, et al
    The impact of implementing the 10-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among children.
    Vaccine. 2023 Jun 21:S0264-410X(23)00724-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  540. FUKUSHIMA S, Kiyohara T, Nakano T, Tada Y, et al
    Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults.
    Vaccine. 2023 Jun 21:S0264-410X(23)00723-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  541. JIANG B, Luo Y, Yan N, Shen Z, et al
    An X-ray inactivated vaccine against Pseudomonas aeruginosa Keratitis in mice.
    Vaccine. 2023 Jun 21:S0264-410X(23)00627-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  542. KIM J, Han K, Chung SJ, Kim C, et al
    Psychometric validation of the Korean versions of the Vaccine Hesitancy Scale and Vaccination Attitudes Examination Scale.
    Vaccine. 2023 Jun 21:S0264-410X(23)00721-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  543. PERRILLO R, Garrido LF, Ma TW, Rahimi R, et al
    Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy.
    Vaccine. 2023 Jun 21:S0264-410X(23)00716-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  544. AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
    A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
    Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  545. LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
    How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
    Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  546. CHEN X, Lin Y, Yue S, Yang Y, et al
    PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
    Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  547. KREMER P, Haruna F, Tuffour Sarpong R, Agamah D, et al
    An impact assessment of the use of aerial logistics to improve access to vaccines in the Western-North Region of Ghana.
    Vaccine. 2023 Jun 19:S0264-410X(23)00701-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  548. SUZUKI H, Fujita H, Iwai K, Kuroki H, et al
    Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
    Vaccine. 2023 Jun 19:S0264-410X(23)00625-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  549. EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
    Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  550. AILLOUD J, Branchereau M, Fall E, Juneau C, et al
    How can we improve the acceptability of vaccination against Human Papillomavirus (HPV) in France? An original qualitative study with focus groups comprising parents and school staff, interviewed separately.
    Vaccine. 2023 Jun 19:S0264-410X(23)00656-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  551. TATON M, Willems F, Widomski C, Martin C, et al
    Impact of pregnancy on polyfunctional IgG and memory B cell responses to Tdap immunization.
    Vaccine. 2023;41:4009-4018.
    PubMed     Abstract available


  552. TAFURI S, Cuscianna E, Bianchi FP
    Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis.
    Vaccine. 2023;41:4057-4063.
    PubMed     Abstract available


  553. HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  554. UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
    Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
    Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  555. TZENG R, Huang FY, Lee J
    Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
    Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  556. ORANGZEB S, Watle SV, Caugant DA
    Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020.
    Vaccine. 2023 Jun 17:S0264-410X(23)00699-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  557. HAMEL BL, Patel J, Still J, Joshi A, et al
    A diagnostic quandary: Rotavirus vaccine associated diarrhea.
    Vaccine. 2023 Jun 17:S0264-410X(23)00715-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  558. MASOUD D, Pierz A, Rauh L, Cruz AK, et al
    Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
    Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  559. DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
    Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
    Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  560. SINGH A, Boggiano C, Eller MA, Maciel M Jr, et al
    Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
    Vaccine. 2023 Jun 16:S0264-410X(23)00694-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  561. DUNN DT, Gilson R, McCormack S, McCoy LE, et al
    Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
    Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  562. BISWAS RK, Afiaz A, Huq S, Farzana M, et al
    Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
    Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  563. PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
    Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
    Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  564. MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
    Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  565. KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
    Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
    Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  566. PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  567. NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
    Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  568. SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
    Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  569. CIEMINS EL, Gillen A, Tallam M
    RSV: A vaccine is coming, time to educate providers.
    Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
    PubMed    


  570. MUWONGE R, Basu P
    Re: Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection: Reply to the commentary written by Christine Velicer, Alain Luxembourg, Ya-Ting Chen, Melvin Kohn, and Alfred Saah, Merck
    Vaccine. 2023 Jun 14:S0264-410X(23)00696-5. doi: 10.1016/j.vaccine.2023.
    PubMed    


  571. WOO EJ, Gee J, Marquez P, Baggs J, et al
    Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  572. YOUNG S, Goldin S, Dumolard L, Shendale S, et al
    National vaccination policies for health workers - A cross-sectional global overview.
    Vaccine. 2023 Jun 13:S0264-410X(23)00518-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  573. CINCONZE E, Rosillon D, Rappuoli R, Vadivelu K, et al
    Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.
    Vaccine. 2023 Jun 13:S0264-410X(23)00552-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  574. SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
    Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
    Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  575. SMITH WJ, Thompson R, Egan PM, Zhang Y, et al
    Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines.
    Vaccine. 2023 Jun 13:S0264-410X(23)00620-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  576. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    BCG∆BCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice.
    Vaccine. 2023;41:3824-3835.
    PubMed     Abstract available


  577. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  578. WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
    Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  579. SATO R
    Revisiting the measurement of vaccine hesitancy: Comparison between routine immunization and supplementary immunization activity in Nigeria.
    Vaccine. 2023 Jun 12:S0264-410X(23)00691-6. doi: 10.1016/j.vaccine.2023.
    PubMed    


  580. AL-RASHEED M, Ball C, Parthiban S, Ganapathy K, et al
    Evaluation of protection and immunity induced by infectious bronchitis vaccines administered by oculonasal, spray or gel routes in commercial broiler chicks.
    Vaccine. 2023 Jun 12:S0264-410X(23)00642-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  581. TINGGAARD M, Slotved HC, Jorgensen CS, Kronborg G, et al
    Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV.
    Vaccine. 2023 Jun 12:S0264-410X(23)00686-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  582. MA D, Tian S, Qin Q, Yu Y, et al
    Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
    Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  583. ACKERSON B, Sy LS, Slezak J, Qian L, et al
    Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine.
    Vaccine. 2023 Jun 10:S0264-410X(23)00661-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  584. NAKAO R, Hirayama S, Yamaguchi T, Senpuku H, et al
    A bivalent outer membrane vesicle-based intranasal vaccine to prevent infection of periodontopathic bacteria.
    Vaccine. 2023 Jun 9:S0264-410X(23)00619-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  585. MADRAN B, Kayi I, Beser A, Ergonul O, et al
    Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
    Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  586. UI M, Hirama T, Akiba M, Honda M, et al
    Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  587. MARTINEZ MR, Gao J, Wan H, Kang H, et al
    Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
    Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  588. DE GIER B, van Asten L, Boere TM, van Roon A, et al
    Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
    Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  589. NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
    Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
    Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  590. KALKOWSKA DA, Badizadegan K, Thompson KM
    Outbreak management strategies for cocirculation of multiple poliovirus types.
    Vaccine. 2023;41:3718-3727.
    PubMed     Abstract available


  591. MWENDA V, Jalang'o R, Miano C, Bor JP, et al
    Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
    Vaccine. 2023 Jun 7:S0264-410X(23)00546-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  592. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  593. KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
    Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
    Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  594. MITCHELL SL, Schulkin J, Power ML
    Vaccine hesitancy in pregnant Women: A narrative review.
    Vaccine. 2023 Jun 6:S0264-410X(23)00608-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  595. KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
    Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  596. PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
    From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
    Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  597. KIM WJ, Roberts CC, Song JY, Yoon JG, et al
    Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
    Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  598. ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
    Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  599. YANAI T, Yoshida S, Takeuchi M, Kawakami K, et al
    Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Vaccine. 2023 Jun 5:S0264-410X(23)00626-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  600. MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
    Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  601. WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
    COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
    Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  602. KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
    Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  603. VOHRA P, Bremner A, Nicholls B, Chintoan-Uta C, et al
    Evaluation of N-glycan-decorated live attenuated Escherichia coli and outer membrane vesicles as vaccines against Campylobacter jejuni colonisation in chickens.
    Vaccine. 2023 Jun 3:S0264-410X(23)00595-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  604. ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
    Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  605. FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
    Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
    Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  606. RAINA MACINTYRE C, Lim S, Gurdasani D, Miranda M, et al
    Early detection of emerging infectious diseases - implications for vaccine development.
    Vaccine. 2023 Jun 2:S0264-410X(23)00630-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  607. MVUNDURA M, Ng J, Reynolds K, Theng Ng Y, et al
    Vaccine wastage in Ghana, Mozambique, and Pakistan: An assessment of wastage rates for four vaccines and the context, causes, drivers, and knowledge, attitudes and practices for vaccine wastage.
    Vaccine. 2023 Jun 1:S0264-410X(23)00582-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  608. SANDERS C, Matthews RL, Esfahani SHZ, Khan N, et al
    Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.
    Vaccine. 2023 Jun 1:S0264-410X(23)00618-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    May 2023
  609. CHORIN O, Markovich MP, Avramovich E, Rahmani S, et al
    Oral and fecal polio vaccine excretion following bOPV vaccination among Israeli infants.
    Vaccine. 2023 May 31:S0264-410X(23)00585-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  610. OLIVERA MESA D, Winskill P, Ghani AC, Hauck K, et al
    The societal cost of vaccine refusal: A modelling study using measles vaccination as a case study.
    Vaccine. 2023 May 30:S0264-410X(23)00589-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  611. SCHLEY K, Borchert K, Seidel K, Jacob C, et al
    Did the change of the vaccination schedule effect pneumococcal conjugate vaccination compliance and adherence of premature and mature born infants in Germany? Answers from a claims database analysis.
    Vaccine. 2023 May 30:S0264-410X(23)00594-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  612. WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
    Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
    Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  613. ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
    Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  614. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  615. PAYNTER J, Howe AS, Best E, Petousis-Harris H, et al
    A retrospective cohort study investigating the comparative effectiveness of pneumococcal vaccines against hospitalisation with otitis media and pneumonia in New Zealand.
    Vaccine. 2023 May 25:S0264-410X(23)00591-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  616. MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
    COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
    Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  617. HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
    Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
    Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  618. CURTIS MG, Davoudpour S, Rodriguez-Ortiz AE, Felt D, et al
    Predictors of Mpox vaccine uptake among sexual and gender minority young adults living in Illinois: Unvaccinated vs. double vs. single dose vaccine recipients.
    Vaccine. 2023 May 24:S0264-410X(23)00593-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  619. RAO S, Abeyratne E, Freitas JR, Yang C, et al
    A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice.
    Vaccine. 2023 May 23:S0264-410X(23)00571-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  620. MOHAMMED AM, Musa A, Etapelong SG, Bolori MT, et al
    Expanding polio surveillance reach beyond vaccination reach in Borno State, Nigeria: The contribution of community informants from insecure areas engaged to conduct polio surveillance in security compromised areas, 2018-2019.
    Vaccine. 2023 May 23:S0264-410X(23)00547-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  621. CHOUDHARY P, Boamah B, Hon Ng S, White A, et al
    Solidified saturated fats coating subunit vaccines greatly extended vaccine booster release and contributed to a Th1/Th2 mixed immune response in mice.
    Vaccine. 2023 May 23:S0264-410X(23)00550-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  622. NUGENT C, Abul Y, White EM, Shehadeh F, et al
    Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Vaccine. 2023;41:3403-3409.
    PubMed     Abstract available


  623. WANG R, Fan X, Jiang Y, Li G, et al
    Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates.
    Vaccine. 2023 May 22:S0264-410X(23)00385-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  624. EGER J, Kaplan LC, Sternberg H
    How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
    Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  625. ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
    Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
    Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  626. GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
    Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
    Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  627. GUO BQ, Li HB, Yang LQ
    Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  628. BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
    A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
    Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  629. JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
    Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  630. EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
    Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  631. MALO B, Labbe F, Meyer SB, Filice E, et al
    "I Want People to Be Able to Make an Informed Choice": How Quebec naturopaths discuss vaccination in their practice.
    Vaccine. 2023 May 18:S0264-410X(23)00553-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  632. SHAW CA, August A, Bart S, Booth PJ, et al
    A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.
    Vaccine. 2023 May 18:S0264-410X(23)00488-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  633. BOING AF, Boing AC, Barberia L, Borges ME, et al
    Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  634. MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al
    A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
    Vaccine. 2023;41:3387-3398.
    PubMed     Abstract available


  635. WANLAPAKORN N, Pruetarat N, Sarawanangkoor N, Phanphanit K, et al
    Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age.
    Vaccine. 2023 May 16:S0264-410X(23)00541-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  636. ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
    Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  637. LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
    COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
    Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  638. SUN W
    Monkeypox, smallpox, FDA, and accelerated approval of vaccines - A regulatory perspective.
    Vaccine. 2023 May 15:S0264-410X(23)00526-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  639. SHATO T, Humble S, Anandarajah A, Barnette A, et al
    Influences of sociodemographic characteristics and parental HPV vaccination hesitancy on HPV vaccination coverage in five US states.
    Vaccine. 2023 May 15:S0264-410X(23)00517-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  640. BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
    Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
    Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  641. OHM M, van Straalen JW, Zijlstra M, de Joode-Smink G, et al
    Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study.
    Vaccine. 2023 May 15:S0264-410X(23)00480-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  642. GARCIA-FOGEDA I, Besbassi H, Lariviere Y, Ogunjimi B, et al
    Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: A systematic review.
    Vaccine. 2023 May 15:S0264-410X(23)00422-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  643. SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
    Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  644. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    A national survey of parents' views on childhood vaccinations in Ireland.
    Vaccine. 2023 May 13:S0264-410X(23)00522-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  645. GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
    Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
    Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  646. VESIKARI T, Langley JM, Spaans JN, Petrov I, et al
    The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.
    Vaccine. 2023 May 11:S0264-410X(23)00528-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  647. CHOI Y, Lee GS, Li S, Lee JW, et al
    Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
    Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  648. PIERRE E, Pladys A, Bayat-Makoei S, Tattevin P, et al
    Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year.
    Vaccine. 2023 May 11:S0264-410X(23)00521-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  649. KEHAGIA E, Papakyriakopoulou P, Valsami G
    Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  650. MIDDLETON BF, Danchin M, Cunliffe NA, Jones MA, et al
    Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination.
    Vaccine. 2023 May 11:S0264-410X(23)00525-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  651. ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
    Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
    Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  652. VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
    Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  653. GOVINDAN V, Ganaie FA, Ramakrishnan SM, Ravindran S, et al
    Estimation of baseline IgG antibody levels to 23 pneumococcal vaccine-type capsular polysaccharides in healthy vaccine naive Indian adults.
    Vaccine. 2023 May 10:S0264-410X(23)00497-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  654. RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
    Building global vaccine manufacturing capacity: Spotlight on Africa.
    Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  655. WILSON RJ, Leigh L, Bah H, Larson HJ, et al
    HPV vaccination acceptance and perceptions related to fertility and population control in the Gambia: An anthropological analysis.
    Vaccine. 2023 May 10:S0264-410X(23)00508-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  656. LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
    Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  657. SMITH K, Hegazy K, Cai MR, McKnight I, et al
    Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  658. BERRY A, Kapelus D, Singh P, Groome M, et al
    ABO blood types, but not Secretor or Lewis blood types, influence strength of antibody response to Hepatitis B vaccine in Black South African children.
    Vaccine. 2023 May 9:S0264-410X(23)00465-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  659. HIEBERT J, Saboui M, Frost JR, Zubach V, et al
    Mumps resurgence in a highly vaccinated population: Insights gained from surveillance in Canada, 2002-2020.
    Vaccine. 2023 May 9:S0264-410X(23)00513-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  660. CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
    Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
    Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  661. OLUSANYA OA, Tomar A, Thomas J, Alonge K, et al
    Application of the theoretical domains framework to identify factors influencing catch-up HPV vaccinations among male college students in the United States: A review of evidence and recommendations.
    Vaccine. 2023 May 8:S0264-410X(23)00509-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  662. SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
    Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
    Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  663. BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
    Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  664. KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
    Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  665. FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
    Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
    Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  666. GOLDBLATT D, Andrews NJ, Sheppard CL, Rose S, et al
    Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
    Vaccine. 2023;41:3019-3023.
    PubMed     Abstract available


  667. KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
    Informing the design of a whole of life immunisation register for Australia.
    Vaccine. 2023;41:3011-3018.
    PubMed     Abstract available


  668. LEWIS CY, Mishra K, Sun Y, Sechrist SJ, et al
    Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Vaccine. 2023 May 5:S0264-410X(23)00491-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  669. CZIBENER C, Rey Serantes DA, Romani AM, Bruno L, et al
    Bm Delta-pgm, a vaccine for the control of Brucella melitensis with cross-species protective properties.
    Vaccine. 2023 May 5:S0264-410X(23)00511-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  670. RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
    Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
    Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  671. KINGSLEY T, Phelan D, Poland GA
    Corrigendum to "A review of 2023 adult immunization schedule updates" [Vaccine 41(16) (2023) 2631-2633].
    Vaccine. 2023 May 3:S0264-410X(23)00462-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  672. TALBIRD SE, Anderson SA, Nossov M, Beattie N, et al
    Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.
    Vaccine. 2023 May 3:S0264-410X(23)00414-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  673. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
    Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  674. BERAN J, Lattanzi M, Costantini M, Pammolli A, et al
    Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
    Vaccine. 2023 May 2:S0264-410X(23)00485-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  675. VOSS SS, Norgaard SK, Valentiner-Branth P
    Identification of subgroups in the Danish population for targeted human papillomavirus vaccination efforts.
    Vaccine. 2023 May 2:S0264-410X(23)00484-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  676. FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
    Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
    Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  677. SIDDIQUE M, Iftikhar S, Dharma VK, Shah MT, et al
    Using geographic information system to track children and optimize immunization coverage and equity in Karachi, Pakistan.
    Vaccine. 2023;41:2922-2931.
    PubMed     Abstract available


  678. VEREEN RJ, Aden JK, Drumm CM
    Newborn medication adherence and childhood under-immunization in military beneficiaries.
    Vaccine. 2023;41:2887-2892.
    PubMed     Abstract available


  679. LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
    Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
    Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  680. MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
    Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
    Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  681. KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
    COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
    Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  682. HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
    COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
    Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    April 2023
  683. CHU K, Li Y, Yu D, Song Y, et al
    Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
    Vaccine. 2023 Apr 29:S0264-410X(23)00259-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  684. MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
    NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  685. HALSEY N, Evans S, Santosham M, Hacker A, et al
    Considerations for unblinding individual study participants during vaccine trials.
    Vaccine. 2023 Apr 28:S0264-410X(23)00425-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  686. COSTA JP, Jesus S, Colaco M, Duarte A, et al
    Endotoxin contamination of nanoparticle formulations: A concern in vaccine adjuvant mechanistic studies.
    Vaccine. 2023 Apr 28:S0264-410X(23)00487-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  687. IMMINK MM, van der Maas NAT, de Melker HE, Ferreira JA, et al
    Socio-psychological determinants of second trimester maternal pertussis vaccination acceptance in the Netherlands.
    Vaccine. 2023 Apr 28:S0264-410X(23)00482-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  688. BLACK S, Evans S
    Serious adverse events following mRNA vaccination in randomized trials in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00432-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  689. VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
    A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  690. DE LA TORRE ARRIETA J, Briceno D, de Castro IG, Roser B, et al
    A thermostable tetanus/diphtheria (Td) vaccine in the StablevaX pre-filled delivery system.
    Vaccine. 2023 Apr 28:S0264-410X(23)00431-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  691. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  692. KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
    COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
    Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  693. GREENBERG V, Vazquez-Benitez G, Kharbanda EO, Daley MF, et al
    Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes.
    Vaccine. 2023 Apr 26:S0264-410X(23)00457-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  694. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Cardiac events following JYNNEOS vaccination for prevention of Mpox.
    Vaccine. 2023 Apr 26:S0264-410X(23)00466-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  695. ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
    Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
    Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  696. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  697. SMITH MJ, Emanuel EJ
    Learning from five bad arguments against mandatory vaccination.
    Vaccine. 2023 Apr 25:S0264-410X(23)00461-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


  698. KIM SJ, Kwon SL, Lee JY, Oh J, et al
    Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
    Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  699. JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
    COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  700. CAI B, Peyrani P, Beeslaar J, Burman C, et al
    Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
    Vaccine. 2023;41:2729-2733.
    PubMed     Abstract available


  701. WALTER D, Ophir Y, Ye H
    Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
    Vaccine. 2023;41:2868-2877.
    PubMed     Abstract available


  702. CHARLTON CL, Bailey AM, Thompson LA, Kanji JN, et al
    What's in a number? The value of titers as routine proof of immunity for medical students.
    Vaccine. 2023;41:2734-2738.
    PubMed     Abstract available


  703. KLOSE SM, De Souza DP, Disint JF, Andrews DM, et al
    Reversion of mutations in a live mycoplasma vaccine alters its metabolism.
    Vaccine. 2023 Apr 24:S0264-410X(23)00459-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  704. ROPER RL, Garzino-Demo A, Del Rio C, Brechot C, et al
    Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.
    Vaccine. 2023 Apr 21:S0264-410X(23)00393-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  705. MA L, Brecher M, Soufal A, Gaiotto T, et al
    Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
    Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  706. CLARKE L, Brighton T, Chunilal SD, Lee CSM, et al
    Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem.
    Vaccine. 2023 Apr 19:S0264-410X(23)00379-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  707. TERRINONI M, Nordqvist SL, Lofstrand M, Nilsson F, et al
    A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.
    Vaccine. 2023 Apr 19:S0264-410X(23)00387-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  708. GIRNDT M, Houser P, Manllo-Karim R, Ervin JE, et al
    Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Vaccine. 2023 Apr 19:S0264-410X(23)00420-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  709. BAO Y, He L, Miao B, Zhong Z, et al
    BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  710. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  711. PILLSBURY A, Phillips A, Deng L, Quinn H, et al
    Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  712. MIDDELDORP M, Steens A, Lagerweij G, van Sorge NM, et al
    The burden of invasive meningococcal disease in the Netherlands, 2011-2020.
    Vaccine. 2023;41:2664-2670.
    PubMed     Abstract available


  713. HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
    COVID-19 vaccine distribution: A high reliability organization approach.
    Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  714. GORDON SF, Lam J, Vasquez JT, Cercone R, et al
    A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
    Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  715. TCHOUALEU DD, Fleming M, Traicoff DA
    A systematic review of pre-service training on vaccination and immunization.
    Vaccine. 2023 Apr 15:S0264-410X(23)00369-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  716. KANG B, Goldlust S, Lee EC, Hughes J, et al
    Spatial distribution and determinants of childhood vaccination refusal in the United States.
    Vaccine. 2023 Apr 15:S0264-410X(23)00402-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  717. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
    COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  718. FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
    Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  719. KUAN-MAHECHA MA, Rahman S, Martinez-Rivera P, Lamb MM, et al
    Differences in parental vaccine confidence and attitudes by health system in Guatemala and their impact on immunization timeliness.
    Vaccine. 2023 Apr 13:S0264-410X(23)00371-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  720. ANDRAUD M, Herve S, Gorin S, Barbier N, et al
    Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
    Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  721. KATTSTROM M, Uggla B, Tina E, Kimby E, et al
    Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
    Vaccine. 2023 Apr 13:S0264-410X(23)00399-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  722. FORTUNA LBDP, Miranda FM, Antunes IMF, Silva AB, et al
    Prevalence, capsular types, antimicrobial resistance and risk factors associated with pneumococcal carriage among children after long-term 10-valent pneumococcal conjugate vaccine use in Brazil.
    Vaccine. 2023 Apr 13:S0264-410X(23)00415-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  723. LI J, Shi LW, Yu BW, Huang LR, et al
    Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
    Vaccine. 2023 Apr 13:S0264-410X(23)00392-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  724. KHANAM F, Babu G, Rahman N, Liu X, et al
    Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Vaccine. 2023 Apr 13:S0264-410X(23)00397-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  725. ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
    Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  726. YOUNG G, Zahralban-Steele M, Dean HJ
    Impact of prior flavivirus vaccination on immunogenicity and efficacy of an inactivated Zika vaccine in Indian rhesus macaques.
    Vaccine. 2023 Apr 11:S0264-410X(23)00398-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  727. KIM GL, Pyo SW, Yi H, Kim SH, et al
    Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model.
    Vaccine. 2023 Apr 11:S0264-410X(23)00386-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  728. UEMURA K, Ono S, Michihata N, Yamana H, et al
    Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
    Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  729. RATHORE APS, St John AL
    Promises and challenges of mucosal COVID-19 vaccines.
    Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  730. KAWADE A, Dayma G, Apte A, Telang N, et al
    Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix(TM) and Prevenar13(TM))) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-lab
    Vaccine. 2023 Apr 10:S0264-410X(23)00388-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  731. PERKINS-OINES S, Dias N, Krafsur G, Abdelsalam K, et al
    The effect of neonatal vaccination for bovine respiratory disease in the face of a dual challenge with bovine viral diarrhea virus and Mannheimia hemolytica.
    Vaccine. 2023 Apr 10:S0264-410X(23)00391-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  732. CHANG CC, Algaissi A, Lai CC, Chang CK, et al
    Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.
    Vaccine. 2023 Apr 10:S0264-410X(23)00390-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  733. DOLD C, Zhu H, Silva-Reyes L, Blackwell L, et al
    Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines.
    Vaccine. 2023 Apr 8:S0264-410X(23)00395-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  734. HARRIS C, Cottrell S, Perry M, Meaden R, et al
    A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
    Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  735. HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
    Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
    Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  736. HAMAD SAIED M, van Straalen JW, de Roock S, de Joode-Smink GCJ, et al
    Safety of Measles-Mumps-Rubella booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study.
    Vaccine. 2023 Apr 7:S0264-410X(23)00381-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  737. JAGNE I, von Mollendorf C, Wee-Hee A, Ortika B, et al
    A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age.
    Vaccine. 2023 Apr 7:S0264-410X(23)00370-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  738. VARGAS-ZAMBRANO JC, Clark LR, Johnson DR, Monfredo C, et al
    Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis.
    Vaccine. 2023 Apr 7:S0264-410X(23)00342-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  739. LIU J, Guo S, Jin Z, Zhao K, et al
    Adjuvanted quaternized chitosan composite aluminum nanoparticles-based vaccine formulation promotes immune responses in chickens.
    Vaccine. 2023 Apr 7:S0264-410X(23)00374-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  740. LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
    Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
    Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  741. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    PubMed     Abstract available


  742. HEMPEL K, McDonald W, Osgood ND, Fisman D, et al
    Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study.
    Vaccine. 2023;41:2430-2438.
    PubMed     Abstract available


  743. AFSAR A, Mallya A, Mohammed AAG, Anand S, et al
    Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Vaccine. 2023;41 Suppl 1:A79-A84.
    PubMed     Abstract available


  744. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    PubMed     Abstract available


  745. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    PubMed     Abstract available


  746. VOORMAN A, O'Reilly K, Lyons H, Goel AK, et al
    Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Vaccine. 2023;41 Suppl 1:A105-A112.
    PubMed     Abstract available


  747. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    PubMed     Abstract available


  748. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    PubMed     Abstract available


  749. PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
    Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
    Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  750. WANG SM, Keegan EA, Bryan KM, Kazma J, et al
    Human papillomavirus vaccination receipt and provider counseling rates among high-risk patients.
    Vaccine. 2023 Apr 5:S0264-410X(23)00378-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  751. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
    Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  752. MACHIDA M, Inoue S
    Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study.
    Vaccine. 2023 Apr 4:S0264-410X(23)00355-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  753. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  754. PRADA E, Langbecker A, Catalan-Matamoros D
    Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
    Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  755. FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
    The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  756. TOSHKOV D
    What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
    Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  757. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  758. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  759. ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
    Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
    Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  760. PRASAD N, Stoecker C, Xing W, Cho BH, et al
    Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
    Vaccine. 2023 Apr 1:S0264-410X(23)00338-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  761. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  762. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    March 2023
  763. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  764. DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
    Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
    Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  765. HU Y, Wang Y, Shao T, Tang W, et al
    Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
    Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  766. STEIN-ZAMIR C, Shoob H, Abramson D
    Measles clinical presentation, hospitalization and vaccination status among children in a community-wide outbreak.
    Vaccine. 2023 Mar 29:S0264-410X(23)00337-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  767. FUKUDA H, Maeda M, Murata F
    Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
    Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  768. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  769. SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
    Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  770. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  771. PANNUS P, Depickere S, Kemlin D, Georges D, et al
    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
    Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  772. GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
    Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
    Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  773. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  774. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  775. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  776. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  777. DE SANTIS R, Faggioni G, Amoroso A, Ciammaruconi A, et al
    Durability of neutralizing antibodies against yellow fever virus after vaccination in healthy adults.
    Vaccine. 2023 Mar 24:S0264-410X(23)00284-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  778. THWAITES CL, Thanh TT, Ny NTH, Nguyet LA, et al
    Seroprotection against tetanus in southern Vietnam.
    Vaccine. 2023;41:2208-2213.
    PubMed     Abstract available


  779. FREEMAN RE, Leary CS, Graham JM, Albers AN, et al
    Geographic proximity to immunization providers and vaccine series completion among children ages 0-24 months.
    Vaccine. 2023 Mar 22:S0264-410X(23)00297-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  780. VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
    Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
    Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  781. PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
    Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  782. SATO R
    Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
    Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  783. MCCARTY JM, Cassie D, Bedell L
    Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States.
    Vaccine. 2023 Mar 21:S0264-410X(23)00260-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  784. XU S, Duan H, An Y, Jin X, et al
    Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE.
    Vaccine. 2023 Mar 21:S0264-410X(23)00319-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  785. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  786. MURPHY A, Kirby A, De Blasio F
    The economic impact of the introduction of universal rotavirus vaccination on rotavirus gastroenteritis related hospitalisations in children in Ireland.
    Vaccine. 2023 Mar 20:S0264-410X(23)00257-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  787. ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
    Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
    Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  788. WILSON GJ, Rodriguez B, Li SS, Allen M, et al
    Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Vaccine. 2023 Mar 17:S0264-410X(23)00262-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  789. SHAHID S, Ahmed S, Qazi MF, Ali R, et al
    Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.
    Vaccine. 2023 Mar 16:S0264-410X(23)00254-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  790. NAKANO T
    Changes in vaccination administration in Japan.
    Vaccine. 2023 Mar 16:S0264-410X(23)00282-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  791. PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
    Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
    Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  792. RIDDLE MS, Louis Bourgeois A, Clifford A, Jeon S, et al
    Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.
    Vaccine. 2023 Mar 15:S0264-410X(23)00250-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  793. LIN JH, Huang YT, Yu JC, Chan KA, et al
    Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
    Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  794. LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
    Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
    Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  795. KELLY D, O'Donnell K, Marron L, Dwyer R, et al
    Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
    Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  796. WONODI C, Moss W
    Editorial from guest editors for vaccine supplement: Vaccine-derived poliovirus type 2 outbreaks after the cessation of use of oral poliovirus vaccine type 2_ 2016-2021 journal supplement.
    Vaccine. 2023 Mar 11:S0264-410X(23)00244-X. doi: 10.1016/j.vaccine.2023.
    PubMed    


  797. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
    Vaccine. 2023;41:1892-1901.
    PubMed     Abstract available


  798. KIM E, He J, Kaufhold RM, McGuinness D, et al
    Evaluation of cross-protection between S. Pneumoniae serotypes 35B and 29 in a mouse model.
    Vaccine. 2023;41:1774-1777.
    PubMed     Abstract available


  799. LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
    Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2023;41:1902-1910.
    PubMed     Abstract available


  800. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  801. ALLEMAN MM, Jorba J, Riziki Y, Henderson E, et al
    Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Vaccine. 2023 Mar 10:S0264-410X(23)00177-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  802. CLAY PA, Thompson TD, Markowitz LE, Ekwueme DU, et al
    Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  803. SEAL AJ, Mohamed HA, Stokes-Walter R, Mohamed S, et al
    Use of an adapted participatory learning and action cycle to increase knowledge and uptake of child vaccination in internally displaced persons camps (IVACS): A cluster-randomised controlled trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00142-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  804. SYLVIE YANG R, Yang Y, Gowetski DB, Tsybovsky Y, et al
    Characterization of Flu MOSAIC nanoparticle vaccine candidate using high performance size-exclusion chromatography to support vaccine process development.
    Vaccine. 2023 Mar 9:S0264-410X(23)00248-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  805. RIVAS DRZ, Ticona JPA, Doss-Gollin S
    Lessons from the Bolivian vaccine mandate.
    Vaccine. 2023 Mar 9:S0264-410X(23)00251-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  806. SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
    Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  807. PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
    Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  808. IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
    Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
    Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  809. CHOWDHURY F, Aziz AB, Ahmmed F, Ahmed T, et al
    The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial.
    Vaccine. 2023 Mar 8:S0264-410X(23)00197-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  810. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Corrigendum to "Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa" [Vaccine 41(1) (2023) 61-67].
    Vaccine. 2023 Mar 8:S0264-410X(23)00168-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  811. GILBERT M, Ablona A, Chang HJ, Grennan T, et al
    Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia.
    Vaccine. 2023 Mar 7:S0264-410X(23)00229-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  812. BACON A, Teixeira M, Costa V, Bone P, et al
    Generation of a thermostable, oral Zika vaccine that protects against virus challenge in non-human primates.
    Vaccine. 2023 Mar 7:S0264-410X(23)00198-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  813. BOONE AC, Kulkarni RR, Cortes AL, Villalobos T, et al
    In ovo HVT vaccination enhances cellular responses at hatch and addition of poly I:C offers minimal adjuvant effects.
    Vaccine. 2023 Mar 7:S0264-410X(23)00238-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  814. YELVERTON V, Hair NL, Ghosh SH, Mfinanga SG, et al
    Corrigendum to "Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania" [Vaccine 40(37) (2022) 5483-5493].
    Vaccine. 2023 Mar 6:S0264-410X(23)00218-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


  815. HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
    Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
    Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  816. PRYSLIAK T, Menghwar H, Perez-Casal J
    Complement-mediated killing of Mycoplasma bovis does not play a role in the protection of animals against an experimental challenge.
    Vaccine. 2023;41:1743-1752.
    PubMed     Abstract available


  817. GELORMINI M, Gripenberg M, Marke D, Murray M, et al
    Coverage survey and lessons learned from a pre-emptive cholera vaccination campaign in urban and rural communities affected by landslides and floods in Freetown Sierra Leone.
    Vaccine. 2023 Mar 3:S0264-410X(23)00037-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  818. WU L, Yang S, Huang Z, Liu J, et al
    Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Vaccine. 2023 Mar 3:S0264-410X(23)00226-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  819. BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
    A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Vaccine. 2023;41:1694-1702.
    PubMed     Abstract available


  820. GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
    From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
    Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  821. ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
    Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  822. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Willingness to vaccinate children against COVID-19 declined during the pandemic.
    Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  823. XIE S, Monteiro K, Gjelsvik A
    The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
    Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  824. NEWALL AT, Beutels P, Kis Z, Towse A, et al
    Placing a value on increased flexible vaccine manufacturing capacity for future pandemics.
    Vaccine. 2023 Mar 2:S0264-410X(23)00219-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  825. NARII N, Kitamura T, Komukai S, Zha L, et al
    Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00240-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  826. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
    COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  827. BEAUJEAN M, Uijen RF, Langereis JD, Boccara D, et al
    The immunological effects of intradermal particle-based vaccine delivery using a novel microinjection needle studied in a human skin explant model.
    Vaccine. 2023 Mar 2:S0264-410X(23)00175-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  828. HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
    The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  829. NA L, Banks S, Wang PP
    Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
    Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    February 2023
  830. DARWAR R, Biya O, Greene SA, Jorba J, et al
    Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
    Vaccine. 2023 Feb 28:S0264-410X(23)00214-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  831. AL ALAWI S, Al Zaabi O, Heffernan ME, Arulappan J, et al
    Knowledge, attitudes and acceptance toward Human papillomavirus (HPV) vaccination: Perspectives of Muslim women and men.
    Vaccine. 2023 Feb 27:S0264-410X(23)00217-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  832. ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
    Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  833. MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
    Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  834. TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
    Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  835. O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
    Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  836. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Erratum to "Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey" [Vaccine 41(1) (2023) 101-108.
    Vaccine. 2023 Feb 25:S0264-410X(23)00107-X. doi: 10.1016/j.vaccine.2023.
    PubMed    


  837. CHANG AM, Chen CC, Lee JW, Hou DL, et al
    Effects of a novel recombinant Gonadotropin-Releasing Hormone-1 vaccine on the reproductive function of mixed-breed dogs (Canis familiaris) in Taiwan.
    Vaccine. 2023 Feb 25:S0264-410X(23)00215-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  838. BAKHSHIZADEH GASHTI A, Chahal PS, Gaillet B, Garnier A, et al
    Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate.
    Vaccine. 2023 Feb 24:S0264-410X(23)00201-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  839. ZHANG Y, Na D, Zhang W, Liu X, et al
    Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform.
    Vaccine. 2023;41:1573-1583.
    PubMed     Abstract available


  840. FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
    A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  841. FANTINATO FFST, Wachira VK, Porto VBG, Peixoto HM, et al
    Factors associated with yellow fever vaccine failure: A systematic literature review.
    Vaccine. 2023 Feb 23:S0264-410X(23)00133-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  842. HOSSEINNEZHAD-LAZARJANI E, Doosti A, Sharifzadeh A
    Novel csuC-DNA nanovaccine based on chitosan candidate vaccine against infection with Acinetobacter baumannii.
    Vaccine. 2023 Feb 23:S0264-410X(23)00181-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  843. BENFIELD T, Ramet M, Valentini P, Seppa I, et al
    Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
    Vaccine. 2023 Feb 23:S0264-410X(23)00176-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  844. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  845. CANNON K, Cardona JF, Yacisin K, Thompson A, et al
    Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  846. KASSTAN B, Chantler T, Marcus B, Mounier-Jack S, et al
    Linked poliovirus incidents in the UK, USA and Israel: Silent transmission or missed warnings of vaccine inequity?
    Vaccine. 2023 Feb 22:S0264-410X(23)00178-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  847. KOUIAVSKAIA D, Mirochnitchenko O, Troy S, Chumakov K, et al
    Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines.
    Vaccine. 2023 Feb 22:S0264-410X(23)00052-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  848. ZHANG H, Chen L, Huang Z, Li D, et al
    The effects of parent's health literacy and health beliefs on vaccine hesitancy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  849. SABATO B, Augusto PSA, Lima Goncalves Pereira R, Coutinho Batista Esteves F, et al
    Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model.
    Vaccine. 2023 Feb 21:S0264-410X(23)00166-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  850. HAMBURG M, Poland GA
    The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
    Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  851. MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  852. MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
    Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
    Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  853. LU L, Ma W, Johnson CH, Khan SA, et al
    In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
    Vaccine. 2023 Feb 20:S0264-410X(23)00183-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  854. DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
    Vaccinomics: A scoping review.
    Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  855. USTYUGOVA IV, Pougatcheva S, Farrell T, Strugnell T, et al
    AF03 adjuvant improves anti-hemagglutinin and anti-neuraminidase immune responses induced by licensed seasonal quadrivalent influenza vaccines in mice.
    Vaccine. 2023 Feb 18:S0264-410X(23)00169-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  856. GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
    Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
    Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  857. YI W, Wang H, Qin H, Wang Q, et al
    Construction and efficacy of a new live chimeric C-strain vaccine with DIVA characteristics against classical swine fever.
    Vaccine. 2023 Feb 18:S0264-410X(23)00179-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  858. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  859. SHERMAN SM, Lingley-Heath N, Lai J, Sim J, et al
    Parental acceptance of and preferences for administration of routine varicella vaccination in the UK: A study to inform policy.
    Vaccine. 2023;41:1438-1446.
    PubMed     Abstract available


  860. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  861. PARODI A, Martini M
    History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
    Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  862. MORAIS A, Morais J, Felix M, Neto Z, et al
    Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  863. DA SILVA AB, Cardoso-Marques NT, Dolores IM, Teixeira LM, et al
    Carriage prevalence, serotype distribution, antimicrobial resistance, pspA typing and pilus islets of Streptococcus pneumoniae isolated from adults living in a Brazilian urban slum.
    Vaccine. 2023;41:1431-1437.
    PubMed     Abstract available


  864. MEYER C, Goffe L, Antonopoulou V, Graham F, et al
    Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
    Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  865. ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
    The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
    Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  866. PILIC A, Reda S, Jo CL, Burchett H, et al
    Use of existing systematic reviews for the development of evidence-based vaccination recommendations: Guidance from the SYSVAC expert panel.
    Vaccine. 2023 Feb 16:S0264-410X(23)00162-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  867. BENEDICT KPOZEHOUEN E, Arrudsivah B, Raina Macintyre C
    Knowledge, attitudes and practices of health care workers in a cardiology department on influenza vaccination.
    Vaccine. 2023 Feb 15:S0264-410X(23)00112-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  868. KLOUWENS MJ, Trentelman JJA, Barriales D, Ersoz JI, et al
    The Ixodes ricinus salivary gland proteome during feeding and B. Afzelii infection: New avenues for an anti-tick vaccine.
    Vaccine. 2023 Feb 14:S0264-410X(23)00129-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  869. WAHAB MT, Tan RKJ, Cook AR, Prem K, et al
    Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
    Vaccine. 2023 Feb 14:S0264-410X(23)00160-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  870. VOJICIC J, Grajales AG, Cane A
    Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vaccine. 2023 Feb 14:S0264-410X(23)00130-5. doi: 10.1016/j.vaccine.2023.
    PubMed    


  871. SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
    Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
    Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  872. WANKHEDE D, Grover S, Hofman P
    Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  873. AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
    Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
    Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  874. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  875. BARNES K, Faasse K, Colagiuri B
    The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
    Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  876. GETCHELL M, Mantaring EJ, Yee K, Pronyk P, et al
    Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review.
    Vaccine. 2023 Feb 11:S0264-410X(23)00132-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  877. O'LEARY ST, Spina CI, Spielvogle H, Robinson JD, et al
    Development of PIVOT with MI: A motivational Interviewing-Based vaccine communication training for pediatric clinicians.
    Vaccine. 2023 Feb 10:S0264-410X(23)00136-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  878. FACCHIN G, Bella A, Del Manso M, Rota MC, et al
    Decline in reported measles cases in Italy in the COVID-19 era, January 2020 - July 2022: The need to prevent a resurgence upon lifting non-pharmaceutical pandemic measures.
    Vaccine. 2023;41:1286-1289.
    PubMed     Abstract available


  879. SELL H, Raj Paudel Y, Voaklander D, MacDonald SE, et al
    School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study.
    Vaccine. 2023;41:1333-1341.
    PubMed     Abstract available


  880. DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
    Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
    Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  881. HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
    Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  882. FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
    Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  883. SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
    Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
    Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  884. BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
    Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  885. OK BAIK Y, Lee Y, Lee C, Kyung Kim S, et al
    A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV(R) in healthy 6 Months-45 years aged participants.
    Vaccine. 2023 Feb 9:S0264-410X(22)01524-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  886. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
    Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  887. WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
    Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  888. PERETTI A, Scorpio DG, Kong WP, Pang YS, et al
    A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques.
    Vaccine. 2023 Feb 8:S0264-410X(23)00128-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  889. BUGHIN J, Cincera M, Peters K, Reykowska D, et al
    Make it or break it: On-time vaccination intent at the time of Covid-19.
    Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  890. DENG HM, Romero N, Allard N, Rowe S, et al
    Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009-2017).
    Vaccine. 2023 Feb 7:S0264-410X(23)00076-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  891. ERDEM R, De Coster I, Withanage K, Mercer LD, et al
    Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
    Vaccine. 2023 Feb 4:S0264-410X(23)00078-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  892. FELL DB, Torok E, Sprague AE, Regan AK, et al
    Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
    Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  893. HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
    Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
    Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  894. SEESEN M, Jearanaiwitayakul T, Limthongkul J, Midoeng P, et al
    A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells.
    Vaccine. 2023 Feb 3:S0264-410X(23)00096-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  895. PARK I, Unger ER, Kemp TJ, Pinto LA, et al
    The second HPV serology meeting: Progress and challenges in standardization of human papillomavirus serology assays.
    Vaccine. 2023;41:1177-1181.
    PubMed     Abstract available


  896. LI R, Liu H, Fairley CK, Ong JJ, et al
    mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  897. MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
    Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
    Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  898. ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
    Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  899. HAMADA H, Futamura M, Ito H, Yamamoto R, et al
    Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  900. JOHNSON R, Djaafara B, Haw D, Doohan P, et al
    The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    January 2023
  901. UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
    Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  902. PATRICIA WODI A, Marquez P, Mba-Jonas A, Barash F, et al
    Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS).
    Vaccine. 2023 Jan 31:S0264-410X(22)01563-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  903. STONE AE, Rambaran S, Trinh IV, Estrada M, et al
    Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients.
    Vaccine. 2023 Jan 31:S0264-410X(23)00055-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  904. HUANG CY, Chi H, Chang L, Chiu NC, et al
    Typical time courses and appearance of skin reactions at the site of Bacillus Calmette-Guerin vaccination for infants inoculated at 5-8 months of age.
    Vaccine. 2023 Jan 30:S0264-410X(23)00083-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  905. KABIR SULAIMAN S, Isma'il Tsiga-Ahmed F, Sale Musa M, Kabir Sulaiman A, et al
    Prevalence, determinants, and reasons for malaria vaccine hesitancy among caregivers of under-five children in Nigeria: Results from a nationwide cross-sectional survey.
    Vaccine. 2023 Jan 30:S0264-410X(23)00089-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  906. RAABE V, Lai L, Morales J, Xu Y, et al
    Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVDeltaG-ZEBOV-GP).
    Vaccine. 2023 Jan 30:S0264-410X(23)00090-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  907. SESHADRI S, Martin SW, Hills SL, Collins LC Jr, et al
    Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019.
    Vaccine. 2023 Jan 30:S0264-410X(23)00093-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  908. GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
    Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
    Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  909. HARBIN A, Laventhal N, Navin M
    Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
    Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  910. PARODI JB, Indavere A, Bobadilla Jacob P, Toledo GC, et al
    Impact of COVID-19 vaccination in post-COVID cardiac complications.
    Vaccine. 2023 Jan 27:S0264-410X(23)00084-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  911. MATTA MG, Pulido L, Herrera-Paz JJ, Picco JM, et al
    Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina.
    Vaccine. 2023 Jan 27:S0264-410X(23)00088-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  912. BARAL R, Levin A, Odero C, Pecenka C, et al
    Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Vaccine. 2023 Jan 27:S0264-410X(23)00064-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  913. PIRAS-DOUCE F, Broudic K, Chautard E, Raynal F, et al
    Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Vaccine. 2023 Jan 24:S0264-410X(22)01464-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  914. SUZUKI F, Maeyama JI, Kubota A, Nishimune A, et al
    Effect of cigarette smoke on mucosal vaccine response with activation of plasmacytoid dendritic cells: The outcomes of in vivo and in vitro experiments.
    Vaccine. 2023 Jan 24:S0264-410X(23)00030-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  915. TENG Y, Hanibuchi T, Machida M, Nakaya T, et al
    Psychological determinants of COVID-19 vaccine acceptance: A comparison between immigrants and the host population in Japan.
    Vaccine. 2023 Jan 23:S0264-410X(23)00056-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  916. ZOLOTAROVA T, Dussault C, Park H, Varsaneux O, et al
    Education increases COVID-19 vaccine uptake among people in Canadian federal prisons in a prospective randomized controlled trial: The EDUCATE study.
    Vaccine. 2023 Jan 23:S0264-410X(23)00061-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  917. MYERS TR, Marquez PL, Gee JM, Hause AM, et al
    The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC's COVID-19 pandemic response.
    Vaccine. 2023 Jan 23:S0264-410X(22)01545-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  918. JOSHI K, Rumpler E, Kennedy-Shaffer L, Bosan R, et al
    Comparative performance of between-population vaccine allocation strategies with applications for emerging pandemics.
    Vaccine. 2023 Jan 23:S0264-410X(22)01579-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  919. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  920. KRAUSE NM, Beets B, Howell EL, Tosteson H, et al
    Collateral damage from debunking mRNA vaccine misinformation.
    Vaccine. 2023;41:922-929.
    PubMed     Abstract available


  921. RENNERT W, Hindiyeh M, Allahham M, Mercer LD, et al
    Introducing ROTAVAC(R) to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.
    Vaccine. 2023;41:945-954.
    PubMed     Abstract available


  922. KUZEL TG, Fu J, Anderson M, Stec M, et al
    Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naive and previously-infected individuals.
    Vaccine. 2023;41:879-882.
    PubMed     Abstract available


  923. FAIZULOEV E, Gracheva A, Korchevaya E, Smirnova D, et al
    Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.
    Vaccine. 2023;41:892-902.
    PubMed     Abstract available


  924. GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
    COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
    Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  925. MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
    Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  926. VATCHARAVONGVAN P, Boonyanitchayakul N, Khampachuea P, Sinturong I, et al
    Health Belief Model and parents' acceptance of the Pfizer-BioNTech and Sinopharm COVID-19 vaccine for children aged 5-18 years Old: A national survey.
    Vaccine. 2023 Jan 23:S0264-410X(23)00050-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  927. GRASSLY NC, Andrews N, Cooper G, Stephens L, et al
    Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial.
    Vaccine. 2023 Jan 21:S0264-410X(23)00057-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  928. KRAMER C, Song M, Sufrin CB, Eber GB, et al
    COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons.
    Vaccine. 2023 Jan 21:S0264-410X(23)00060-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  929. DARBY B, Alexander V, Murphy J
    SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
    Vaccine. 2023 Jan 20:S0264-410X(23)00062-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  930. BIANCHI FP, Stefanizzi P, Martinelli A, Brescia N, et al
    COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis.
    Vaccine. 2023 Jan 20:S0264-410X(23)00058-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  931. DUDLEY MZ, Schuh HB, Shaw J, Rimal RN, et al
    COVID-19 vaccination among different types of US Healthcare Personnel.
    Vaccine. 2023 Jan 20:S0264-410X(23)00051-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  932. TRICOU V, Eyre S, Ramjee M, Collini P, et al
    A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Vaccine. 2023 Jan 19:S0264-410X(23)00007-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  933. MARSHALL S, Fleming A, Sahm LJ, Moore AC, et al
    Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory.
    Vaccine. 2023 Jan 18:S0264-410X(23)00036-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  934. GHORBANI A, Ngunjiri JM, Edward C Abundo M, Pantin-Jackwood M, et al
    Development of in Ovo-Compatible NS1-truncated live attenuated influenza vaccines by modulation of hemagglutinin cleavage and polymerase Acidic X Frameshifting sites.
    Vaccine. 2023 Jan 18:S0264-410X(23)00029-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  935. ZABALZA-BARANGUA A, Poveda-Urkixo I, Mena-Bueno S, Ramirez GA, et al
    Vaccine properties of Brucella melitensis 16MDeltawzm and reactivation of placental infection in pregnant sheep.
    Vaccine. 2023 Jan 16:S0264-410X(23)00028-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  936. MOINI A, Rabiei M, Pirjani R, Abiri A, et al
    COVID‑19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran.
    Vaccine. 2023 Jan 16:S0264-410X(23)00032-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  937. YANG H, Li Z, Zhang R, Guo S, et al
    Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac(R)) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Vaccine. 2023 Jan 13:S0264-410X(23)00031-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  938. KALRA S, Kalra D, Grafova I, Rubin JS, et al
    Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
    Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  939. BEDSTON S, Lowthian E, Jarvis CI, Akbari A, et al
    COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study.
    Vaccine. 2023 Jan 13:S0264-410X(23)00034-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  940. KLUWER B, Margrethe Rydland K, Nybru Gleditsch R, Mamelund SE, et al
    Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21.
    Vaccine. 2023 Jan 11:S0264-410X(23)00013-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  941. DU J, Liu B, Wang T, Zhu Z, et al
    A non-toxic recombinant bivalent chimeric protein rETX(m3)CSA(m4/TMD) as a potential vaccine candidate against enterotoxemia and braxy.
    Vaccine. 2023 Jan 10:S0264-410X(22)01419-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  942. ELLISON TJ, Talbott GC, Henderson DR
    Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.
    Vaccine. 2023;41:304-314.
    PubMed     Abstract available


  943. MOELLER-ARENDT M, van de Witte S, Nauta J, de Voogd H, et al
    Enhanced passive safety surveillance of Influvac(R) and Influvac(R) Tetra: Results from seven consecutive seasons.
    Vaccine. 2023;41:606-613.
    PubMed     Abstract available


  944. TAKAHASHI H, Morita M, Kamiya H, Fukusumi M, et al
    Genomic characterization of Japanese meningococcal strains isolated over a 17-year period between 2003 and 2020 in Japan.
    Vaccine. 2023;41:416-426.
    PubMed     Abstract available


  945. DESCHANVRES C, Levieux K, Launay E, Huby AC, et al
    Non-immunization associated with increased risk of sudden unexpected death in infancy: A national case-control study.
    Vaccine. 2023;41:391-396.
    PubMed     Abstract available


  946. WAGNER AL, Moniz MH, Stout MJ, Townsel C, et al
    Experiences, risk perceptions, and COVID-19 vaccination outcomes among hospital workers.
    Vaccine. 2023 Jan 9:S0264-410X(23)00012-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  947. NAVIN MC, Scherer AM, Bradley E, Attwell K, et al
    School staff as vaccine advocates: Perspectives on vaccine mandates and the student registration process.
    Vaccine. 2023 Jan 9:S0264-410X(23)00014-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  948. MENON I, Kang SM, Braz Gomes K, Uddin MN, et al
    Laser-assisted intradermal delivery of a microparticle vaccine for respiratory syncytial virus induces a robust immune response.
    Vaccine. 2023 Jan 9:S0264-410X(23)00002-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  949. KEVIN YIN J, Harris RC, Loiacono MM, Chit A, et al
    Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al.
    Vaccine. 2023 Jan 9:S0264-410X(22)01559-6. doi: 10.1016/j.vaccine.2022.
    PubMed    


  950. CHAWANPAIBOON S, Anuwutnawin S, Kanjanapongporn A, Pooliam J, et al
    Breastfeeding women's attitudes towards and acceptance and rejection of COVID-19 vaccination: Implementation research.
    Vaccine. 2023 Jan 9:S0264-410X(23)00015-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  951. OZAKI T, Nishimura N, Gotoh K, Takemoto K, et al
    Anti-varicella-zoster virus antibody titers and seroprotection status from before the first dose of varicella vaccination to before entering elementary school in one region in Japan.
    Vaccine. 2023 Jan 9:S0264-410X(23)00010-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  952. WHITEHEAD HS, French CE, Caldwell DM, Letley L, et al
    A systematic review of communication interventions for countering vaccine misinformation.
    Vaccine. 2023 Jan 9:S0264-410X(22)01593-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  953. TULLOCH JSP, Lawrenson K, Gordon AL, Ghebrehewet S, et al
    COVID-19 vaccine hesitancy in care home staff: A survey of Liverpool care homes.
    Vaccine. 2023 Jan 9:S0264-410X(23)00009-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  954. MORO PL, Zhang B, Ennulat C, Harris M, et al
    Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Vaccine. 2023 Jan 9:S0264-410X(23)00016-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  955. EBRAHIMI N, Mazdak M, Shaygannejad V, Mirmosayyeb O, et al
    CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Vaccine. 2023 Jan 6:S0264-410X(23)00004-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  956. JANG Y, Cho H, Chun J, Park K, et al
    Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
    Vaccine. 2023 Jan 6:S0264-410X(22)01602-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  957. LUPINACCI R, Rupp R, Wittawatmongkol O, Jones J, et al
    A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Vaccine. 2023 Jan 6:S0264-410X(22)01575-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  958. LONG Z, He J, Shuai Q, Zhang K, et al
    Influenza vaccination-induced H3 stalk-reactive memory B-cell clone expansion.
    Vaccine. 2023 Jan 6:S0264-410X(22)01603-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  959. CUTLAND CL, Peyrani P, Webber C, Newton R, et al
    A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
    Vaccine. 2023 Jan 6:S0264-410X(22)01461-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  960. XIE L, Ren J, Min S, Zhu X, et al
    Knowledge, attitude, and perception regarding HPV-related diseases and vaccination among the general public in Guizhou Province of China.
    Vaccine. 2023 Jan 5:S0264-410X(22)01538-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  961. TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
    Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  962. TORALES J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, et al
    An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Vaccine. 2023;41:109-118.
    PubMed     Abstract available


  963. HOMAIRA N, Strachan R, Quinn H, Beggs S, et al
    Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.
    Vaccine. 2023;41:85-91.
    PubMed     Abstract available


  964. MAERTZDORF KM, Rietman ML, Lambooij MS, Verschuren WMM, et al
    Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population.
    Vaccine. 2023 Jan 4:S0264-410X(23)00001-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  965. VALENCIA-HERNANDEZ AM, Zillinger T, Ge Z, Tan PS, et al
    Complexing CpG adjuvants with cationic liposomes enhances vaccine-induced formation of liver T(RM) cells.
    Vaccine. 2023 Jan 4:S0264-410X(22)01572-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  966. IMMINK MM, Kemmeren JM, Broeders L, Bekker MN, et al
    Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands.
    Vaccine. 2023 Jan 3:S0264-410X(22)01596-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  967. BAGGA S, Krishnan A, Dar L
    Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
    Vaccine. 2023 Jan 3:S0264-410X(22)01594-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  968. REGO RT, Kenney B, Ngugi AK, Espira L, et al
    COVID-19 vaccination refusal trends in Kenya over 2021.
    Vaccine. 2023 Jan 3:S0264-410X(22)01601-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  969. OVERBO J, Aziz A, Zaman K, Clemens J, et al
    Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01599-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  970. SONGOL A, Amiri-Farahani L, Haghani S, Pezaro S, et al
    Comparing the effect of parental education via both lecture and film upon vaccination uptake for children under one year of age: A cluster randomized clinical trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01522-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  971. SHOOK NJ, Oosterhoff B, Sevi B
    A longitudinal assessment of variability in COVID-19 vaccine hesitancy and psychosocial correlates in a national United States sample.
    Vaccine. 2023 Jan 2:S0264-410X(22)01600-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  972. FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
    Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
    Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    December 2022
  973. MOETLHOA B, Tjale M, Pretorius A, Hayeshi R, et al
    Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13.
    Vaccine. 2022 Dec 31:S0264-410X(22)01591-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  974. AZUMA M, Oishi K, Akeda Y, Morino S, et al
    Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naive adults aged >/= 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
    Vaccine. 2022 Dec 31:S0264-410X(22)01595-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  975. KIM TV, Pham TND, Le DH, Dao DVB, et al
    Significant gaps in hepatitis B vaccination in adults in Viet Nam: Important targets toward hepatitis B elimination by 2030.
    Vaccine. 2022 Dec 30:S0264-410X(22)01577-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  976. BURROWS H, Antillon M, Gauld JS, Kim JH, et al
    Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Vaccine. 2022 Dec 29:S0264-410X(22)01557-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  977. ZUBKOVA I, Zhao Y, Cui Q, Kachko A, et al
    Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Vaccine. 2022 Dec 29:S0264-410X(22)01590-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  978. WANG H, Cao L, Logue CM, Barbieri NL, et al
    Evaluation of immunogenicity and efficacy of the enterobactin conjugate vaccine in protecting chickens from colibacillosis.
    Vaccine. 2022 Dec 28:S0264-410X(22)01592-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  979. TOTTEY S, Shoji Y, Mark Jones R, Musiychuk K, et al
    Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.
    Vaccine. 2022 Dec 28:S0264-410X(22)01573-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  980. GAMBLE A, Hastings TJ, Westrick SC, Smith M, et al
    COVID-19 booster vaccination in rural community pharmacies.
    Vaccine. 2022 Dec 26:S0264-410X(22)01576-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  981. XIE Z, Hamadi HY, Mainous AG, Hong YR, et al
    Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity.
    Vaccine. 2022 Dec 23:S0264-410X(22)01568-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  982. ANDREJKO KL, Myers JF, Openshaw J, Fukui N, et al
    Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
    Vaccine. 2022 Dec 23:S0264-410X(22)01578-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  983. CURRY S, Kaufhold RM, Monslow MA, Zhang Y, et al
    Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models.
    Vaccine. 2022 Dec 22:S0264-410X(22)01531-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  984. SAIAG E, Alcalay Y, Marudi O, Orr-Urtreger A, et al
    Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older.
    Vaccine. 2022 Dec 21:S0264-410X(22)01560-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  985. WAND O, Breslavsky A, Bar-Shai A, Levy C, et al
    One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine.
    Vaccine. 2022 Dec 21:S0264-410X(22)01567-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  986. TYAGI P, Ganguly M, Manney S, Wadkar K, et al
    Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates.
    Vaccine. 2022 Dec 21:S0264-410X(22)01543-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  987. SIENA E, Schiavetti F, Borgogni E, Taccone M, et al
    Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.
    Vaccine. 2022 Dec 21:S0264-410X(22)01519-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  988. XU S, Huang R, Sy LS, Hong V, et al
    A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination.
    Vaccine. 2022 Dec 20:S0264-410X(22)01561-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  989. RANE MS, Robertson MM, Kulkarni SG, Frogel D, et al
    Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Vaccine. 2022 Dec 20:S0264-410X(22)01564-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  990. WILLIAMS KV, Moehling Geffel K, Alcorn JF, Patricia Nowalk M, et al
    Factors associated with humoral immune response in older adults who received egg-free influenza vaccine.
    Vaccine. 2022 Dec 19:S0264-410X(22)01566-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  991. DUDLEY MZ, Barnett EE, Paulenich A, Omer SB, et al
    Characterization of parental intention to vaccinate elementary school aged children in the state of California.
    Vaccine. 2022 Dec 19:S0264-410X(22)01544-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  992. BOISSON A, Morgan CE, Stover A, Ngimbi P, et al
    Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool.
    Vaccine. 2022 Dec 16:S0264-410X(22)01542-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  993. YIH WK, Daley MF, Duffy J, Fireman B, et al
    A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
    Vaccine. 2022 Dec 16:S0264-410X(22)01541-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  994. MIDDLETON BF, Danchin M, Fathima P, Bines JE, et al
    Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006 - 2021.
    Vaccine. 2022 Dec 16:S0264-410X(22)01525-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  995. SONOYAMA T, Iwata S, Shinkai M, Iwata-Yoshikawa N, et al
    Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Vaccine. 2022 Dec 16:S0264-410X(22)01540-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  996. PAPAZACHARIOU A, Tsioutis C, Lytras T, Malikides O, et al
    The impact of seasonal influenza vaccination uptake on COVID-19 vaccination attitudes in a rural area in Greece.
    Vaccine. 2022 Dec 15:S0264-410X(22)01539-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  997. VAUX S, Fonteneau L, Pefau M, Venier AG, et al
    Vaccination against influenza, measles, pertussis and varicella in workers in healthcare facilities in France: A national cross-sectional study in 2019.
    Vaccine. 2022 Dec 15:S0264-410X(22)01537-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  998. OLAYINKA F, Sauer M, Menning L, Summers D, et al
    Building and sustaining public and political commitment to the value of vaccination: Recommendations for the Immunization Agenda 2030 (Strategic Priority Area 2).
    Vaccine. 2022 Dec 15:S0264-410X(22)01451-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  999. MAERTENS K, Orije MRP, Huoi C, Boisnard F, et al
    Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP approximately T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy.
    Vaccine. 2022 Dec 15:S0264-410X(22)01535-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1000. CHEN L, Levine MZ, Zhou S, Bai T, et al
    Mild and asymptomatic influenza B virus infection among unvaccinated pregnant persons: Implication for effectiveness of non-pharmaceutical intervention and vaccination to prevent influenza.
    Vaccine. 2022 Dec 14:S0264-410X(22)01468-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1001. OHNO M, Sagata M, Sekiya T, Nomura N, et al
    Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.
    Vaccine. 2022 Dec 14:S0264-410X(22)01534-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1002. IBROCI E, Liu X, Lieb W, Jessel R, et al
    Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort.
    Vaccine. 2022 Dec 14:S0264-410X(22)01226-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1003. PALMU AAM, Nieminen H, Lahdenkari M, Palmu AA, et al
    A retrospective nationwide register-based study to evaluate the non-specific effects of first MMR vaccination among children in Finland.
    Vaccine. 2022 Dec 14:S0264-410X(22)01536-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1004. BISANZIO D, Davis AE, Talbird SE, Van Effelterre T, et al
    Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study.
    Vaccine. 2022 Dec 14:S0264-410X(22)01449-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1005. GATWOOD J, Brookhart A, Kinney O, Hagemann T, et al
    Impact of patient and provider nudges on addressing herpes zoster vaccine series completion.
    Vaccine. 2022 Dec 14:S0264-410X(22)01530-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1006. SUN L, Zhao N, Li H, Wang B, et al
    Construction of a Lactobacillus plantarum-based claudin-3 targeting delivery system for the development of vaccines against Eimeria tenella.
    Vaccine. 2022 Dec 14:S0264-410X(22)01528-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1007. SAINI SJ, Carle AC, Forsyth AR, Chi DL, et al
    Association between caregiver opposition to topical fluoride and COVID-19 vaccines.
    Vaccine. 2022 Dec 14:S0264-410X(22)01532-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1008. MARIA FP, Maria BA, Dario RO, Paula AP, et al
    Effectiveness of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies.
    Vaccine. 2022 Dec 13:S0264-410X(22)01521-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1009. BILI A, Dobson S, Quinones J, Phongsamart W, et al
    A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
    Vaccine. 2022 Dec 13:S0264-410X(22)01344-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1010. GUO J, Zhang H, Zhang H, Lai X, et al
    Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Vaccine. 2022 Dec 13:S0264-410X(22)01515-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1011. SALVATORE PP, Lee CC, Sleweon S, McCormick DW, et al
    Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021.
    Vaccine. 2022 Dec 13:S0264-410X(22)01458-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1012. HALL PA, Meng G, Boudreau C, Hudson A, et al
    Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
    Vaccine. 2022 Dec 12:S0264-410X(22)01526-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1013. CHO BH, Athar HM, Bates LG, Yarnoff BO, et al
    Patient flow time data of COVID-19 vaccination clinics in 23 sites, United States, April and May 2021.
    Vaccine. 2022 Dec 12:S0264-410X(22)01527-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1014. CHIBA S, Hatta M, Pattinson D, Yasuhara A, et al
    Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
    Vaccine. 2022 Dec 12:S0264-410X(22)01518-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1015. CUDDIHY MT, Berger WL, Cummings PL, Keith R, et al
    An organizational assessment of 101 Community-Based Adult Services centers to identify and address gaps in influenza vaccination among Medicare-Medicaid beneficiaries.
    Vaccine. 2022 Dec 10:S0264-410X(22)01490-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1016. PEPIN S, Samson SI, Alvarez FP, Dupuy M, et al
    Corrigendum to "Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres" [Vaccin
    Vaccine. 2022 Dec 9:S0264-410X(22)01483-9. doi: 10.1016/j.vaccine.2022.
    PubMed    


  1017. FERNANDES NEHAB M, Goncalves Camacho K, Teixeira Reis A, Junqueira-Marinho MF, et al
    Willingness of Brazilian caregivers in having their children and adolescents vaccinated against Covid-19.
    Vaccine. 2022 Dec 9:S0264-410X(22)01520-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1018. WALLACE AS, Ryman TK, Privor-Dumm L, Morgan C, et al
    Leaving no one behind: Defining and implementing an integrated life course approach to vaccination across the next decade as part of the immunization Agenda 2030.
    Vaccine. 2022 Dec 8:S0264-410X(22)01452-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1019. CHEN S, Gao S, Li J, Li J, et al
    Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China.
    Vaccine. 2022 Dec 8:S0264-410X(22)01498-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1020. CERNUSCHI T, Hall S, Malvolti S, Bloem P, et al
    Improving access to human papillomavirus vaccines: A case study in the IA2030 core principle of partnership.
    Vaccine. 2022 Dec 7:S0264-410X(22)01453-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1021. HEININGER U, Buttery J, Kochhar S
    Harmonized case definitions for endpoints in vaccine efficacy trials are needed.
    Vaccine. 2022 Dec 7:S0264-410X(22)01494-3. doi: 10.1016/j.vaccine.2022.
    PubMed    


  1022. NAGEL J, Jonsson G, Nilsson JA, Manuswin C, et al
    Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis.
    Vaccine. 2022 Dec 7:S0264-410X(22)01499-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1023. ANDERSON-CHAVARRIA M, Turner J
    Searching for the 'Trigger': An ethnographic analysis of parental beliefs regarding autism causation and vaccination in Puerto Rico.
    Vaccine. 2022 Dec 7:S0264-410X(22)01488-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1024. LATKIN C, Dayton L, Miller J, Eschliman E, et al
    Trusted information sources in the early months of the COVID-19 pandemic predict vaccination uptake over one year later.
    Vaccine. 2022 Dec 6:S0264-410X(22)01510-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1025. NGUYEN KH, Zhao R, Mullins C, Corlin L, et al
    Trends in vaccination schedules and up-to-date status of children 19-35 months, United States, 2015-2020.
    Vaccine. 2022 Dec 5:S0264-410X(22)01422-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1026. PROSPERI C, Thangaraj JWV, Hasan AZ, Kumar MS, et al
    Added value of the measles-rubella supplementary immunization activity in reaching unvaccinated and under-vaccinated children, a cross-sectional study in five Indian districts, 2018-20.
    Vaccine. 2022 Dec 5:S0264-410X(22)01396-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1027. SERISIER A, Beale S, Boukari Y, Hoskins S, et al
    A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales.
    Vaccine. 2022 Dec 5:S0264-410X(22)01497-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1028. UTTEKAR S, MacDonald N, Orenstein WA, Danchin M, et al
    Empowering Health Workers to Build Public Trust in Vaccination: Experience from the International Pediatric Association's Online Vaccine Trust Course, 2020-2021.
    Vaccine. 2022 Dec 2:S0264-410X(22)01485-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1029. FENG T, Wang X, Li J, Wang C, et al
    Common issues and improvement solution of vaccine hesitancy in children with underlying neurological conditions: Experience from one National Children's Medical Center in China.
    Vaccine. 2022 Dec 2:S0264-410X(22)01486-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1030. HOES J, King AJ, Berkhof J, de Melker HE, et al
    High vaccine effectiveness persists for ten years after HPV16/18 vaccination among young Dutch women.
    Vaccine. 2022 Dec 2:S0264-410X(22)01471-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1031. IWAI-SAITO K, Sato K, Kondo K
    Associations of influenza and pneumococcal vaccinations with burdens of older family caregivers: The Japan Gerontological Evaluation study (JAGES) cross-sectional study.
    Vaccine. 2022 Dec 2:S0264-410X(22)01460-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1032. MACAJ M, Perdochova L, Jakubikova J
    Streptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008-2019).
    Vaccine. 2022 Dec 2:S0264-410X(22)01423-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1033. CASPERSEN IH, Juvet LK, Feiring B, Laake I, et al
    Menstrual disturbances in 12- to 15-year-old girls after one dose of COVID-19 Comirnaty vaccine: Population-based cohort study in Norway.
    Vaccine. 2022 Dec 2:S0264-410X(22)01492-X. doi: 10.1016/j.vaccine.2022.
    PubMed    


  1034. STOLIAROFF-PEPIN A, Peine C, Herath T, Lachmann J, et al
    Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
    Vaccine. 2022 Dec 2:S0264-410X(22)01489-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1035. AL-KASSAB-CORDOVA A, Silva-Perez C, Mendez-Guerra C, Sangster-Carrasco L, et al
    Inequalities in infant vaccination coverage during the COVID-19 pandemic: A population-based study in Peru.
    Vaccine. 2022 Dec 2:S0264-410X(22)01491-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1036. INGRAM C, Roe M, Downey V, Phipps L, et al
    Exploring key informants' perceptions of Covid-19 vaccine hesitancy in a disadvantaged urban community in Ireland: Emergence of a '4Cs' model.
    Vaccine. 2022 Dec 2:S0264-410X(22)01496-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1037. BENDER FL, Rief W, Wilhelm M
    Really just a little prick? A meta-analysis on adverse events in placebo control groups of seasonal influenza vaccination RCTs.
    Vaccine. 2022 Dec 1:S0264-410X(22)01431-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1038. WONG HL, Tworkoski E, Ke Zhou C, Hu M, et al
    Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.
    Vaccine. 2022 Dec 1:S0264-410X(22)01493-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    November 2022
  1039. HSIAO A, Struckmann V, Stephani V, Mmbando D, et al
    Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
    Vaccine. 2022 Nov 29:S0264-410X(22)01430-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1040. TURNER OVERTON E, Schmidt D, Vidojkovic S, Menius E, et al
    A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN(R) vaccine in healthy adults.
    Vaccine. 2022 Nov 29:S0264-410X(22)01333-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1041. SULLIVAN KM, Farraye FA, Winthrop KL, Willer DO, et al
    Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Vaccine. 2022 Nov 29:S0264-410X(22)01329-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1042. TANG S, Liu X, Jia Y, Chen H, et al
    Education level modifies parental hesitancy about COVID-19 vaccinations for their children.
    Vaccine. 2022 Nov 29:S0264-410X(22)01484-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1043. SUN Y, Huang SK, Arlikatti S, Lindell MK, et al
    What attributes influence rural household's willingness to get vaccinated for COVID-19? Perspectives from six Chinese townships.
    Vaccine. 2022 Nov 29:S0264-410X(22)01487-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1044. POOLEY HB, Panag G, Plain KM, de Silva K, et al
    IP10 is a predictor of successful vaccine protection against paratuberculosis infection in sheep.
    Vaccine. 2022 Nov 28:S0264-410X(22)01418-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1045. UIJEN RF, van Beek LF, van Opzeeland F, Simonetti E, et al
    Intradermal administration of the pneumococcal conjugate vaccine in mice results in lower antibody responses as compared to intramuscular administration.
    Vaccine. 2022 Nov 26:S0264-410X(22)01456-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1046. CHRISTOU-ERGOS M, Wiley KE, Leask J
    Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Vaccine. 2022 Nov 26:S0264-410X(22)01447-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1047. JOSHI S, Anantharaman D, Muwonge R, Bhatla N, et al
    Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.
    Vaccine. 2022 Nov 26:S0264-410X(22)01457-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1048. STOCKER A, Hoffmann J, Mause L, Neufeind J, et al
    What impact does the attitude toward COVID-19 vaccination have on physicians as vaccine providers? A cross sectional study from the German outpatient sector.
    Vaccine. 2022 Nov 25:S0264-410X(22)01466-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1049. ZARZECZNA N, Bertlich T, Veckalov B, Rutjens BT, et al
    Spirituality is associated with Covid-19 vaccination scepticism.
    Vaccine. 2022 Nov 25:S0264-410X(22)01463-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1050. RADER B, Chiang ME, Kriner DL, Weintraub RL, et al
    Persistent drop in confidence following US recommended pause of Ad26.COV2.S vaccine administration.
    Vaccine. 2022 Nov 25:S0264-410X(22)01448-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1051. MICHELLE DRIEDGER S, Capurro G, Tustin J, Jardine CG, et al
    "I won't be a guinea pig": Rethinking public health communication and vaccine hesitancy in the context of COVID-19.
    Vaccine. 2022 Nov 25:S0264-410X(22)01469-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1052. LIP A, Pateman M, Fullerton MM, Chen HM, et al
    Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping review.
    Vaccine. 2022 Nov 24:S0264-410X(22)01225-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1053. BUDIGAN NI H, de Broucker G, Patenaude BN, Dudley MZ, et al
    Economic impact of vaccine safety incident in Ukraine: The economic case for safety system investment.
    Vaccine. 2022 Nov 24:S0264-410X(22)01374-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1054. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
    Vaccine. 2022 Nov 24:S0264-410X(22)01467-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1055. HUMBLE RM, Scott SD, Dube E, Olson J, et al
    The impact of the COVID-19 pandemic on parents' perceptions and acceptance of routine childhood vaccination in Canada: A national longitudinal study.
    Vaccine. 2022 Nov 24:S0264-410X(22)01465-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1056. TANAKA H, Mukai J, Kushibiki K, Mizushima S, et al
    Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
    Vaccine. 2022 Nov 24:S0264-410X(22)01462-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1057. TSURANE K, Umehara N, Nakayama T, Okada K, et al
    Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society.
    Vaccine. 2022;40:7122-7129.
    PubMed     Abstract available


  1058. CAETANO C, Morgado ML, Patricio P, Leite A, et al
    Measuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal.
    Vaccine. 2022;40:7115-7121.
    PubMed     Abstract available


  1059. MARCHETTI F, Lamiani G, Bona M, Amerighi C, et al
    Developing communication tools on rotavirus vaccination to support family paediatricians in Italy.
    Vaccine. 2022;40:7108-7114.
    PubMed     Abstract available


  1060. KAUFMANN J, DeVoe JE, Angier H, Moreno L, et al
    Association of parent influenza vaccination and early childhood vaccinations using linked electronic health record data.
    Vaccine. 2022;40:7097-7107.
    PubMed     Abstract available


  1061. HASSAN YAM, Daud Ali M, Al-Eid RR, Al-Ghuraya FA, et al
    A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Vaccine. 2022;40:7087-7096.
    PubMed     Abstract available


  1062. FRANCO C, Herazo-Padilla N, Castaneda JA
    A queueing Network approach for capacity planning and patient Scheduling: A case study for the COVID-19 vaccination process in Colombia.
    Vaccine. 2022;40:7073-7086.
    PubMed     Abstract available


  1063. ZHOU W, Tang B, Bai Y, Shao Y, et al
    The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Vaccine. 2022;40:7141-7150.
    PubMed     Abstract available


  1064. WILLAME C, Dodd C, Duran CE, Elbers R, et al
    Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.
    Vaccine. 2022 Nov 22:S0264-410X(22)01429-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1065. OZDARENDELI A, Sezer Z, Pavel STI, Inal A, et al
    Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
    Vaccine. 2022 Nov 22:S0264-410X(22)01380-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1066. MATHEWS KO, Norris JM, Phalen D, Malikides N, et al
    Factors associated with Q fever vaccination in Australian wildlife rehabilitators.
    Vaccine. 2022 Nov 21:S0264-410X(22)01364-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1067. TRAN QM, Soda J, Siraj A, Moore S, et al
    Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling.
    Vaccine. 2022 Nov 21:S0264-410X(22)01426-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1068. SEEGER JD, Amend KL, Turnbull BR, Zhou L, et al
    Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States.
    Vaccine. 2022 Nov 21:S0264-410X(22)01307-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1069. ELICABE RJ, Distel MN, Jofre BL, Leporati M, et al
    Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.
    Vaccine. 2022 Nov 21:S0264-410X(22)01416-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1070. UTAZI CE, Aheto JMK, Wigley A, Tejedor-Garavito N, et al
    Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria.
    Vaccine. 2022 Nov 19:S0264-410X(22)01420-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1071. FEKETE M, Horvath A, Santa B, Tomisa G, et al
    COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary.
    Vaccine. 2022 Nov 18:S0264-410X(22)01415-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1072. ZHANG Z, Shi J, Zhang X, Guo X, et al
    Willingness of parents of 9-to-18-year-old females in China to vaccinate their daughters with HPV vaccine.
    Vaccine. 2022 Nov 18:S0264-410X(22)01404-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1073. NOVAK A, Hindriks E, Hoek A, Veraart C, et al
    Cellular and humoral immune responsiveness to inactivated Leptospira interrogans in dogs vaccinated with a tetravalent Leptospira vaccine.
    Vaccine. 2022 Nov 18:S0264-410X(22)01417-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1074. NIQUEUX E, Flodrops M, Allee C, Lebras MO, et al
    Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks.
    Vaccine. 2022 Nov 18:S0264-410X(22)01398-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1075. AMPOFO AG, Mackenzie L, Boyes AW
    HPV vaccination: Intention to participate among female senior high school students in Ghana.
    Vaccine. 2022 Nov 18:S0264-410X(22)01383-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1076. MCCORMICK DW, Hagan LM, Salvatore PP, Magleby R, et al
    SARS-CoV-2 viral shedding in vaccinated and unvaccinated persons: A case series.
    Vaccine. 2022 Nov 18:S0264-410X(22)01428-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1077. KAHN AL, Steffen CA, Henaff L, MacDonald NE, et al
    COVID-19 vaccine policy development in a sample of 44 countries - Key findings from a December 2021 survey of National Immunization Technical Advisory Groups (NITAGs).
    Vaccine. 2022 Nov 17:S0264-410X(22)01427-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1078. KIM J, Kim ED, Shin HS, Han SJ, et al
    Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops.
    Vaccine. 2022 Nov 16:S0264-410X(22)01192-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1079. KALKOWSKA DA, Wassilak SGF, Pallansch MA, Burns CC, et al
    Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Vaccine. 2022 Nov 16:S0264-410X(22)01336-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1080. POURIAYEVALI MH, Teimoori A, Esmaeili S, Abdoli A, et al
    Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856-2868].
    Vaccine. 2022;40:7009.
    PubMed    


  1081. PANICKAN S, Bhatia S, Bhat S, Bhandari N, et al
    Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens.
    Vaccine. 2022;40:6998-7008.
    PubMed     Abstract available


  1082. ALFANO V, Ercolano S
    Your vaccine attitude determines your altitude. What are the determinants of attitudes toward vaccination?
    Vaccine. 2022;40:6987-6997.
    PubMed     Abstract available


  1083. TURBYFILL C, Adams K, Tenforde MW, Murray NL, et al
    Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.
    Vaccine. 2022;40:6979-6986.
    PubMed     Abstract available


  1084. KULKARNI AV, Jaggaiahgari S, Iyengar S, Simhadri V, et al
    Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.
    Vaccine. 2022;40:6971-6978.
    PubMed     Abstract available


  1085. MOORE KL, Tan L
    Preferential recommendations for vaccines: Time for a structured, transparent process.
    Vaccine. 2022;40:6893-6894.
    PubMed    


  1086. HE H, Zhu Y, Jin M, Zhou Y, et al
    The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study.
    Vaccine. 2022;40:6956-6962.
    PubMed     Abstract available


  1087. ATTWELL K, Rizzi M, Paul KT
    Consolidating a research agenda for vaccine mandates.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01384.
    PubMed     Abstract available


  1088. HANSEN J, Yee A, Lewis N, Li S, et al
    Safety of 9-valent human papillomavirus vaccine administered to males and females in routine use.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01395.
    PubMed     Abstract available


  1089. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01301.
    PubMed     Abstract available


  1090. FIX J, Vielot NA, Lund JL, Weber DJ, et al
    Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01347.
    PubMed     Abstract available


  1091. ZIMMERMAN T, Shiroma K, Fleischmann KR, Xie B, et al
    Misinformation and COVID-19 vaccine hesitancy.
    Vaccine. 2022 Nov 14:S0264-410X(22)01402-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1092. VANWORMER JJ, Alicea G, Weichelt BP, Berg RL, et al
    COVID-19 vaccine coverage disparities in rural and farm children.
    Vaccine. 2022 Nov 14:S0264-410X(22)01403-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1093. FABIANI M, Mateo-Urdiales A, Sacco C, Rota MC, et al
    Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Vaccine. 2022 Nov 14:S0264-410X(22)01399-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1094. JACKSON ML, Phillips CH, Wellwood S, Kiniry E, et al
    Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01397.
    PubMed     Abstract available


  1095. KPOZEHOUEN EB, Tan T, Macintyre CR
    Uptake of influenza, pneumococcal and herpes zoster vaccines among people with heart failure and atrial fibrillation.
    Vaccine. 2022 Nov 12. pii: S0264-410X(22)01377.
    PubMed     Abstract available


  1096. QI W, Qingfeng L, Jing Z, Maolin Z, et al
    A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model.
    Vaccine. 2022 Nov 11. pii: S0264-410X(22)01327.
    PubMed     Abstract available


  1097. LUKEHART SA, Molini B, Gomez A, Godornes C, et al
    Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum.
    Vaccine. 2022 Nov 11. pii: S0264-410X(22)01372.
    PubMed     Abstract available


  1098. DE FIGUEIREDO A, Simas C, Larson HJ
    COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: A multi-country cross-sectional study.
    Vaccine. 2022 Nov 10:S0264-410X(22)01310-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1099. YU Z, Keskinocak P, Sokol J, Chen YH, et al
    Flexible analytic model to inform multi-stakeholder pediatric vaccine scheduling decisions.
    Vaccine. 2022 Nov 9. pii: S0264-410X(22)01198.
    PubMed     Abstract available


  1100. BAI Q, Wang Z, An Y, Tian J, et al
    Chitosan-functionalized graphene oxide as adjuvant in HEV P239 vaccine.
    Vaccine. 2022 Nov 9. pii: S0264-410X(22)01375.
    PubMed     Abstract available


  1101. YU X, Suo L, Li W, Chen W, et al
    Molecular surveillance of rubella virus in Beijing, China during 2010-2021: Progress and challenges in rubella elimination.
    Vaccine. 2022;40:6857-6863.
    PubMed     Abstract available


  1102. REN H, Li H, Cao L, Wang Z, et al
    Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice.
    Vaccine. 2022;40:6830-6838.
    PubMed     Abstract available


  1103. ECHEVERRIA-LONDONO S, Hartner AM, Li X, Roth J, et al
    Exploring the subnational inequality and heterogeneity of the impact of routine measles immunisation in Africa.
    Vaccine. 2022;40:6806-6817.
    PubMed     Abstract available


  1104. MARTINI M, Orsini D
    The fight against poliomyelitis through the history: past, present and hopes for the future. Albert Sabin's missing Nobel and his "gift to all the world's children".
    Vaccine. 2022;40:6802-6805.
    PubMed     Abstract available


  1105. TRENTELMAN JJA, de Vogel FA, Colstrup E, Sima R, et al
    Identification of novel conserved Ixodes vaccine candidates; a promising role for non-secreted salivary gland proteins.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01292.
    PubMed     Abstract available


  1106. MARSHALL T, Addison M, Crawford NW, Buttery JP, et al
    Aiming too high: Shoulder injury related to vaccine administration (SIRVA): A case series.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01368.
    PubMed     Abstract available


  1107. HASHIMOTO M, Aoe S, Kawazu Y, Seki NM, et al
    Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Vaccine. 2022 Nov 8. pii: S0264-410X(22)01379.
    PubMed     Abstract available


  1108. MOLL K, Lufkin B, Fingar KR, Ke Zhou C, et al
    Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
    Vaccine. 2022 Nov 8:S0264-410X(22)01373-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1109. LOPEZ-DORIGA RUIZ P, Gunnes N, Michael Gran J, Karlstad O, et al
    Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01367.
    PubMed     Abstract available


  1110. KIRTLAND KA, Raghunathan T, Patel Murthy B, Li J, et al
    Estimating vaccination coverage for routinely recommended vaccines among children aged 24months and adolescents aged 13 through 17years using data from immunization information systems in the United States.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01341.
    PubMed     Abstract available


  1111. OSOWICKI J, Morgan HJ, Harris A, Clothier HJ, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01366.
    PubMed     Abstract available


  1112. HAO XB, Anand M, Wang TR, Rao AR, et al
    Reducing COVID vaccine hesitancy by inducing a comparative mindset.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01359.
    PubMed     Abstract available


  1113. BEALE S, Burns R, Braithwaite I, Byrne T, et al
    Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01362.
    PubMed     Abstract available


  1114. SKAWRAN S, Schiesser H, Maurer A, Sartoretti T, et al
    Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01376.
    PubMed     Abstract available


  1115. WU YY, Zhang W
    Demographic disparities in COVID-19 vaccine hesitancy among U.S. adults: Analysis of household pulse survey data from Jul 21 to Oct 11 in 2021.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01381.
    PubMed     Abstract available


  1116. TAKEUCHI Y, Iwagami M, Ono S, Michihata N, et al
    A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01370.
    PubMed     Abstract available


  1117. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey.
    Vaccine. 2022 Nov 7:S0264-410X(22)01371-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1118. GHIANI M, Hagemann C, Friedrich J, Maywald U, et al
    Can risk area designation help increase vaccination coverage for Tick-Borne Encephalitis? Evidence from German claims data.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01346.
    PubMed     Abstract available


  1119. LEUNG J, Gray EB, Anderson TC, Sharkey SM, et al
    Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01328.
    PubMed     Abstract available


  1120. THOMMES E, Coudeville L, Muhammad R, Martin M, et al
    Public health impact and cost-effectiveness of implementing a 'pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01343.
    PubMed     Abstract available


  1121. KRASSELT J, Robin D, Fadda M, Geutjes A, et al
    Tick-Talk: Parental online discourse about TBE vaccination.
    Vaccine. 2022 Nov 5. pii: S0264-410X(22)01326.
    PubMed     Abstract available


  1122. PRIYAMVADA L, Carson WC, Ortega E, Navarra T, et al
    Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo.
    Vaccine. 2022 Nov 4. pii: S0264-410X(22)01360.
    PubMed     Abstract available


  1123. MORSTEAD T, Zheng J, Sin NL, DeLongis A, et al
    Perceived threat and coping responses during the COVID-19 pandemic: Prospective associations with vaccine hesitancy.
    Vaccine. 2022 Nov 4. pii: S0264-410X(22)01363.
    PubMed     Abstract available


  1124. RICKS T, Trent MJ, MacIntyre CR
    Predictors of herpes zoster vaccination among Australian adults aged 65 and over.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01332.
    PubMed     Abstract available


  1125. WATESKA AR, Patricia Nowalk M, Lin CJ, Harrison LH, et al
    Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01340.
    PubMed     Abstract available


  1126. MALDEN DE, Gee J, Glenn S, Li Z, et al
    Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Vaccine. 2022 Nov 3. pii: S0264-410X(22)01361.
    PubMed     Abstract available


  1127. KURATA T, Miyama T, Kanbayashi D, Kaida Y, et al
    Increasing seroprevalence but waning herd immunity against measles after elimination: Longitudinal seroepidemiology of measles in Osaka Prefecture, Japan, 2003-2020.
    Vaccine. 2022;40:6581-6588.
    PubMed     Abstract available


  1128. HAYMAN B, Kumar Suri R, Downham M
    Sustainable vaccine manufacturing in low- and middle-Income countries.
    Vaccine. 2022 Nov 2. pii: S0264-410X(22)01305.
    PubMed     Abstract available


  1129. FISHER DG, Gnazzo V, Holthausen DJ, Lopez CB, et al
    Non-standard viral genome-derived RNA activates TLR3 and type I IFN signaling to induce cDC1-dependent CD8+ T-cell responses during vaccination in mice.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01312.
    PubMed     Abstract available


  1130. CAREY KA, Newman LM, Spicknall IH
    Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01291.
    PubMed     Abstract available


  1131. MORRILL JC, Peters CJ, Bettinger GE, Palermo PM, et al
    Rift Valley fever MP-12 vaccine elicits an early protective immune response in mice.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01339.
    PubMed     Abstract available


  1132. TOMPKINS LK, Baggs J, Myers TR, Gee JM, et al
    Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01342.
    PubMed     Abstract available


  1133. CHANG CT, Lim XJ, Chew CC, Rajan P, et al
    Preferences and willingness of accepting COVID-19 vaccine booster: Results from a middle-income country.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01334.
    PubMed     Abstract available


  1134. LUCINDE RK, Karia B, Ouma N, Amadi D, et al
    The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.
    Vaccine. 2022 Nov 1:S0264-410X(22)01345-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    October 2022
  1135. KUNASEKARAN M, Moa A, Hooshmand E, Trent M, et al
    Effectiveness estimates for enhanced trivalent influenza vaccines in an aged care summer outbreak.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00766.
    PubMed     Abstract available


  1136. KUNASEKARAN M, Poulos CJ, Chughtai AA, Heslop DJ, et al
    Factors associated with repeated influenza vaccine uptake among aged care staff in an Australian sample from 2017 to 2019.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)00981.
    PubMed     Abstract available


  1137. TONG C, Liu H, Wang J, Sun Y, et al
    Safety, efficacy, and DIVA feasibility on a novel live attenuated CSFV marker vaccine candidate.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01293.
    PubMed     Abstract available


  1138. THULUVA S, Paradkar V, Gunneri S, Yerroju V, et al
    Safety, tolerability and immunogenicity of Biological E's CORBEVAX vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01308.
    PubMed     Abstract available


  1139. LIMAYE RJ, Paul A, Gur-Arie R, Zavala E, et al
    A socio-ecological exploration to identify factors influencing the COVID-19 vaccine decision-making process among pregnant and lactating women: Findings from Kenya.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01331.
    PubMed     Abstract available


  1140. CAPURRO G, Maier R, Tustin J, Jardine CG, et al
    "They're trying to bribe you and taking away your freedoms": COVID-19 vaccine hesitancy in communities with traditionally low vaccination rates.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01338.
    PubMed     Abstract available


  1141. SIANI A, Tranter A
    Is vaccine confidence an unexpected victim of the COVID-19 pandemic?
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01337.
    PubMed     Abstract available


  1142. MARIE REINHART A, Tian Y, Lilly AE
    The role of trust in COVID-19 vaccine hesitancy and acceptance among Black and White Americans.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01330.
    PubMed     Abstract available


  1143. CRUZ MC, Nascimento-Carvalho CM
    The early evolution of COVID-19 incidence and mortality among people aged under 80 years or 80 years and above after COVID-19 vaccine implementation in the state of Bahia, Brazil.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01335.
    PubMed     Abstract available


  1144. GILLES C, Rozenberg S, Buxant F, Manigart Y, et al
    HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01288.
    PubMed     Abstract available


  1145. XIE L, Li Y
    Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development.
    Vaccine. 2022 Oct 29. pii: S0264-410X(22)01311.
    PubMed     Abstract available


  1146. HEYERDAHL LW, Dielen S, Dodion H, Van Riet C, et al
    Strategic silences, eroded trust: The impact of divergent COVID-19 vaccine sentiments on healthcare workers' relations with peers and patients.
    Vaccine. 2022 Oct 27. pii: S0264-410X(22)01306.
    PubMed     Abstract available


  1147. BAMOUH Z, Hamdi J, Elkarhat Z, Fellahi S, et al
    Attenuation and genetic characteristics of a Moroccan strain of Camel pox virus.
    Vaccine. 2022;40:6471-6480.
    PubMed     Abstract available


  1148. SCHIFF J, Schmidt AR, Pham PK, Perez JB, et al
    Parental attitudes in the pediatric emergency department about the COVID-19 vaccine.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01309.
    PubMed     Abstract available


  1149. MALTEZOU HC, Ledda C, Gagneux-Brunon A, Botelho-Nevers E, et al
    Mandatory COVID-19 vaccination for healthcare personnel in the era of new SARS-CoV-2 variants.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01313.
    PubMed    


  1150. MALTEZOU HC, Gamaletsou MN, Koukou DM, Giannouchos TV, et al
    Association between COVID-19 vaccination status, time elapsed since the last vaccine dose, morbidity, and absenteeism among healthcare personnel: A prospective, multicenter study.
    Vaccine. 2022 Oct 26. pii: S0264-410X(22)01304.
    PubMed     Abstract available


  1151. TADDIO A, McMurtry CM, Logeman C, Gudzak V, et al
    Prevalence of pain and fear as barriers to vaccination in children - Systematic review and meta-analysis.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01287.
    PubMed     Abstract available


  1152. PHOKSAWAT W, Nithichanon A, Lerdsamran H, Wongratanacheewin S, et al
    Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01265.
    PubMed     Abstract available


  1153. SHU Y, Yu Y, Ji Y, Zhang L, et al
    Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01281.
    PubMed     Abstract available


  1154. SERRA L, Webber C, Burman C, Bueti P, et al
    Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01197.
    PubMed     Abstract available


  1155. RABE APJ, Costello P, Were JJ, Farrer A, et al
    The burden of selected vaccine-preventable diseases on the secondary care health system in England: Results from a five-year administrative healthcare dataset.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01263.
    PubMed     Abstract available


  1156. MADEWELL ZJ, Chacon-Fuentes R, Badilla-Vargas X, Ramirez C, et al
    Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01284.
    PubMed     Abstract available


  1157. NAYAR R, Pattath B, Mantha N, Debnath S, et al
    Routine childhood vaccination in India from 2005-2006 to 2015-2016: Temporal trends and geographic variation.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01285.
    PubMed     Abstract available


  1158. ARASA J, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A, et al
    Impact of rotavirus vaccination on seizure hospitalizations in children: A systematic review.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01228.
    PubMed     Abstract available


  1159. ARRIETA A, Garcia-Prado A, Sarmiento JP, Paz Castro C, et al
    Identifying early adopters of COVID-19 vaccines in Latin America.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01294.
    PubMed     Abstract available


  1160. SUN R, Budhwani H
    Negative sentiments toward novel coronavirus (COVID-19) vaccines.
    Vaccine. 2022 Oct 21. pii: S0264-410X(22)01297.
    PubMed     Abstract available


  1161. BLANCO S, Spinsanti L, Javier Aguilar J, Diaz A, et al
    Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01283.
    PubMed     Abstract available


  1162. SANTIBANEZ TA, Black CL, Vogt TM, Chatham-Stephens K, et al
    Where are children ages 5-17 years receiving their COVID-19 vaccinations? Variations over time and by sociodemographic characteristics, United States.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01282.
    PubMed     Abstract available


  1163. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    PubMed     Abstract available


  1164. DUCLOS P, MacDonald NE, Dochez C, Thacker N, et al
    Report of the 2nd workshop of the International Collaboration on advanced vaccinology training.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01222.
    PubMed     Abstract available


  1165. ZHONG VW, Li X, Ran J, Hu G, et al
    Vaccination, symptomatic infection and negative conversion of viral RNA by body mass index, diabetes, and age: An observational study.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01262.
    PubMed     Abstract available


  1166. HOSHI SL, Shono A, Seposo X, Okubo R, et al
    Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01259.
    PubMed     Abstract available


  1167. LAI L, Rouphael N, Xu Y, Kabbani S, et al
    An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cTFH) cells and antibody responses.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01146.
    PubMed     Abstract available


  1168. HALL PA, Meng G, Sakib MN, Quah ACK, et al
    Do the vaccinated perform less distancing, mask wearing and hand hygiene? A test of the risk compensation hypothesis in a representative sample during the COVID-19 pandemic.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01289.
    PubMed     Abstract available


  1169. FUJI N, Pichichero M, Kaur R
    Pathogenesis of Streptococcus pneumoniae serotype 3 during natural colonization and infections among children and its IgG correlate of protection in a mouse model.
    Vaccine. 2022;40:6412-6421.
    PubMed     Abstract available


  1170. RUAN J, Dong W, Liu Y, Zhang Y, et al
    Establishment of a model to assess mumps virus neurovirulence in neonatal Wistar rats.
    Vaccine. 2022;40:6397-6403.
    PubMed     Abstract available


  1171. GOLLAMUDI J, Sartain SE, Navaei AH, Aneja S, et al
    Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2022;40:6431-6444.
    PubMed     Abstract available


  1172. SAPUAN S, Andrews N, Hallis B, Hole L, et al
    An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-containing vaccines or received no pertussis-containin
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01243.
    PubMed     Abstract available


  1173. PENG M, Joo J, Alvarado-Martinez Z, Tabashsum Z, et al
    Intracellular autolytic whole cell Salmonella vaccine prevents colonization of pathogenic Salmonella Typhimurium in chicken.
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01261.
    PubMed     Abstract available


  1174. URUENA A, Ruiz JI, Lew DA, David J, et al
    Opinions, attitudes, and barriers to pediatric vaccination in Argentina.
    Vaccine. 2022 Oct 19. pii: S0264-410X(22)01256.
    PubMed     Abstract available


  1175. LIAO SH, Chang WJ, Hsu CY, Ming-Fang Yen A, et al
    Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01258.
    PubMed     Abstract available


  1176. AKSOY N, Ozturk N, Ulusoy S, Omur MF, et al
    Knowledge and attitude of students studying at health department towards HPV and HPV vaccination.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01264.
    PubMed     Abstract available


  1177. TAKAHASHI Y, Ishitsuka K, Sampei M, Okawa S, et al
    COVID-19 vaccine literacy and vaccine hesitancy among pregnant women and mothers of young children in Japan.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01227.
    PubMed     Abstract available


  1178. RHODES S, Smith N, Evans T, White R, et al
    Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling.
    Vaccine. 2022 Oct 17. pii: S0264-410X(22)01260.
    PubMed     Abstract available


  1179. CREISHER PS, Campbell AD, Perry JL, Roznik K, et al
    Influenza subtype-specific maternal antibodies protect offspring against infection but inhibit vaccine-induced immunity and protection in mice.
    Vaccine. 2022 Oct 14. pii: S0264-410X(22)01241.
    PubMed     Abstract available


  1180. HUDSON A, Hall PA, Hitchman SC, Meng G, et al
    Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01242.
    PubMed     Abstract available


  1181. AROCHO ROSARIO CM, Miller RJ, Klafke GM, Coates C, et al
    Interaction between anti-tick vaccine and a macrocyclic lactone improves acaricidal efficacy against Rhipicephalus (Boophilus) microplus (Canestrini) (Acari: Ixodidae) in experimentally infested cattle.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01230.
    PubMed     Abstract available


  1182. SAADE EA, Abul Y, McConeghy K, Edward Davidson H, et al
    High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial.
    Vaccine. 2022 Oct 13. pii: S0264-410X(22)01215.
    PubMed     Abstract available


  1183. MO Y, Li Y, Liu G, Chen J, et al
    A phase II, single-center, randomized, double-blind, parallel control clinical study evaluating the immunogenicity and safety of a two-dose schedule of serogroups ACYW meningococcal polysaccharide conjugate vaccine.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)00948.
    PubMed     Abstract available


  1184. LIU S, Yang G, Li M, Sun F, et al
    Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge.
    Vaccine. 2022 Oct 12. pii: S0264-410X(22)01102.
    PubMed     Abstract available


  1185. WHALEY M, Axon DR
    Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting.
    Vaccine. 2022 Oct 10. pii: S0264-410X(22)01229.
    PubMed     Abstract available


  1186. BUDDY CREECH C, Jimenez-Truque N, Kown N, Sokolow K, et al
    Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01196.
    PubMed     Abstract available


  1187. VOGELSANG EM, Polonijo AN
    Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01183.
    PubMed     Abstract available


  1188. CHONG CY, Tan NW, Yung CF, Li J, et al
    Effectiveness of maternal pertussis vaccination in Singapore: A test-negative case-control study.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01219.
    PubMed     Abstract available


  1189. RUGHINIS C, Vulpe SN, Flaherty MG, Vasile S, et al
    Shades of doubt: Measuring and classifying vaccination confidence in Europe.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01147.
    PubMed     Abstract available


  1190. CHEN JY, Hsieh SM, Hwang SJ, Liu CS, et al
    Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01200.
    PubMed     Abstract available


  1191. RUSTANDI RR, Hamm M, Onimus M, Yuan Y, et al
    Monitoring bromide loss in bromoacetyl-derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB(R) by capillary electrophoresis and NMR spectroscopy.
    Vaccine. 2022;40:6012-6016.
    PubMed     Abstract available


  1192. KATZ S, Townsend-Payne K, Louth J, Lee-Jones L, et al
    Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
    Vaccine. 2022;40:6042-6047.
    PubMed     Abstract available


  1193. MARLOWE E, Pranikoff S, Borsheim B, Salafian K, et al
    Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01194.
    PubMed     Abstract available


  1194. KRAAY ANM, Steele MK, Baker JM, Hall EW, et al
    Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01193.
    PubMed     Abstract available


  1195. WOLF AS, Mitsi E, Jones S, Jochems SP, et al
    Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01190.
    PubMed     Abstract available


  1196. BYRNE A, Thompson LA, Filipp SL, Ryan K, et al
    COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01221.
    PubMed     Abstract available


  1197. SIMON JK, Kennedy SB, Mahon BE, Dubey SA, et al
    Immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine (ERVEBO(R)) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01145.
    PubMed     Abstract available


  1198. PAGUIO JA, Ojikutu BO, Alfonso PG, Yao JS, et al
    Association of culturally competent care with influenza vaccination coverage in the United States.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01065.
    PubMed     Abstract available


  1199. CHUGHTAI AA, Mohammed S, Al Ariqi L, McCarron M, et al
    Development of a road map to scale up the uptake and utilization of influenza vaccine in 22 countries of Eastern Mediterranean Region.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01159.
    PubMed     Abstract available


  1200. VAN EWIJK CE, Hazelhorst EI, Hahne SJM, Knol MJ, et al
    COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    Vaccine. 2022 Oct 4. pii: S0264-410X(22)01213.
    PubMed     Abstract available


  1201. AL-SHAIKH A, Mahmoud RI, Boukerdenna H, Muthu N, et al
    Counselling of non-communicable diseases' patients for COVID-19 vaccine uptake in Jordan: Evaluating the intervention.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01214.
    PubMed     Abstract available


  1202. FERREIRA LS, de Almeida GB, Borges ME, Simon LM, et al
    Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01216.
    PubMed     Abstract available


  1203. CHAO CR, Xu L, Cannizzaro N, Bronstein D, et al
    Trends in HPV vaccine administration and HPV vaccine coverage in children by race/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01195.
    PubMed     Abstract available


  1204. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    PubMed     Abstract available


    September 2022
  1205. MANJATE F, Quinto L, Chirinda P, Acacio S, et al
    Impact of rotavirus vaccination on diarrheal hospitalizations in children younger than 5 years of age in a rural southern Mozambique.
    Vaccine. 2022 Sep 30. pii: S0264-410X(22)01158.
    PubMed     Abstract available


  1206. NAKASHIMA K, Suzuki K, Aoshima M, Murabata M, et al
    Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study
    Vaccine. 2022 Sep 29. pii: S0264-410X(22)01163.
    PubMed     Abstract available


  1207. SILVA-VALENCIA J, Soto-Becerra P, Escobar-Agreda S, Fernandez-Navarro M, et al
    Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study usi
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01189.
    PubMed     Abstract available


  1208. TRAKARNVANICH T, Ngamvichchukorn T, Phumisantiphong U, Pholtawornkulchai K, et al
    Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01187.
    PubMed     Abstract available


  1209. MERDRIGNAC L, Acosta L, Habington A, Garcia Cenoz M, et al
    Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01160.
    PubMed     Abstract available


  1210. SPETZ M, Lundberg L, Nwaru C, Li H, et al
    An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01186.
    PubMed     Abstract available


  1211. HATHAWAY CA, Siegel EM, Gonzalez BD, Oswald LB, et al
    Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01184.
    PubMed     Abstract available


  1212. MARCHESE AM, Beyhaghi H, Orenstein WA
    With established safe and effective use, protein vaccines offer another choice against COVID-19.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01185.
    PubMed    


  1213. CERVANTES-TORRES J, Rosales-Mendoza S, Cabello C, Montero L, et al
    Towards the development of an epitope-focused vaccine for SARS-CoV-2.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01168.
    PubMed     Abstract available


  1214. LLOYD PC, Hu M, Wong HL, Shoaibi A, et al
    Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years.
    Vaccine. 2022 Sep 27. pii: S0264-410X(22)01167.
    PubMed     Abstract available


  1215. ZHU H, Li X, Ren X, Chen H, et al
    Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01165.
    PubMed     Abstract available


  1216. OHTA M, Kambayashi Y, Mita H, Kuroda T, et al
    Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01155.
    PubMed     Abstract available


  1217. STOFFEL ST, Colaninno A, Bram R, Schwenkglenks M, et al
    Pneumococcal vaccination among adult risk patient with axial spondyloarthritis in Switzerland: Data from the survey of the ankylosing spondylitis association of Switzerland (SVMB).
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01164.
    PubMed     Abstract available


  1218. TOLSTRUP WESTER C, Lybecker Scheel-Hincke L, Bovil T, Andersen-Ranberg K, et al
    Prayer frequency and COVID-19 vaccine hesitancy among older adults in Europe.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01153.
    PubMed     Abstract available


  1219. GATES DM, Cohen SA, Orr K, Caffrey AR, et al
    Pediatric influenza vaccination rates lower than previous estimates in the United States.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01162.
    PubMed     Abstract available


  1220. NOMURA Y, Noda K, Oohashi Y, Okuda S, et al
    Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01144.
    PubMed     Abstract available


  1221. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    PubMed     Abstract available


  1222. POLAND GA
    The human immune response to vaccines is symphonic, polyphonic, homophonic, and megaphonic.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01099.
    PubMed    


  1223. MOHAMMED AH, Hassan BAR, Wayyes AM, Gadhban AQ, et al
    Parental health beliefs, intention, and strategies about covid-19 vaccine for their children: A cross-sectional analysis from five Arab countries in the Middle East.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01161.
    PubMed     Abstract available


  1224. KUIPER VP, van der Plas P, Hoogerwerf MA, Pieter R Koopman J, et al
    A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01100.
    PubMed     Abstract available


  1225. RUCKSTUHL L, Czock A, Haile SR, Lang P, et al
    Influence of cantonal health policy frameworks & activities on the influenza vaccination rate in patients with non-communicable diseases in Switzerland.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01148.
    PubMed     Abstract available


  1226. ROMER D, Winneg KM, Jamieson PE, Brensinger C, et al
    Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5-11-year-olds in the United States.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01154.
    PubMed     Abstract available


  1227. KIEFER MK, Mehl R, Rood KM, Germann K, et al
    Association between social vulnerability and COVID-19 vaccination hesitancy and vaccination in pregnant and postpartum individuals.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01152.
    PubMed     Abstract available


  1228. DYSON EH, Simpson AJH, Gwyther RJ, Cuthbertson H, et al
    Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01045.
    PubMed     Abstract available


  1229. LIU B, Gidding H, Stepien S, Cretikos M, et al
    Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01126.
    PubMed     Abstract available


  1230. FENG T, Li M, Zhang L, Li S, et al
    Immunity of two novel hepatitis C virus polyepitope vaccines.
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01115.
    PubMed     Abstract available


  1231. BANNIETTIS N, Wysocki J, Szenborn L, Phongsamart W, et al
    A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, c
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01086.
    PubMed     Abstract available


  1232. SHAPIRO JR, Privor-Dumm L, Rosser EN, Leng SX, et al
    The intersection of gender and race in older adults' decision to receive COVID-19 vaccines.
    Vaccine. 2022 Sep 20:S0264-410X(22)01151-3. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1233. GRAAF A, Petric PP, Sehl-Ewert J, Henritzi D, et al
    Cold-passaged isolates and bat-swine influenza a chimeric viruses as modified live-attenuated vaccines against influenza a viruses in pigs.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01108.
    PubMed     Abstract available


  1234. SHI T, Meng L, Li D, Jin N, et al
    Effect of different vaccine strategies for the control of Japanese encephalitis in mainland China from 1961 to 2020: A quantitative analysis.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01127.
    PubMed     Abstract available


  1235. NTZIORA F, Georgia Kostaki E, Karapanou A, Mylona M, et al
    Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01150.
    PubMed     Abstract available


  1236. HUANG ST, Huang YC, Kuo E, Yang YM, et al
    Impacts of Catch-Up Immunization program with the 13-Valent pneumococcal Conjugate vaccine in Taiwan: Focus on age-stratified differences and high-risk population (2001-2015).
    Vaccine. 2022 Sep 17. pii: S0264-410X(22)01084.
    PubMed     Abstract available


  1237. LI L, Li Y, Bai Y, Li G, et al
    Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase b randomized, double-blind, parallel-controlled study.
    Vaccine. 2022 Sep 16. pii: S0264-410X(22)01114.
    PubMed     Abstract available


  1238. TILEY KS, White JM, Andrews N, Tessier E, et al
    Equity of the Meningitis B vaccination programme in England, 2016-2018.
    Vaccine. 2022 Sep 15. pii: S0264-410X(22)01111.
    PubMed     Abstract available


  1239. YU M, Chi X, Huang S, Wang Z, et al
    A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26.
    Vaccine. 2022 Sep 15. pii: S0264-410X(22)01103.
    PubMed     Abstract available


  1240. FRANKENTHAL D, Zatlawi M, Karni-Efrati Z, Keinan-Boker L, et al
    COVID-19 vaccine hesitancy among Israeli adults before and after vaccines' availability: A cross-sectional national survey.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01078.
    PubMed     Abstract available


  1241. CREVECOEUR J, Hens N, Neyens T, Lariviere Y, et al
    Change in COVID19 outbreak pattern following vaccination in long-term care facilities in Flanders, Belgium.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01124.
    PubMed     Abstract available


  1242. CARRENO JM, Singh G, Tcheou J, Srivastava K, et al
    mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01003.
    PubMed     Abstract available


  1243. ACEIL J, Paschall AV, Knoot CJ, Robinson LS, et al
    Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine.
    Vaccine. 2022 Sep 14. pii: S0264-410X(22)01112.
    PubMed     Abstract available


  1244. SUZUKI H, Noguchi T, Matsugu N, Suzuki A, et al
    Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01104.
    PubMed     Abstract available


  1245. STANFIELD BA, Bravo FJ, Dixon DA, Chouljenko VN, et al
    Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01119.
    PubMed     Abstract available


  1246. DIEMERT DJ, Zumer M, Campbell D, Grahek S, et al
    Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naive adults.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01113.
    PubMed     Abstract available


  1247. OSEI I, Sarwar G, Hossain I, Sonko K, et al
    Attendance and vaccination at immunization clinics in rural Gambia before and during the COVID-19 pandemic.
    Vaccine. 2022 Sep 13. pii: S0264-410X(22)01125.
    PubMed     Abstract available


  1248. ZACE D, La Gatta E, Petrella L, Di Pietro ML, et al
    The impact of COVID-19 vaccines on fertility-A systematic review and meta-analysis.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01118.
    PubMed     Abstract available


  1249. MONFARED IG
    The connection between COVID-19 vaccine abundance, vaccination coverage, and public trust in government across the globe.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01107.
    PubMed     Abstract available


  1250. FRIEDMAN-KLABANOFF DJ, Tjaden AH, Santacatterina M, Munawar I, et al
    Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01116.
    PubMed     Abstract available


  1251. YAMANAKA A, Rattanaamnuaychai P, Matsuda M, Suzuki R, et al
    Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01110.
    PubMed     Abstract available


  1252. HAO F, Bai Y, Xie X, Yuan T, et al
    Phenotypic characteristics and protective efficacy of an attenuated Mycoplasma hyopneumoniae vaccine by aerosol administration.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01080.
    PubMed     Abstract available


  1253. DAY ME, Klein M, Sucharew H, Carol Burkhardt M, et al
    Declining influenza vaccination rates in an underserved pediatric primary care center during the COVID-19 pandemic.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01121.
    PubMed     Abstract available


  1254. NAEIM A, Guerin RJ, Baxter-King R, Okun AH, et al
    Strategies to increase the intention to get vaccinated against COVID-19: Findings from a nationally representative survey of US adults, October 2020 to October 2021.
    Vaccine. 2022 Sep 12. pii: S0264-410X(22)01117.
    PubMed     Abstract available


  1255. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Corrigendum to "Estimating the burden of adult hospitalized RSV infection including special populations". [Vaccine 40(31) (2022) 4121-4127].
    Vaccine. 2022 Sep 10. pii: S0264-410X(22)01123.
    PubMed    


  1256. NIEMINEN H, Lahdenkari M, Syrjanen RK, Nohynek H, et al
    Lower incidence of hospital-treated infections in infants under 3 months of age vaccinated with BCG.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01087.
    PubMed     Abstract available


  1257. DEIFALLAH YOUSIF M, Felek A, Saydam M, Wilson S, et al
    Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01062.
    PubMed     Abstract available


  1258. ISHIGURO C, Mimura W, Murata F, Fukuda H, et al
    Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Vaccine. 2022 Sep 9. pii: S0264-410X(22)01077.
    PubMed     Abstract available


  1259. VANDEBRIEL RJ, Stalpers CAL, Vermeulen JP, Remkes M, et al
    Development of a cell line-based in vitro assay for assessment of Diphtheria, Tetanus and acellular Pertussis (DTaP)-induced inflammasome activation.
    Vaccine. 2022;40:5601-5607.
    PubMed     Abstract available


  1260. MOORE KA, Osterholm MT, Lackritz EM, Poland GA, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: Setting a path to address coronavirus threats.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01079.
    PubMed    


  1261. TEPEROWSKI MONRAD J, Quaade S, Powell-Jackson T
    Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.
    Vaccine. 2022 Sep 8. pii: S0264-410X(22)01041.
    PubMed     Abstract available


  1262. JOSE PRIYA TA, Kappalli S
    Modern biotechnological strategies for vaccine development in aquaculture - Prospects and challenges.
    Vaccine. 2022 Sep 7. pii: S0264-410X(22)01083.
    PubMed     Abstract available


  1263. CEANNT R, Vallieres F, Burns H, Murphy J, et al
    Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland.
    Vaccine. 2022 Sep 7. pii: S0264-410X(22)01082.
    PubMed     Abstract available


  1264. MOK CC, Chan KL, Tse SM
    Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01067.
    PubMed     Abstract available


  1265. LUBIS TA, Gunardi H, Herqutanto, Soedjatmiko S, et al
    Educational videos to address vaccine hesitancy in childhood immunization.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01035.
    PubMed     Abstract available


  1266. HABERSAAT KB, Narayan S, Malue Nielsen S, Scherzer M, et al
    How health workers can make a difference in the public COVID-19 vaccination response.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01081.
    PubMed    


  1267. PERRIER Q, Lupo J, Gerster T, Augier C, et al
    SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01064.
    PubMed     Abstract available


  1268. NUORTI JP, Rinta-Kokko H, Toropainen M, Siira L, et al
    Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
    Vaccine. 2022 Sep 5. pii: S0264-410X(22)01037.
    PubMed     Abstract available


  1269. LUHATA LUNGAYO C, Burke RM, Cikomola A, Mukamba E, et al
    Epidemiology and pre-vaccine burden of rotavirus diarrhea in Democratic Republic of Congo (DRC): Results of sentinel surveillance, 2009-2019.
    Vaccine. 2022 Sep 3. pii: S0264-410X(22)01031.
    PubMed     Abstract available


  1270. ARORA AK, Chinsky K, Keller C, Mayers I, et al
    A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial.
    Vaccine. 2022 Sep 3. pii: S0264-410X(22)01042.
    PubMed     Abstract available


  1271. QI L, Sun Y, Juraska M, Moodie Z, et al
    Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.
    Vaccine. 2022 Sep 3. pii: S0264-410X(22)01043.
    PubMed     Abstract available


  1272. SALUJA T, Rai GK, Chaudhary S, Kanodia P, et al
    Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)01009.
    PubMed     Abstract available


  1273. MANOHAR MM, Campbell BE, Walduck AK, Moore RJ, et al
    Enhancement of live vaccines by co-delivery of immune modulating proteins.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)01049.
    PubMed     Abstract available


  1274. SAEZ-LLORENS X, Chan M, DeAntonio R, Petersen T, et al
    Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax(R), a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)00858.
    PubMed     Abstract available


  1275. LEWIN B, Qian L, Huang R, Sy LS, et al
    Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink.
    Vaccine. 2022 Sep 2. pii: S0264-410X(22)01002.
    PubMed     Abstract available


  1276. VESGA JF, Metras R, Clark MHA, Ayazi E, et al
    Vaccine efficacy trials for Crimean-Congo haemorrhagic fever: Insights from modelling different epidemiological settings.
    Vaccine. 2022 Sep 1. pii: S0264-410X(22)01051.
    PubMed     Abstract available


  1277. BOLSEWICZ KT, Steffens MS, Karpish L, Bullivant B, et al
    "Every interaction you have ...should be an opportunity to discuss and offer influenza vaccination". Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families living in New South Wales, Australia.
    Vaccine. 2022 Sep 1. pii: S0264-410X(22)01047.
    PubMed     Abstract available


    August 2022
  1278. HRIN ML, Emmerich VK, Ip EH, Feldman SR, et al
    Development and validation of a COVID-19 vaccine hesitancy scale for adults in the United States.
    Vaccine. 2022 Aug 31. pii: S0264-410X(22)01052.
    PubMed     Abstract available


  1279. FRAIMAN J, Erviti J, Jones M, Greenland S, et al
    Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01028.
    PubMed     Abstract available


  1280. JACOBSON M, Chang TY, Shah M, Pramanik R, et al
    Can financial incentives and other nudges increase COVID-19 vaccinations among the vaccine hesitant? A randomized trial.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01050.
    PubMed     Abstract available


  1281. SANCHEZ-SAEZ F, Peiro S, Cuenca L, Vanaclocha H, et al
    Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01007.
    PubMed     Abstract available


  1282. SARKAR P, Chandrasekaran V, Gunasekaran D, Chinnakali P, et al
    COVID-19 vaccine hesitancy among health care worker-parents (HCWP) in Puducherry, India and its implications on their children: A cross sectional descriptive study.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01040.
    PubMed     Abstract available


  1283. CAO X, Zai J, Zhao Q, Xie L, et al
    Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.
    Vaccine. 2022 Aug 29. pii: S0264-410X(22)01044.
    PubMed     Abstract available


  1284. KAMAL HOSSAIN M, Hassanzadeganroudsari M, Feehan J, Deraos G, et al
    Development and characterization of a novel conjugated methamphetamine vaccine.
    Vaccine. 2022 Aug 27. pii: S0264-410X(22)01033.
    PubMed     Abstract available


  1285. DOYON-PLOURDE P, Fortin E, Quach C
    Evaluation of the 2018-2019 vaccine effectiveness against medically attended influenza-like illness using medical records and claims data.
    Vaccine. 2022 Aug 27. pii: S0264-410X(22)00976.
    PubMed     Abstract available


  1286. ROSHCHINA Y, Roshchin S, Rozhkova K
    Determinants of COVID-19 vaccine hesitancy and resistance in Russia.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01032.
    PubMed     Abstract available


  1287. TERESA VIETRI M, D'Elia G, Caliendo G, Passariello L, et al
    Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01034.
    PubMed     Abstract available


  1288. PHAM D, Shukla A, Welch K, Villa A, et al
    Assessing knowledge of human papillomavirus among men who have sex with men (MSM) using targeted dating applications.
    Vaccine. 2022;40:5376-5383.
    PubMed     Abstract available


  1289. CHUAN VOO T, Savulescu J, Schaefer O, Ho Zhi Ling A, et al
    COVID-19 differentiated measures for unvaccinated individuals: The need for clear goals and strong justifications.
    Vaccine. 2022;40:5333-5337.
    PubMed     Abstract available


  1290. HEMMI T, Ainai A, Hashiguchi T, Tobiume M, et al
    Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01038.
    PubMed     Abstract available


  1291. KIKUT A, Clark D, Jesch E, Hornik R, et al
    Strengthened belief in vaccine effectiveness predicted increased COVID-19 vaccination intention and behaviour: Results from a nationally representative longitudinal survey of U.S. adults from July 2020 to April/May 2021.
    Vaccine. 2022 Aug 26. pii: S0264-410X(22)01036.
    PubMed     Abstract available


  1292. OKUYAMA M, Morino S, Tanaka K, Nakamura-Miwa H, et al
    Vasovagal reactions after COVID-19 vaccination in Japan.
    Vaccine. 2022 Aug 25. pii: S0264-410X(22)01046.
    PubMed     Abstract available


  1293. CATHARINA DE BEER J, Goto D, Miller-Janson H, Holl R, et al
    Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)00817.
    PubMed     Abstract available


  1294. CALO WA, Lennon RP, Ruffin Iv MT, Keller C, et al
    Support for HPV vaccine school-entry requirements in the United States: The role of exemption policies.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)00983.
    PubMed     Abstract available


  1295. LIM AH, Ab Rahman N, Ong SM, Paraja J, et al
    Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study.
    Vaccine. 2022 Aug 24. pii: S0264-410X(22)01005.
    PubMed     Abstract available


  1296. ESSON R, Rodrigues De Sousa E, Benair L, Devard N, et al
    Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate.
    Vaccine. 2022 Aug 23. pii: S0264-410X(22)00939.
    PubMed     Abstract available


  1297. KURUKULASURIYA S, Ahmed KA, Ojkic D, Gunawardana T, et al
    Evaluation of five circulating strains of variant infectious bursal disease virus (varIBDV) for their immunogenicity as broiler breeder vaccines and protective efficacy in neonatal broiler chicks.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01000.
    PubMed     Abstract available


  1298. ROMANO L, Tosti ME, Zanetti AR
    Beyond 30 years of universal anti-hepatitis B vaccination in Italy: Success and areas of improvement.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00966.
    PubMed    


  1299. PRUDDEN HJ, Achilles SL, Schocken C, Broutet N, et al
    Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00999.
    PubMed     Abstract available


  1300. MACKLIN GR, Goel AK, Mach O, Tallis G, et al
    Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)00962.
    PubMed     Abstract available


  1301. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    Views on COVID-19 vaccination of young children in Ireland, results from a cross-sectional survey of parents.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01013.
    PubMed     Abstract available


  1302. STIVANELLO E, Beghelli C, Cardoni F, Giansante C, et al
    Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01029.
    PubMed     Abstract available


  1303. WANG X, Deng Y, Zhao L, Wang L, et al
    Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01030.
    PubMed     Abstract available


  1304. KANOKUDOM S, Assawakosri S, Suntronwong N, Chansaenroj J, et al
    Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01011.
    PubMed     Abstract available


  1305. DOCHEZ C, Duclos P, MacDonald N, Steffen C, et al
    Advanced vaccinology training globally: Update and impact of the COVID-19 crisis.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01006.
    PubMed     Abstract available


  1306. KURASHIMA K, Numano T, Yoshino A, Osawa A, et al
    Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01027.
    PubMed     Abstract available


  1307. WILLIS GA, Bloomfield L, Berry M, Bulsara C, et al
    The impact of a vaccine mandate and the COVID-19 pandemic on influenza vaccination uptake in Western Australian health care students.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01026.
    PubMed     Abstract available


  1308. TOAPANTA-YANCHAPAXI L, Chiquete E, Avila-Rojo E, Lopez-Yanez S, et al
    Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01012.
    PubMed     Abstract available


  1309. CLEMENS SAC, Fortaleza CMCB, Crowe M, Pollard A, et al
    Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01010.
    PubMed     Abstract available


  1310. JAFFRY M, Mostafa F, Mandava K, Rosario S, et al
    No significant increase in Guillain-Barre syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Vaccine. 2022 Aug 22. pii: S0264-410X(22)01025.
    PubMed     Abstract available


  1311. PSARIDI L, Maltezou HC, Simonidou S, Lialliou I, et al
    Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection.
    Vaccine. 2022 Aug 19. pii: S0264-410X(22)01008.
    PubMed     Abstract available


  1312. MOHAMED TJ, Fong SM, Nadarajaw T, Choo CM, et al
    Burden of pertussis among young infants in Malaysia: A hospital-based surveillance study.
    Vaccine. 2022;40:5241-5247.
    PubMed     Abstract available


  1313. DEJONG MA, Wolf MA, Bitzer GJ, Hall JM, et al
    CpG 1018(R) adjuvant enhances Tdap immune responses against Bordetella pertussis in mice.
    Vaccine. 2022;40:5229-5240.
    PubMed     Abstract available


  1314. STOECKEL F, Stockli S, Phillips J, Lyons B, et al
    Stamping the vaccine passport? Public support for lifting COVID-19 related restrictions for vaccinated citizens in France, Germany, and Sweden.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00965.
    PubMed     Abstract available


  1315. LAFFAN MA, Rees S, Yadavalli M, Ferstenberg LB, et al
    Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00964.
    PubMed     Abstract available


  1316. PRINGLE W, Greyson D, Graham JE, Dube E, et al
    Suitable but requiring support: How the midwifery model of care offers opportunities to counsel the vaccine hesitant pregnant population.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)00953.
    PubMed     Abstract available


  1317. AMANI A, Ngo Bama S, Dia M, Nguefack Lekelem S, et al
    Challenges, best practices, and lessons learned from oral cholera mass vaccination campaign in urban Cameroon during the COVID-19 era.
    Vaccine. 2022 Aug 18. pii: S0264-410X(22)01004.
    PubMed     Abstract available


  1318. ISHIDA M, Mulou N, Mahal A
    Travel time to health facilities in Papua New Guinea: Implications for coverage and equity in child vaccinations.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00958.
    PubMed     Abstract available


  1319. LINNANDER E, Ineza L, Mupeta Bobo P, Bechtold K, et al
    Improving management of vaccine supply chains: A multi-methods evaluation of vSTEP in Zambia.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00914.
    PubMed     Abstract available


  1320. WYMORE BRAND M, Anderson TK, Kitikoon P, Brian Kimble J, et al
    Bivalent hemagglutinin and neuraminidase influenza replicon particle vaccines protect pigs against influenza a virus without causing vaccine associated enhanced respiratory disease.
    Vaccine. 2022 Aug 17. pii: S0264-410X(22)00937.
    PubMed     Abstract available


  1321. VISKUPIC F, Wiltse DL, Badahdah A
    Reminders of existing vaccine mandates increase support for a COVID-19 vaccine mandate: Evidence from a survey experiment.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00978.
    PubMed     Abstract available


  1322. ELLIOTT CBP, Chambers CS
    A historical analysis of vaccine mandates in the United States military and its application to the COVID-19 vaccine mandate.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00982.
    PubMed     Abstract available


  1323. ALKETBI LMB, Al Hosani F, Al Memari S, Al Mazrouei S, et al
    Parents' views on the acceptability of a COVID-19 vaccine for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00954.
    PubMed     Abstract available


  1324. MATSUURA T, Fukushima W, Nakagama Y, Kido Y, et al
    Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00984.
    PubMed     Abstract available


  1325. CASEROTTI M, Gavaruzzi T, Girardi P, Sellaro R, et al
    People's perspectives about COVID-19 vaccination certificate: Findings from a representative Italian sample.
    Vaccine. 2022 Aug 15. pii: S0264-410X(22)00980.
    PubMed     Abstract available


  1326. SCHMIDTKE KA, Skrybant M, Kudrna L, Russell S, et al
    A workshop to co-design messages that may increase uptake of vaccines: A case study.
    Vaccine. 2022 Aug 12. pii: S0264-410X(22)00951.
    PubMed     Abstract available


  1327. XIROGIANNI A, Marmaras N, Georgakopoulou T, Papandreou A, et al
    Pneumococcal meningitis in Greece: A retrospective serotype surveillance study in the post-PCV13 era (2010-2020).
    Vaccine. 2022;40:5079-5087.
    PubMed     Abstract available


  1328. OMER SB, O'Leary ST, Bednarczyk RA, Ellingson MK, et al
    Multi-tiered intervention to increase maternal immunization coverage: A randomized, controlled trial.
    Vaccine. 2022;40:4955-4963.
    PubMed     Abstract available


  1329. HALASA N, Williams J, Faouri S, Shehabi A, et al
    Corrigendum to "Natural history and epidemiology of respiratory syncytial virus infection in the Middle East: Hospital surveillance for children under age two in Jordan" [Vaccine 33(47) (2015) 6479-6487].
    Vaccine. 2022 Aug 11. pii: S0264-410X(22)00959.
    PubMed    


  1330. HOSHI SL, Okubo R, Tabuchi K, Seposo X, et al
    Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children.
    Vaccine. 2022 Aug 11. pii: S0264-410X(22)00960.
    PubMed     Abstract available


  1331. MARKOWITZ LE, Drolet M, Lewis RM, Lemieux-Mellouki P, et al
    Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs.
    Vaccine. 2022 Aug 11. pii: S0264-410X(22)00834.
    PubMed     Abstract available


  1332. MAEDA H, Gopal Dhoubhadel B, Sando E, Suzuki M, et al
    Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
    Vaccine. 2022 Aug 10. pii: S0264-410X(22)00938.
    PubMed     Abstract available


  1333. GUSMAO MR, Ostolin TLVDP, Carvalho LM, Costa AFP, et al
    Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
    Vaccine. 2022 Aug 10. pii: S0264-410X(22)00961.
    PubMed     Abstract available


  1334. YELVERTON V, Hair NL, Ghosh SH, Mfinanga SG, et al
    Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania.
    Vaccine. 2022 Aug 9. pii: S0264-410X(22)00907.
    PubMed     Abstract available


  1335. PROUT A, Rustandi RR, Tubbs C, Winters MA, et al
    Functional profiling of Covid 19 vaccine candidate by flow virometry.
    Vaccine. 2022 Aug 9. pii: S0264-410X(22)00963.
    PubMed     Abstract available


  1336. PERROUD JM, Soldano S, Avancena ALV, Wagner A, et al
    Adult vaccination uptake strategies in low- and middle-income countries: A systematic review.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00952.
    PubMed     Abstract available


  1337. HU S, Xiong C, Li Q, Wang Z, et al
    COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States.
    Vaccine. 2022 Aug 8. pii: S0264-410X(22)00947.
    PubMed     Abstract available


  1338. THOBANI RS, Yousafzai MT, Sultana S, Kazi AM, et al
    Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
    Vaccine. 2022 Aug 6. pii: S0264-410X(22)00840.
    PubMed     Abstract available


  1339. ESTRELA M, Magalhaes Silva T, Roque V, Rebelo Gomes E, et al
    Unravelling the drivers behind COVID-19 vaccination hesitancy and refusal among teachers: A nationwide study.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00955.
    PubMed     Abstract available


  1340. BURGER E, Baussano I, Kim JJ, Laprise JF, et al
    Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00910.
    PubMed    


  1341. GAGNEUX-BRUNON A, Guyot E, Detoc M, Botelho-Nevers E, et al
    Midwives' attitudes toward participation of pregnant individuals in a preventive vaccine hypothetical clinical trial.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00945.
    PubMed     Abstract available


  1342. DE SWART RL, de Leeuw OS, Oreshkova N, Gerhards NM, et al
    Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    Vaccine. 2022;40:4676-4681.
    PubMed     Abstract available


  1343. HAO L, Kuttel MM, Ravenscroft N, Thompson A, et al
    Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.
    Vaccine. 2022;40:4872-4880.
    PubMed     Abstract available


  1344. LI YA, Sun Y, Zhang Y, Wang S, et al
    Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a virus-like particles induces a protective immune response against porcine circovirus type 2 in mice.
    Vaccine. 2022;40:4732-4741.
    PubMed     Abstract available


  1345. YEO J, Furr Gudmundsen C, Fazel S, Corrigan A, et al
    A behavior change model to address caregiver hesitancy around COVID-19 vaccination in pediatrics.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00949.
    PubMed     Abstract available


  1346. ULRICH AK, Pankratz GK, Bohn B, Yendell S, et al
    COVID-19 vaccine confidence and reasons for vaccination among health care workers and household members.
    Vaccine. 2022 Aug 5. pii: S0264-410X(22)00956.
    PubMed     Abstract available


  1347. TOIZUMI M, Satoh C, Quilty BJ, Nguyen HAT, et al
    Effect of pneumococcal conjugate vaccine on prevalence of otitis media with effusion among children in Vietnam.
    Vaccine. 2022 Aug 4. pii: S0264-410X(22)00944.
    PubMed     Abstract available


  1348. SQUIRE JD, Joshi AY
    Response to mRNA COVID-19 vaccination in three XLA patients.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00941.
    PubMed     Abstract available


  1349. LOURENCO GUIMARAES E, Chissaque A, Pecenka C, Clark A, et al
    Cost-effectiveness of rotavirus vaccination in Mozambique.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00940.
    PubMed     Abstract available


  1350. QUIAMBAO BP, Lim JG, Bosch Castells V, Augard C, et al
    One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess im
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00923.
    PubMed     Abstract available


  1351. SINGH H, Chase AJ
    Measuring vaccine acceptance and knowledge within health professions education.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00926.
    PubMed     Abstract available


  1352. SNYDER J, Goldenberg M, Crooks VA, Katz R, et al
    Crowdfunding narratives and the valuation of vaccines for COVID-19.
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00946.
    PubMed     Abstract available


  1353. CIMA MJ, McCormick D, Porter A 3rd, Zohoori N, et al
    COVID-19 vaccine uptake among Arkansas public K-12 school teachers and staff.
    Vaccine. 2022 Aug 2. pii: S0264-410X(22)00942.
    PubMed     Abstract available


  1354. DE MUNTER AC, Hautvast JLA, Ruijs WLM, Henri Spaan D, et al
    Deciding about maternal pertussis vaccination: associations between intention, and needs and values in a vaccine-hesitant religious group.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00924.
    PubMed    


  1355. NARSINGAM S, Munson J, Drescher F
    Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00922.
    PubMed     Abstract available


  1356. BAUMER-MOURADIAN SH, Hart RJ, Bone JN, Seiler M, et al
    Should COVID-19 vaccines be mandated in schools? - an international caregiver perspective.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00921.
    PubMed     Abstract available


  1357. KORODI M, Horvath I, Rakosi K, Jenei Z, et al
    Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
    Vaccine. 2022 Aug 1. pii: S0264-410X(22)00936.
    PubMed     Abstract available


    July 2022
  1358. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    PubMed     Abstract available


  1359. DE BROUWER L, David D, Espitia Ballestas M, Sloots A, et al
    Prevalidation of the cAMP-PTx reporter assay for quantitative assessment of pertussis toxin activity.
    Vaccine. 2022;40:4513-4521.
    PubMed     Abstract available


  1360. COWLING BJ, Wong IOL, Shiu EYC, Lai AYT, et al
    Strength and durability of antibody responses to BNT162b2 and CoronaVac.
    Vaccine. 2022;40:4312-4317.
    PubMed     Abstract available


  1361. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    PubMed     Abstract available


  1362. LIU Z, Hosomi K, Kunisawa J
    Utilization of gut environment-mediated control system of host immunity in the development of vaccine adjuvants.
    Vaccine. 2022 Jul 30. pii: S0264-410X(22)00918.
    PubMed     Abstract available


  1363. NOWALK MP, D'Agostino H, Dauer K, Stiegler M, et al
    Estimating the burden of adult hospitalized RSV infection including special populations.
    Vaccine. 2022;40:4121-4127.
    PubMed     Abstract available


  1364. BOTTCHER J, Bauer BU, Ambros C, Alex M, et al
    Long-term control of Coxiellosis in sheep by annual primary vaccination of gimmers.
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00917.
    PubMed     Abstract available


  1365. CHEN H, Huang Z, Chang S, Hu M, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiorit
    Vaccine. 2022 Jul 29. pii: S0264-410X(22)00919.
    PubMed     Abstract available


  1366. ROSE O, Erzkamp S, Schobel W, Grajeda M, et al
    COVID-19 vaccinations in German pharmacies: A survey on patient and provider satisfaction.
    Vaccine. 2022 Jul 28. pii: S0264-410X(22)00925.
    PubMed     Abstract available


  1367. MARIN-LOPEZ A, Wang Y, Jiang J, Ledizet M, et al
    Erratum to "AgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection" [Vaccine 39(12) (2021) 1675-1679].
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00608.
    PubMed    


  1368. BYRNE C, Coombs D, Gantt S
    Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00913.
    PubMed     Abstract available


  1369. RAMMAURO F, Carrion F, Olivero-Deibe N, Flo M, et al
    Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Vaccine. 2022 Jul 27. pii: S0264-410X(22)00911.
    PubMed     Abstract available


  1370. QUIAMBAO B, Montalban C, Minutello AM, Guinet-Morlot F, et al
    Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00830.
    PubMed     Abstract available


  1371. KRAUSE PR, Arora N, Dowling W, Munoz-Fontela C, et al
    Making more COVID-19 vaccines available to address global needs: Considerations and a framework for their evaluation.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00916.
    PubMed    


  1372. SHENYU W, Xiaoqian D, Bo C, Xuan D, et al
    Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00908.
    PubMed     Abstract available


  1373. O'KENNEDY MM, Coetzee P, Koekemoer O, du Plessis L, et al
    Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR(-/-) mice.
    Vaccine. 2022 Jul 25. pii: S0264-410X(22)00848.
    PubMed     Abstract available


  1374. SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al
    EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice.
    Vaccine. 2022 Jul 22. pii: S0264-410X(22)00891.
    PubMed     Abstract available


  1375. CHANG MJ, Ollivault-Shiflett M, Schuman R, Ngoc Nguyen S, et al
    Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00886.
    PubMed     Abstract available


  1376. SIMSEK C, Bloemen M, Jansen D, Descheemaeker P, et al
    Rotavirus vaccine-derived cases in Belgium: Evidence for reversion of attenuating mutations and alternative causes of gastroenteritis.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00853.
    PubMed     Abstract available


  1377. PAWASKAR M, Gil-Rojas Y, Irene Parellada C, Rey-Velasco A, et al
    The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008-2019.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00889.
    PubMed     Abstract available


  1378. MCADAMS D, Estrada M, Holland D, Singh J, et al
    Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.
    Vaccine. 2022 Jul 21. pii: S0264-410X(22)00892.
    PubMed     Abstract available


  1379. LORENZETTI L, Haydarov R, Namey E, Lawton A, et al
    Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria.
    Vaccine. 2022 Jul 20. pii: S0264-410X(22)00591.
    PubMed     Abstract available


  1380. DUGORD C, Franc C
    Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00855.
    PubMed     Abstract available


  1381. MCMILLAN CLD, Amarilla AA, Modhiran N, Choo JJY, et al
    Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00888.
    PubMed     Abstract available


  1382. SETHY G, Chisema M, Sharma L, Joshi K, et al
    COVID-19 vaccine express strategy in Malawi: An effort to reach the un-reach.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00887.
    PubMed     Abstract available


  1383. MIMURA W, Ishiguro C, Fukuda H
    Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged>/=75years in Japan: The LIFE-VENUS Study.
    Vaccine. 2022 Jul 15. pii: S0264-410X(22)00852.
    PubMed     Abstract available


  1384. WALTON S, Cortina-Borja M, Dezateux C, Griffiths LJ, et al
    Linking cohort data and Welsh routine health records to investigate children at risk of delayed primary vaccination.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00849.
    PubMed     Abstract available


  1385. IMANISHI Y, Kinoshita T, Sakamoto M, Ichimiya M, et al
    Importance of human papillomavirus vaccination leaflets focusing on the safety profile targeted pediatricians in Japan.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00861.
    PubMed     Abstract available


  1386. VASUDEVAN L, Bruening R, Hung A, Woolson S, et al
    COVID-19 vaccination intention and activation among health care system employees: A mixed methods study.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00884.
    PubMed     Abstract available


  1387. ORTQVIST AK, Dahlqwist E, Magnus MC, Ljung R, et al
    COVID-19 vaccination in pregnant women in Sweden and Norway.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00859.
    PubMed     Abstract available


  1388. PRIDDY FH, Williams M, Carson S, Lavender B, et al
    Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00885.
    PubMed     Abstract available


  1389. GODDARD K, Lewis N, Fireman B, Weintraub E, et al
    Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00860.
    PubMed     Abstract available


  1390. CUFFEL A, Maylin S, Le Buanec H, Delaugerre C, et al
    Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00857.
    PubMed     Abstract available


  1391. PADRON-REGALADO E, Medina-Rivero E
    Perspectives for licensing vaccines in Mexico.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00854.
    PubMed     Abstract available


  1392. HATFALUDI T, Rezaee MS, Liebhart D, Bilic I, et al
    Experimental reproduction of histomonosis caused by Histomonas meleagridis genotype 2 in turkeys can be prevented by oral vaccination of day-old birds with a monoxenic genotype 1 vaccine candidate.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00851.
    PubMed     Abstract available


  1393. COURCIER EA, Collins SF, McCormick CM, Arnold ME, et al
    The impact of BCG strains and repeat vaccinations on immunodiagnostic tests in Eurasian badgers (Meles meles).
    Vaccine. 2022 Jul 9. pii: S0264-410X(22)00850.
    PubMed     Abstract available


  1394. WYPLOSZ B, Fernandes J, Sultan A, Roche N, et al
    Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00841.
    PubMed     Abstract available


  1395. MISCHLINGER J, Jaeger VK, Ciurea A, Gabay C, et al
    Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls.
    Vaccine. 2022 Jul 7. pii: S0264-410X(22)00760.
    PubMed